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1.1 Glutamine / Glutamate cycle:   
The glutamine / glutamate cycle is a highly regulated system found in the central / 
peripheral nervous system that’s function is thought to involve the shuttling of glutamate 
and glutamine in or out of cells through a diversity of cell membrane spanning amino 
acid transporters [Bröer and Brookes 2001; Heckel et al. 2003; Gegelashvili, G.; and 
Schousboe 1997].  The cycle’s primary role within the central nervous system (CNS) is 
the recycling of synaptically released L-glutamate, the primary excitatory amino acid 
involved in neurotransmission [Beryl et al. 1968, Danbolt, 2001].   Following vesicular 
release of L-glutamate at a glutamatergic neuronal synapse, glutamate is free to bind and 
activate the glutamate gated ionotropic receptors NMDA (N-methyl-D-aspartate), AMPA 
(alpha-amino-3-hydroxy-5-methyl-4-isoxazole-4-propionic acid receptor) and kainate 
receptors (KA) or the metabotropic glutamate receptors (mGluR’s) that may be locally 
present.  The ionotropic glutamate receptors are first and foremost ligand gated ion 
channels that are thought to be responsible for mediating excitatory neurotransmission 
involved in learning and memory, cell-cell communication, and synaptic plasticity.  The 
mGluR’s on the other hand are glutamate activated G-protein coupled receptors that are 
thought to both modulate ionotropic glutamate receptors and function in the regulation of 
gene expression through downstream activation of protein kinase C or down regulation of 
adenylyl cyclase.   Additionally, mGluRs have also been suggested to affect synaptic 
plasticity.   
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Glutamatergic signaling is terminated by rapid sequestering and clearing of L-
glutamate via the excitatory amino acid transporters (EAATs (subtypes 1-5)) expressed 
on peri-synaptic astrocytes or neuron (post or pre-synaptic) [Cousin and Robinson 2000; 
Danbolt 2001].  At this point there are two divergent paths which L-glutamate may take.  
L-glutamate may be translocated into the pre-synaptic neuron by EAAT-3 [Nieoullon et 
al. 2006] and shuttled into a glutamate containing vesicle by the vesicular glutamate 
transporter (VGLUT) [Takamori 2006] therefore ready for the next signaling event.  
Alternatively, if taken up by glial cell where EAAT1 and EAAT-2 are generally 
expressed [Arriza et al. 1994; Lehre et al. 1995; Chaudhry et al., 1995], L-glutamate can 
be converted to L-glutamine by the enzyme glutamine synthetase.  Glutamine, while 
highly profuse in plasma and cerebral spinal fluid (CSF) at 0.13-0.5 mM  [Jacobson et al. 
1985; ErecinÂska and Silver 1990; Xu et al. 1998], is thought to act in the cycle as an 
intermediate of L-glutamate to be safely shuttled between glial cell to CSF and ultimately 
back to the neuron where it can be converted to glutamate by the enzyme glutaminase.  
There are a number of amino acid transporters which are suggested to take part in the 
shuttling of glutamine between glia (astrocyte) cell and neuron.   The neutral amino acid 
transporters ASCT2, SN1, LAT2, and ATA2 have all been thought to be involved in the 
transport of glutamine in or out of astrocytes and into the CSF [Bröer and Brookes 2001; 
Gliddon et al. 2009].  Glutamine is then shuttled into the pre-synaptic neuron via ATA1, 
ATA2, LAT1 / LAT2 or ASCT2 transporter [Heckel et al. 2003; Bak et al. 2006] where it 
is converted to glutamate catalyzed by the enzyme glutaminase.  Glutamate is then 
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concentrated into a glutamate containing vesicle by VGLUT, thus completing the cycle 
(Figure 1).   
 
Figure 1: Glutamatergic neuronal synapse – Illustrating the glutamine / glutamate cycle.  
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Impairment of the glutamate / glutamine cycle’s proper functioning has been 
implicated in the progression of a few pathological disease processes such as 
neurodegenerative diseases, and even cancer [Albrecht et al. 2007].   Dysregulation of the 
cycle may lead to excessive accumulation of L-glutamate at neuronal synapses or 
excessive spillage in other extracellular spaces which may lead to cell damage / death.  
This damage is thought to occur by a mechanism known as excitotoxicity, where 
prolonged activation of the glutamate activated ionotropic receptors AMPA and NMDA 
leads to excessive Ca
2+
 and Na
+
 influx that triggers a cascade of intracellular events 
which in turn leads to cell death by necrosis or apoptosis. The continuing release of 
glutamate can then lead to the spreading of this process and damage in other parts of the 
CNS.  Therefore the dysfunction of cycle has been suggested to play an integral role in 
many proposed models of pathologic mechanism or consequent CNS damage that occurs 
in the neurodegenerative diseases Alzheimer’s, Parkinson’s, and amyotrophic lateral 
sclerosis (ALS) [Walton and Dodd 2007].  Though, it is not clear whether dysfunction of 
the glutamate / glutamine cycle is the pathological cause or a downstream effect resulting 
in chronic CNS damage that occurs in neurodegenerative diseases.  The link between the 
cycle and glutamate mediated chronic CNS damage as cause of neurodegeneration is still 
quite valid especially considering that allosteric antagonists of NMDA, such as 
memantine, are an effective preventative measure and treatment for Alzheimer’s related 
CNS damage [Walton and Dodd 2007].  More directly, the ischemic injury that occurs 
following stroke or traumatic brain injury is arguably the result of when the Gln / Glu 
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cycles proper functioning and capacity is overwhelmed.  Likewise, the damage that 
occurs as a result of an epileptic seizure seems also to be dependant upon the proper 
functioning of the glutamine / glutamate cycle [Tani et al. 2010].    
Glutamine availability, supplied through the Glu/Gln cycle, has shown to be 
essential for the growth of some highly prolific cell lines such as tumors [Bode, 2002], 
Thus indicating a role for its regulation in cancer therapy.  The cycle employs ligand 
selective membrane bound transporters to maintain physiologic concentrations of 
glutamine needed to grow and proliferate such as found in gliomas over-expressing 
neutral amino acid transporters LAT1 and ASCT2 [Fuchs et al. 2005].  The physiologic 
need for glutamine is explained by the high demand of rapidly dividing cells for amino 
acids such as glutamine / glutamate to provide energy via the Krebs cycle of which the 
transporters involved in the Gln / Glu cycle supply [Baggetto 1992].  Being that Gln is 
the most abundant amino acid in mammalian plasma, glutamine is in steady supply to be 
converted by glutaminases to glutamate for production of glutathione a neuroprotective 
antioxidant, or α-ketoglutarate, a starting material for energy in the Krebs cycle [Medina 
2001; Hu et al. 2010]. Therefore, specific inhibitors of the Gln / Glu cycle at key points 
in the cycle may make promising candidates as antimetabolic chemotherapeutic agents.  
The availability of glutamine via the cycle and cycle dependent transporters also seems to 
regulate the growth and proliferation of tumor cells as well as acting as an exchanger for 
other essential amino acids [Nicklin et al. 2009].  This is yet another example how 
dysfunction of the glutamine / glutamate cycle may contribute to pathology, particularly 
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in gliomas.  In order to better understand the mechanisms by which glutamate / glutamine 
cycle dysfunction may contribute to neurodegenerative diseases and/or cancer, it would 
be logical to utilize transporter and enzyme specific inhibitors to investigate the role and 
significance of each molecular participant involved within the cycle.  Unfortunately, 
there exist only a handful of inhibitors to evaluate the role of a few amino acid 
transporters.  
1.2 Glutamine transporters: 
A combination of radiolabled uptake and electrophysiology based experiments 
has identified an abundance of neutral amino acids transporters which shuttle glutamine 
in and out of mammalian cells.  Most of these transporters were first discovered in the 
mid 1960’s and early 1970’s and functionally characterized by radiolabeled uptake in 
Ehrlich ascite tumor cells and various red blood cells collected from pigeons, and rabbits, 
common work preformed by Halvor N. Christensen [for review see Christensen 1984; or 
Barker, G.A.; and Ellory, J.C 1990].  These neutral amino acid transporters were 
classified by their function in transporting preferred amino acids and designated the 
names system A for alanine preferring, system ASC for alanine, cystein, serine 
preferring; system N for nitrogen side chain preferring, and system L for leucine 
preferring.  Worth mentioning, these names do not imply that these transporter systems 
exclusively transport the amino acid they were named after.  System L however, does 
transport glutamine with low affinity though its expression and/or function as a 
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transporter of glutamine within the CNS has yet to be found.  Cloning has allowed for the 
identification of subclasses of these transporter systems, most of which transport 
glutamine as a preferred substrate.   These include SN1 of system N, ASCT2 of system 
ASC, LAT2 and to a lesser extent LAT1 of system L, and ATA1 and ATA2 both of 
system A.   All of these transporters function as bidirectional transporters of glutamine as 
well other amino acids.   Essentially, these transporters may operate by uptake or efflux 
depending on the substrate (amino acid) concentration gradient and the electrochemical 
concentration gradient [Bröer and Brookes 2001].  
 Although not entirely complete, the localization and cellular distribution of these 
transporters in many mammalian tissues has been determined by immunoblotting and 
functional radiolabled uptake competition using known substrates.  From initial 
characterization it has been revealed that there exists a fairly considerable overlap in 
substrate specificity between the various amino acid transporters, particularly the 
glutamine transporters.  This is suggestive of the versatile physiological roles in which 
glutamine might play.   Pertaining to the CNS, the glutamine transporters that have been 
detected in astrocytes include the neutral amino acid transporters SN1, LAT2, and 
ASCT2.  Interestingly their expression or overall contribution to the glutamine shuttling 
greatly depends on the tissue involved.  For example SN1 is generally the primary 
transporter of glutamine in hippocampal astrocytes, where as in reactive astrocytes this 
transport is shifted to ASCT2 and LAT1.  Where as in astrocytes localized to other 
regions of mouse brain glutamine uptake is well transported by both SN1 and ASCT2. 
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 In neurons, the glutamine transporters ATA2, ATA1, LAT2, and ASCT2, have 
been detected by both immunohistochemical staining and functional uptake.  As with 
glutamine transporters expressed in astrocytes, the expression of functionally detectable 
glutamine transporters in neurons also varies depending on the tissue being observed.  
System A has traditionally been thought of as the primary transporter of L-glutamine near 
peri-synaptic terminals, though it has been shown to account for only 10% of glutamine 
uptake [Heckel et al. 2003], therefore ~90% of the glutamine uptake that is observed in 
these primary neurons must be transported by an alternative transport system.  Functional 
analysis using a series of substrates to block glutamine uptake suggested that ~30-40% of 
glutamine uptake is mediated by system L and another remaining 30% by an unknown D-
aspartate sensitive uptake.  Until recently ASCT2 had been thought of as an astrocyte 
specific transporter.  However, ASCT2 has now been detected in Purkinje neurons 
bodies, dendrites, and dendrites in hippocampus, striatum, and cortex from mouse brain 
slices identified by immunohistochemical staining, and by D-serine radio labeled uptake 
[Gliddon et al. 2009; Shao et al. 2009].   This is inconsistent with previous reports in 
which in situ hybridization or antibodies failed to detect ASCT2 mRNA or protein 
expression in neuronal cultures.  Previous functional assays also failed to detect ASCT2 
like transport using radiolabeled uptake within these neuronal cultures.  What is clear 
from the multitude of studies is that expression of glutamine transporters is highly 
variable with respect to region and tissue type.  Glutamine transporter expression is also 
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highly variable with regard to how the cells were obtained by culture, primary culture or 
tissue slices.   
 
1.2.1- ATA1 / ATA2: 
System A of the solute carrier 38 gene family includes two Na
+ 
dependent 
glutamine / neutral amino acid transporters ATA1 and ATA2 [Varoqui et al. 2000; 
Sugawara et al. 2000].  Previously named GlnT / SAT1 for ATA1 and SAT2 for ATA2, 
these transporters exhibit cotransport of one amino acid substrate coupled to the transport 
of one sodium ion along its electrochemical gradient.  ATA1 and ATA2 transport short 
chain neutral amino acids alanine, glutamine, serine, asparagine, glycine, proline, 
cysteine and histidine with affinities ranging between Km of 0.5-1.5 mM for preferred 
substrates [Yao et al. 2000; Sugawara et al. 2000].  Interestingly both ATA1 and ATA2 
are pH sensitive and with decreasing pH their rate of transport diminishing quickly from 
approximately Km of 3.5 mM at pH 7.4 to 32 mM at pH of 6.0 [Mackenzie and Erickson 
2004].  However, with increasing pH the rate of substrate transport by system A 
transporters increases [Varoqui et al. 2000; Sugawara et al. 2000].  This change in 
transport rate is thought to occur by a H
+
 competing for the same binding site that 
requires Na
+
 binding for translocation of a substrate [Chaudhry et al. 2002].   
In the CNS, the system A transporters are widely distributed amongst neurons 
localized in the spinal cord, cerebral cortex, hippocampus and in cerebellar neurons 
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typically of GABA or glutamatergic neurons.  Rarely, these two transporters have been 
found on astrocyte cultures.  The distribution of ATA1 and ATA2 would seem to suggest 
a possible role for these transporters in the glutamine / glutamate cycle.  Currently the 
only synthetic inhibitor of these transporters is methyl amino isobutyric acid (MeAIB), 
which acts as a transportable and specific System A inhibitor.  The affinity the system A 
transporters express for MeAIB ranges between Km ≈ 0.2-0.6 mM at ATA2 and a Km ≈ 
1-2 mM at ATA1 [Yao et al. 2000; Sugawara et al. 2000; Albers et al. 2001, Chaudhry et 
al. 2002].  Recent studies in brain slices have used MeAIB to competitively inhibit 
glutamine transport via system A to probe the contribution of ATA1 and ATA2 in 
supplying glutamine for production of glutamate have had remarkable results.  Neurons 
treated with MeAIB leads to a measurable decrease of dendritic glutamate containing 
pools [Jenstad et al. 2009].  This may be attributable to blocking of glutamine uptake by 
neurons resulting in accumulation in extracellular spaces [Kanamori and Ross 2004]. 
However, there is no evidence to support that MeAIB decreases vesicular glutamate in 
neurons, though, this is effect is seen when applying histidine [Rae et al. 2003].   
Application of MeAIB has been observed to decrease amplitude and frequency of 
miniature EPSP (mEPSP) [Armano et al. 2002] in cultured hippocampal neurons and 
evoked field potential (EFP) in disinhibited neocortical slices [Tani et al. 2010], though 
this effect was rapidly reversible in field excitatory post synaptic potential (fEPSP) 
recorded in hippocampal slices [Kam and Nicoll 2007].  Little can be concluded from 
these studies as to the role of the system A transporters in neurons.  In the first example 
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glutamine supplied by system A is suggested to be crucial for glutamatergic signaling.  
The second example suggests that system A does contribute to neuronal glutamine 
uptake; however, system A’s contribution in glutamine uptake that is destined to be 
converted to glutamate is negligible.  It was thus determined that this function is really an 
unknown transporter that is inhibited by amino isobutyric acid (AIB) or histidine which 
accounts for most of the glutamine uptake that is available for glutamatergic signaling, 
therefore system A transport is not essential.  The last example concludes that the 
Glutamate / Glutamine cycle is not essential for glutamatergic signaling, though it may 
contribute in part.  The irresolute conclusions derived from these numerous studies places 
emphasis on the need for potent and selective pharmacologic inhibitors of the system A 
transporters so as to more precisely determine their physiological significance, 
particularly within the CNS. 
1.2.2 - ASCT1 / ASCT2: 
Discovery and characterization of system ASC was first accomplished through 
radiolabeled uptake [Christensen et al. 1967].  Expressed ubiquitously in mammals, this 
neutral amino acid transport system was properly named after its preferred transport of 
alanine, serine, and cysteine.  Though, as with system A, there are other naturally 
occurring neutral amino acids, such as L-glutamine, that are transported with equivalent 
or higher affinity.  System ASC consists of two transporter types, ASCT1 and ASCT2, 
which were cloned (SLC1A4 & SLC1A5 respectively) and functionally characterized 
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[Arriza et al. 1993; Utsunomiya-Tate et al. 1996; Kekuda et al. 1996].  The transporters 
were classified as Na
+
 dependent solute carrier’s type 1 (SLC1) belonging within the 
same family of amino acid transporters taht includes the EAATs.  ASCT1 transports a 
limited number of short chain amino acids including alanine, serine, cysteine and to a 
lesser extent threonine by an electroneutral Na
+
 dependent obligate amino acid exchange 
process.  ASCT2 by contrast transports a slightly broader range of amino acids which 
also includes glutamine, asparagine, and threonine.  Both transporters express a 
stoichiometrically uncoupled substrate gated anion conductance that is associated with 
translocation of a substrate [Zerangue and Kavanaugh 1996; Bröer et al. 2000] which is 
consistent with other transporters found in the SLC1 family.  Additionally, transport of L-
glutamate mediated by ASCT2 is pH dependant.  With increasing acidity L-glutamate is 
transported with higher efficiency by ASCT2.  This observation may in fact be suggestive 
of conserved homology between system ASC and other members of the SLC1 family 
which primarily transport L-glutamate the EAATs.  The most fundamentally useful 
information that has arisen from the cloning of the SLC1 family is their homology to a 
bacterial aspartate transporter Pyrococcus horikoshii which has been crystallized 
[Yernool et al. 2004; Boudker et al. 2007].  The crystal structure alone has provided 
invaluable structural understanding into the binding dynamics of the glutamate 
transporters the EAATs which has fueled the development for inhibitors of glutamate 
transport.  The GltPH homology structure (Figure 2) could also be potential used for 
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computational modeling of the other SLC1 carrier related transporters including system 
ASC.   
Figure 2:  GltPH open form trimer,  protein data bank- 2NWW.  [Boudker et al. 2007] 
Within the CNS, both ASCT1 and ASCT2 are widely distributed amongst 
astrocytes.   ASCT2 is thought to be highly concentrative with respect to glutamine efflux 
from glia / astrocyte in exchange for other amino acid substrates alanine, serine, cysteine 
[Bröer et al. 1999].  Though, the apparent contribution of ASCT2 to pooling of glutamine 
in the CSF in is unknown.  Most of the concentrative effort of glutamine into the CSF 
may instead be as a result of SN1 mediated transport.  ASCT1 has been found 
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ubiquitously on neurons [Yamamoto et al. 2003], though, being that this transporter is an 
obligate exchanger of amino acids the implications for its function are obscure.  ASCT2 
has also recently been found on a small subset of neurons in corticle, striatum and 
cerebellar regions [Gliddon et al. 2009; Shao et al. 2009].  The significance and function 
of ASCT2 expressed in these neurons, however has remained elusive.  ASCT2 and 
ASCT1 may function together in neurons to supply essential amino acids or maintain 
appropriate amino acid reserves.  Equally, glutamine may be used as a currency for 
obligate exchange for recruitment of essential amino acids through ASCT1 or system L 
transport [Nicklin et al. 2009].  It is also probable that glutamine supplied by ASCT2 
may be used as an energy source by production α-ketogluterate which enters into the 
Krebs cycle, or alternatively converted to glutamate for glutamatergic signaling.  Though 
much work in functional characterization and distribution has been made, the significance 
and contribution of the ASC transporters in normal physiologic processes such as the 
glutamate / glutamine cycle and / or pathologic conditions is unknown. Regardless, the 
transporter ASCT2 may have other more demonstrable physiological implications within 
the CNS such as by functioning in uptake of D-serine [Shao et al. 2009].   D-serine is 
recognized as a high affinity co-agonist of the glutamate ionotropic receptor NMDA, like 
that of glycine. D-serine has been suggested to contribute to neuronal damage via 
activation of NMDA in ischemic induced injury [Katsuki et al. 2004; Katsuki et al. 
2007].  Thus it may be conceivable that under hypoxic circumstances ASCT2 functions 
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as a scavenger of D-serine at glutamatergic synapses to reduce over stimulation of 
NMDA receptors which otherwise may result in neuronal injury.  
Radiolabeled uptake has identified trans-4-hydroxy-L-proline (4-HP) as a high 
affinity substrate of ASCT1 while conversely L-proline exhibits low affinity uptake.  
These results indicate that system ASC may have a preference for recognizing H-bond 
capable small side chain containing amino acids [Pinilla-Tenas et al. 2003].  Importantly, 
this is the first reporting of a homo-chiral amino acid as a high affinity substrate of ASC 
transport.  The finding also highlights the possibility of a chiral switch or diastereomer 
selectivity that may exist within this SLC1 family of transporters.  This is also consistent 
with a previous report in which the EAATs, another group of transporters within the 
SLC1 family of transporters, were shown to transport pyrrolidine-2,4-dicarboxylate with 
high affinity.  
1.2.3 - Synthetic inhibitors of ASCT2 
To date there are very few inhibitors that may be capable to discern the 
physiological function or relevance of the ASC transporters. Benzylserine and 
benzylcysteine were revealed as non-substrate inhibitors of ASCT2 [Grewer and Grabsch 
2004].  The activity of these compounds at ASCT2 is quite low Ki >700 µM.  Most 
interesting is that these inhibitors exposed the presence of a tonic anion current that is 
uncoupled to ligand binding.  They demonstrated that non-substrate inhibitors of ASCT2 
block this anion leak with saturable kinetics that is competitive with transportable 
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substrates.  Furthermore, a direct measure of the dissociation constant or Ki was 
attainable by a relatively straightforward dose response curve.  Though, these compounds 
have not been used to elucidate structure or physiological function of the ASC 
transporters they still serve as proof of concept to effectively screen and/or establish the 
activity of non-substrate inhibitors at ASCT2.   
Nγ-Aryl-glutamine analogues were reported to inhibit uptake of radiolabeled 
glutamine in C6 rat glioma cell line [Esslinger et al. 2005].  Though not very potent ~Ki 
> 800 µM, these inhibitors indicate a hydrophobic pocket that can accommodate an 
aromatic ring.  Additionally, these aryl-glutamine analogs were used to demonstrate the 
pH sensitivity of ASCT2.  It was observed that the inhibitory activity of these analogs 
increased with decreasing pH, supporting a hypothesis that the amide functionality 
participates in a hydrogen bond donating or dipole-dipole interaction.  With respect to 
pKa of the amide however, the effects of electron withdrawing or donating by the various 
phenyl ring substituents had no detectable influence on activity.  Rather, it may have been 
the lipophilicity of the phenyl substituents which is accountable for the observed change 
in inhibitory activity.  It is therefore reasonable to infer from this study that both 
lipophilic and hydrogen bonding interactions are important to consider when designing 
inhibitors of the ASCT2 transporter.  Interestingly, the most active anolog of this series 
reported, N-γ-glutamyl-p-nitro-aniline, is the only pharmacologic inhibitor to be used in 
delineating the physiological role of ASCT2 in proliferating cells [Nicklin et al. 2009], 
even though this compound as an inhibitor of ASCT2 is quite poor. 
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1.2.4 - ASCT2 relation to proliferating cells 
A role for ASCT2 is emerging in relation to regulating growth and proliferation in 
certain cancerous tumor cell lines [see Fuchs and Bode 2005 for review].  ASCT2 has 
long been known to be highly expressed and distributed amongst reactive astrocytes and 
other forms of prolific glial tumor lines such as C6 glioma, as [Dolinska et al. 2001].  
Additionally, ASCT2 been seen to be upregulated in a neuroblastoma cell line [Wasa et 
al. 2002].  This transporter has also been shown to be upregulated in a number of other 
tumor cell lines that are un-related to the CNS.  The upregulation of ASCT2 and function 
as the primary glutamine transporter in prolific cell lines is not limited to CNS tumor 
lines, ASCT2 has been observed as the primary glutamine transporter in other tumor cell 
lines such as human hepatoma cells [Bode et al. 1995].    Additionally, ASCT2 is thought 
to be the primary transporter of glutamine in colon carcinoma cells and when inhibited by 
abundant competing substrates, effectively slows the growth of these cells [Pawlik et al. 
2000].   
It is thought that ASCT2 may supply rapidly dividing cells with glutamine for 
converting to energy.  This is also consistent with findings in the developing embryonic 
brain where ASCT2 is highly distributed in an area of high energy demand [Wu and 
Schwartz 1998].  There is also indication that ASCT2 regulates growth and proliferation 
of cells indirectly by activation of the mammalian target-of-rapamycin (mTOR) an 
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energy sensing pathway that mediates growth / proliferation of cells if energy reserves 
and various conditions are reached (Figure 3) [Fuchs and Bode 2005].   
Figure 3:  ASCT2 transport indirectly or directly regulates mTOR which is linked to cell 
growth/proliferation and survival [Fuchs and Bode 2005]. 
 
 
Another mechanism relating ASCT2 to the activation of mTOR has also been proposed 
whereby ASCT2 functions to concentrate L-glutamine into rapidly dividing cells to be 
used as an efflux substrate to bring in larger essential amino acids via LAT1, which 
otherwise cannot be synthesized ex novo [Nicklin et al. 2009].  The availability of 
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essential amino acids tryptophan, phenyl-alanine, and valine may then trigger the 
activation of mTOR.  Unfortunately, there are no available inhibitors of ASCT2 to test 
this concept.  The only evidence that would suggest that ASCT2 transport is a valid target 
to inhibit cell growth within tumors has been by silencing of ASCT2 mRNA expression 
via RNAi [Fuchs et al. 2007].  Silencing of ASCT2 in human derived hepatoma cells 
resulted in repression of growth followed by induction of apoptosis regulated by mTOR 
complex-1 (mTORC1).  Indeed, it appears that ASCT2 does have a significant role in this 
cell line; this notion may also be true in other tumor cell lines.  
An alternative mechanism yet to emerge in discussion or literature which portrays 
its novelty is to affect glutathione production by inhibition ASCT2 mediated transport.  A 
rational that might also explain ASCT2 up-regulation in rapidly dividing cells may be to 
supply cells with L-glutamine for the production of glutathione.  As mentioned before, L-
glutamine can be converted to glutamate by glutaminase and glutamate is a precursor for 
biosynthesis of glutathione.  ASCT2 may also function to supply these cells with 
cysteine, also a precursor of glutathione.  Although premature, these suggestions 
exemplify the need for ASCT2 selective inhibitors to act as probes to examine the 
biological significance of this transporter within these systems.   
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Abstract 
L-Aspartate provides as a synthetically useful starting material for the rapid synthesis and 
biologic screening of chiral α amino acid analogs to be evaluated as inhibitors of amino 
acid transporters.  A series of β-aryl-aspartamides and α-arylamide-aspartates were 
synthesized and screened against the amino acid transporters including the excitatory 
amino acid transporters subtypes 1-3 (EAATs 1-3), and the neutral amino acid 
transporters ATA2, ASCT2, and SN1 in order to generate new pharmacologic leads.  The 
pharmacologic leads will serve in identifying structure activity relationship (SAR) and 
may prove useful towards developing transporter subtype selective inhibitors to 
ultimately delineate the physiological relevance or discover new therapeutic strategies 
related to these amino acid transporters of interest. 
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INTRODUCTION 
Amino acid transporters are ubiquitously expressed in nearly every mammalian 
tissue.  The capacity of researchers to investigate the physiological function of these 
various amino acids transporters is limited in scope by the pharmacologic tools as 
inhibitors that are available.  Considering the many diseases that amino acid transporters 
may be involved in, including cancer and/or neurodegenerative diseases [Allen et al. 
2004], there remains a need for selective and potent inhibitors to investigate the 
physiological significance of the numerous amino acid transporters that exist [see Bröer 
2002; & Bröer 2008 for review of transporters].  Amongst the various scaffolds available 
for generating inhibitors of amino acid transport, the α-amino acids, the substrates of the 
transporters themselves, are often a good starting point.    
Naturally occurring α-amino acids have found wide application as molecular 
scaffolds to synthesize unnatural amino acid inhibitors of both membrane bound 
receptors, such as those involved in neurotransmission, and membrane spanning amino 
acid transporters.  Incorporation of bulky, hydrophobic groups to an endogenously 
transported amino acid has led to the discovery of highly potent inhibitors of amino acid 
transporters.  For example, it was discovered that addition of a benzyl, benzyloxy or 
larger groups such as fluorene to L-aspartate created highly potent and, in some cases, 
selective inhibitors of the excitatory amino acid transporters (EAATs) [Shimamoto et al. 
1998; Esslinger et al. 2005; Greenfield et al. 2005].  Of particular interest to our lab are 
the L-glutamine transporters SN1, ATA2, and ASCT2 and the L-glutamate transporters, 
 23 
excitatory amino acid transporters EAAT’s (1-5).  These transporters are suggested to 
play a central role in the Glutamate / Glutamine cycle for the recycling of the 
neurotransmitter L-glutamate near neuronal synapses [Hertz et al. 1999; Shank and 
Aprison 1981].  Interestingly, both system ATA2 and ASCT2 transport have shown to be 
pH sensitive [Chaudhry et al. 2002; Utsunomiya-Tate et al. 1996] whereas SN1, an 
amino acid cotransporter with antiport proton exchange, is pH insensitive [Chaudhry et 
al. 1999], and then of course the glutamate transporters transport an acidic amino acid.  In 
addition to structural differences, we reasoned that dissimilarity between transporters 
which may account for pH sensitivity verses ligand specificity might also be exploited to 
create potent transporter selective inhibitors.  What was needed was a useful method to 
quickly synthesize the desired tools or potential inhibitors for biological screening to 
generate initial pharmacologic leads that may facilitate a developing pharmacophore 
model.  Here we describe an effective synthetic route used to produce a series of β-aryl-
aspartamides & α-aryl-amide aspartates as probes for biological evaluation at the 
Glutamine / Glutamate amino acid transporters.   
 
L-aspartate can be used to synthesize a large variety of aryl substituted 
derivatives.  Of these, aspartyl aryl-amides are readily accessible via aspartyl anhydride 
[Witiak et al. 1971] such as to produce a series of these analogs rapidly and in scalable 
quantity.  In the series reported here (Figure 1), we aimed to produce a number of amino 
acid analogs with varying electron withdrawing / donating properties, various 
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spatial/geometrical configuration, or finally analogs with fluorescent properties.   To 
preliminarily assess the influence of probable hydrogen bond interactions with the amide 
functionality, the β or α carboxylic acid of the aspartate scaffold could be coupled to 
anilines with electron withdrawing groups, such as p-chloro or 2,3-dichloro anilines 8, 9 
(Figure 1), which may decrease the pKa of the amide N-H and therefore increase its 
capacity as an H-bond donating group. Alternatively, electron donating anilines, such as 
2,3-methyl aniline 10 (Figure 1), could be coupled to the aspartate scaffold to enhance the 
H-bond accepting properties of the amide.  Analogs for surveying larger hydrophobic 
binding sites were synthesized by coupling with larger aryl-amines such as biphenyl, 
naphthyl, or fluorenyl substituent’s, 11-14.  The spatial and geometrical limitations of a 
hydrophobic pocket or other suspected interactions within the binding domain could be 
assessed in this manner.  Lastly, aspartyl aryl-amide analogs intended to function as 
fluorescent or photoactive inhibitors were also synthesized by L-aspartate coupling with 
9-fluorenone 15, 7-nitro-fluorene 16, or carbazole 17 (Figure 1). 
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Figure 1:   Synthesized β-aryl-aspartamides and α-aryl-amide aspartates 
 
β-Aryl-aspartamides and α-arylamide-aspartates were synthesized from L-
aspartate by nucleophilic addition of an aryl amine to an anhydride of the N-protected L-
aspartate (Scheme 1) [Huang et al. 1997; Timko 2005].  Briefly, amine protection of 
aspartic acid with di-tert-butyl dicarbonate (Boc anhydride) resulted in formation of the 
tert-butyl carbamate aspartic acid 2 with quantitative yield.  After crude workup, the 
remaining product N-tBoc-protected-aspartate 2 was then dissolved in acetic anhydride to 
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form the N-tBoc-aspartic-anhydride 3.  The acidic anhydride was removed by vacuum 
and multiple washes using toluene and hexanes.  The remaining aspartic anhydride was 
immediately used in the following addition reaction to avoid hydrolysis.  Addition via a 
nucleophilic aryl amine to the anhydride 3 was carried out using DMSO or ethyl acetate 
as the solvent.   
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Scheme 1: Synthesis of β-aryl-aspartamides and α-arylamide-aspartates.  (i) Boc  
anhydride, 50/50 TEA / methanol at 22˚C; (ii) acetic anhydride, 40˚C; (iii)  aryl-amine in 
DMSO, 60˚
 
C;  (iv).  1.)  1:1 TFA and CH2Cl2 at 22
◦ 
C.   2.)  1.2 eq. 0.01 M HCl, 
lyophilize. 
 
 
Nucleophilic addition of an aryl amine to the anhydride 3 in 0.05 M DMSO with 
heating afforded the product N-tBoc protected aryl-aspartamide 4b in 85-90% yield and 
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N-tBoc protected α-arylamide-aspartate 4a accounting for the remaining 5-10%.  The two 
isomers could then be easily separated by silica gel using 94-97% CH2Cl2, 2-5% 
methanol, 1% acetic acid for the mobile phase.   Deprotection of the N-tBoc protected 
aspartic aryl-amide 4a or 4b to produce the target β-aryl-L-aspartamide 6 or α-arylamide-
L-aspartate 5 was accomplished by the addition of excess trifluoroacetic acid (TFA) in 
dichloromethane, typically 30-50% by volume.  The remaining product and TFA salt 
after aspiration and multiple washes with dichloromethane was then treated with 1.2 
equivalents of HCl solution and frozen and lyophilized (freeze dried) to remove the any 
remaining TFA salt.  The remaining pure products 5 or 6 (Scheme 1) were stored as an 
HCl salt.  
 
Solvent controlled regioselective addition:  
Typically, ring opening of the N-protected aspartic anhydride yields two isomers, 
the β-carbonyl amide and the α-carbonyl amide (Figure 2).  We have observed in this 
series that nucleophillic addition by various aryl amines consistently and strongly favors 
substitution to the β-carbonyl group under dilute conditions in DMSO (0.01-0.025 M). 
The selectivity ranges between 85-95% β-addition depending upon the aryl amine 
employed.  However, when the addition is accomplished in non-polar or polar-aprotic 
solvents, such as ethyl-acetate or ethanol, it was observed that the α-addition is favored 
8:2, α:β or 80% alpha.  The selectivity is thought to occur by an existing H-bond between 
the carbamate NH and the α-carbonyl of the anhydride in nonpolar solvents.  This results 
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in a more electropositive α-carbon center that is more reactive towards a nucleophillic 
amine, thus favoring the α-addition.  Using DMSO or DMF as the solvent disrupts this H-
bond, and therefore nucleophillic substitution is most energetically favored at the β-
carbonyl [Yang 1986].   
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Figure 2:  Alpha and beta isomers produced from nucleophillic addition of an aryl amine 
(X) to N-tBoc-aspartic-anhydride.  
 
 
Biological Discussion & Conclusions: 
The activity of a select aspartyl aryl-amide analogs were screened by radiolabeled uptake 
competition in C17 neuroprogenitor cells or by electrophysiological recordings of 
substrate induced current inhibition in Xenopus lavies oocytes expressing transgenic 
ATA2, ASCT-2, SN1 or EAAT 1-3 transporters.  The objective here was to identify 
potential lead inhibitors of the excitatory amino acid transporters (EAATs, subtypes 1-5), 
or the neutral amino acid transporters ASCT-2, SN1, and ATA2 from the synthetic series 
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of β-aryl-aspartamides and α-arylamide-aspartates.  The estimated Ki of some of these 
compounds were calculated from a dose response (Figure 3 & 4) using non-linear 
regression to calculate an IC50 followed by Cheng-Prusoff [Cheng and Prusoff 1973] 
conversion which can then be entered into a table to compare activity between the amino 
acid transporters relative to endogenous substrate in Km (Table 1).  
 Cheng-Prusoff equation – 
 
 
 hATA2 mASCT2 rSN1 EAAT1 EAAT2 EAAT3 
Gln or Glu Km = 655 
µM 
Km = 55 
µM 
Km = 1884 
µM 
Km = 20 
µM 
Km = 20 
µM 
Km = 20 
µM 
CSE79 [β-9] Ki = 1780 
µM 
Ki = 373 
µM 
small effect Ki = 280 
µM 
Ki = 69 µM Ki = 13.3 
µM 
CSE84 [β-12] Ki = 2000 
µM 
Ki = 954 
µM 
small effect Ki = 65 µM Ki = 29 µM Ki = 8.6 µM 
CSE99 [β-13] Ki = 2900 
µM 
Ki = 2800 
µM 
small effect Ki = 48 µM Ki = 15 µM Ki = 4.1 µM 
CSE67 [β-15] n/e n/e n/e Ki = 0.19 
µM 
Ki = 3.5 µM Ki = 0.13 
µM 
CSE97 [α-11]    Ki = 11 µM Ki = 18 µM Ki = 6.0 µM 
CSE72 / 2-FAA 
[β-11] 
n/e n/e @ 10  
µM 
n/e 
 
Ki = 0.054 
µM 
Ki =0 .059 
µM 
Ki = 0.005 
µM 
MeAIB Km = 277 
µM 
n/e n/e n/e n/e n/e 
Table 1: Ki estimated using the Cheng- Prusoff conversion of the IC50 values obtained 
from screening CSE aspartamides across various amino acid transporters; n/e = no effect 
at 1 mM.  Where glutamine (Gln) or glutamate (Glu) represent endogenous substrates and 
MeAIB = methyl amino isobutyric acid, a selective system A inhibitor.  Brackets [] 
designate α or β carboxylic acid coupled to arylamide R.  
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Figure 3: Dose response curves showing fractional block of radiolabeled 
3
H-L-alanine 
uptake at ASCT-2 or fractional block of L-glutamine current at EAAT-3 by aryl-
aspartamides CSE79, CSE84, CSE99. 
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Figure 4:  CSE72 dose response (µM) showing percent block of a 3 µM L-Glu current: 
hEAAT1 (diamonds), hEAAT2 (squares), and hEAAT3 (circles) @ (-60 mV). 
 
 
Analysis of the estimated Ki for a particular aspartyl-aryl-amide across various 
transporters reveals potential lead inhibitors with limited selectivity.  Once completed, 
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this table will provide an improved perspective to evaluate the selectivity/activity of the 
aspartyl-aryl-amides at these transporters.  More importantly, the generated data will 
support a developing pharmacophore for each of these transporters to facilitate the 
discovery of more potent and selective next generation inhibitors.   The activity of these 
aspartyl-aryl-amides compounds across the numerous transporters may also provide a 
more clear understanding of their biological activity and mechanism of action.   For 
example, CSE79, CSE84, and CSE99 were all tested in a rat spinal nerve ligation model 
that measures paw withdrawal as an indication of pain mitigation (Figure 5).  In 
comparing the in vivo activity to the inhibitory activity between these three compounds 
screened across the 6 amino acid transporters, it would appear that the biological activity 
of these aryl-aspartamides may be acting through inhibition of the EAATs or ASCT2.  
Although unlikely, these compounds display a relatively low inhibitory activity towards 
ASCT2, it is possible that the observed response in rats treated is mediated in part or 
entirely by inhibition of ASCT2.  Therefore, a role for ASCT2 within this model for 
neuropathic pain cannot be completely ruled out.  
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Figure 5:  Various aryl-aspartamides CSE84, CSE79, CSE99 at 30 mg/kg or aryl-
glutamide CSE102 tested in rat spinal nerve ligation model over time course of 20 
minutes.  An increased paw withdrawal threshold indicates the rat is less sensitive to 
pain.  
 
 
Further examination of this withdrawal effect in rats when using an EAAT specific 
inhibitor, aryl-aspartamide CSE67 at 20 mg/kg, revealed that the observed biological 
activity may instead be primarily mediated through the EAATs, particularly EAAT-3 
(Figure 6).  This is indicated by the activity of CSE67 at 20 mg/kg in paw withdrawal 
threshold vs paw withdrawal threshold with CSE84 at 20 mg/kg.  These observations 
stress the necessity to fully characterize the activity of these aspartyl-aryl-amides at 
multiple amino acid transporters not only for pharmacologic design to produce novel 
inhibitors but also to determine a plausible mechanism of action.   
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Figure 6: CSE67 shows a greater effect than does CSE84 at 20 mg/kg measure by paw 
withdrawal threshold;  A. CSE67 at 20 mg/kg in rat spinal nerve ligation model;  B. 
CSE84 dose response in rat spinal nerve ligation model at 40, 30, 20, & 10 mg/kg. 
 
Ultimately the activity of this series of compounds can be placed into a table that 
will lead to the generation or development of a pharmacophore model for these 
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transporters of interest.  Currently there is already a developing pharmacophore of the 
EAATs subtypes 1-3.  There has also been much effort to design selective inhibitors of 
EAAT-3 [Esslinger et al. 2005; Mavencamp et al. 2008].  An efficient synthetic route to 
rapidly synthesize a large series or library of compounds to facilitate and explore 
hypothesis driven pharmacological design will be highly beneficial towards discovering 
selective inhibitors of EAAT-3.  The synthetic route we have developed here is quite 
capable to meet the demands for large screenings for activity and biological evaluation at 
these various glutamate / glutamine transporters. 
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Experimental section: 
Proton 
1
H and carbon 
13
C nuclear magnetic resonance (NMR) spectra were obtained from 
Varian VXR 400 MHz or Varian 500 MHz spectrometers as specified.  Both 
1
H and 
13
C 
spectra are reported in parts per million (ppm or δ) downfield from tetramethylsilane as 
an internal standard.  All chemical shifts reported were referenced to residual protonated 
DMSO solvent peaks at 2.5 ppm for 
1
H proton spectra or 39.5 ppm for 
13
C carbon spectra 
unless specified otherwise.  Multiplicity is reported as doublets (d), doublet of doublets 
(dd) etc. where Σ represents the sum of all couplings, b = broad.  Optical rotations of 
compounds dissolved in DMSO or methanol, as specified, with concentrations given in 
g/100 mL were determined via a Perkin-Elmer Model 241 polarimeter in a 1.0 dm glass 
cell sodium D line.  High resolution mass spectra (HRMS) were determined on a Waters 
LC-MS spectrometer using caffeine or trimethoprim as a mass standard at m/z 195.0882 
or 291.1457 respectively for HRMS.  All reagents were purchased from Acros Organics 
and used without further purification.  Solvents as well as 40-60 µM silica gel for flash 
chromatography were obtained from EMD chemicals (Gibbstown, NJ).  Intermediates 
were initially isolated by silica gel and used for the addition step without further 
purification.  A mobile phase consisting of 95% CH2Cl2 / 4% MeOH / 1% AcOH was 
used for TLC and flash chromatography.  All final products were isolated by multiple 
washes with dichloromethane and ethyl acetate to remove organic impurities.   
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 tBoc anhydride 1.2 eq.
50% Et3N / MeOH
+H3N
O
OH
O
OH
21
N
H
O
OH
O
OH
O
O
 
 
N-tBoc-aspartic-acid:  BRL:26 
L-Aspartic acid (13.492, 101.4 mmol) was added to a round bottom flask.  Cold (~4
◦
 C) 
triethylamine (21.20 mL, 1.5 eq.) and methanol (21 mL) were added followed by the 
slow addition of tBoc anhydride (26.58 g, 1.2 eq).  The reaction solution was then 
allowed to stir at rt (~23
◦
 C) for 24 h, where upon the reaction was determined to be 
complete by TLC.  The reaction solution was then placed on a rotovap to remove all 
remaining triethylamine and methanol.  Water (200 mL) was then added to the remaining 
residue and the pH was adjusted to ~2 via addition of H3PO4 (conc.).  The aqueous 
solution was then saturated with NaCl and extracted with 3 x 200 mL ethyl acetate 
portions.  The ethyl acetate portions were then combined and concentrated by rotovap.  
The remaining viscous oil was then chased with multiple portions of methylene chloride 
and concentrated leaving 21.529 g of a white solid, N-tBoc protected L-aspartate, an 
apparent 91.2% yield.  This material was then used in the next synthetic step without 
further purification. 
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1
H-NMR (400 MHz, d6-DMSO at 2.5 ppm) δ 7.02 (d, J = 9.1 Hz, 1H), 4.24 (ddd, J = 
22.0Σ, 7.3 Hz, 1H), 2.65 (dd, J = 21.4Σ, 16.2, 5.2 Hz, 1H), 2.50 (dd, J = 24.6Σ, 16.8, 7.8 
Hz, 1H), 1.36 (s, 9H).  
 
 
Acetic anhydride
2
N
H
O
OH
O
OH
O
O N
H
O
O
O 3
O
O
 
 
N-tBoc-aspartic-anhydride:  BRL:22  
N-tBoc protected L-aspartate (1.502 g, 6.44 mmol) was added to a round bottom flask 
followed by added of 15 mL acetic anhydride.   The mixture was allowed to stir at ~40
◦
 C 
overnight until N-tBoc-L-aspartate appeared to be completely dissolved.  The mixture 
was then concentrated by rotovap at 50
◦
 C.  Evaporation of the acetic anhydride took 2-3 
h where upon the remaining solid was chased 3-4 times with 20 mL of toluene and placed 
on rotovap to remove any remaining acetic anhydride from the solid anhydride product.  
The remaining solid was then chased three times with 20 mL of hexanes in a similar 
manner and removed by reduced pressure. The product N-tBoc-aspartic anhydride was 
then used immediately in the amine addition step without further purification. 
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DMSO H2N
HOOC
H
NO
O
O
O
N
H
O
O
O
2-amino-9-fluorenone
C22H22N2O6
Mol. Wt.: 410.42
O
O
 
 
N-tBoc-2-fluoren-9-one-aspartamide: BRL:22 
 The N-protected aspartate anhydride (1.386 g, 6.44 mmol) was stirred in DMSO (64 mL, 
to make the final 0.1 M) and to this 2-amino-9-fluorenone (1.132 g, .85 eq.-assuming 
85% yield from previous anhydride formation) was added.  The solution was allowed to 
stir for 48 h, when the reaction had reached completion (determined by absence of 2-
amino-2-fluoren-9-one by TLC), at ~ 45
◦
 C.  The product in DMSO was then diluted with 
CHCl3 (400 mL) and washed water, 6 x 250 mL aliquots (pH = 2, total 1.5 L) to remove 
any remaining DMSO.  Extracted products, observed by TLC, contained primarily the β-
amide addition product; N-tBoc protected 2-fluoren-9-one aspartamide, but also included 
small amounts of the α-amide addition product and starting material tBoc protected 
aspartate. The extracted products were then subsequently concentrated by rotovap to a 
dry solid and separated by silica gel (mobile phase = 95% CH2Cl2 / 4% MeOH / 1% 
acetic acid). The β addition product was then collected and concentrated by rotovap to 
afford N-tBoc-2-fluoren-9-one-aspartamide (1.460 g, 3.557 mmol, 65% yield), as a 
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yellow/orange powder, which was used in the next synthetic step without further 
purification. 
 
1
H-NMR (400 MHz, d6-DMSO at 2.5 ppm) δ 10.42 (s, 1H), 7.92 (s, 1H), 7.68 (m, 3H), 
7.56 (m, 2H), 7.30 (dd, J = 14.9Σ, 7.4 Hz, 1H), 7.01 (d, 7.1 Hz, 1H), 4.32 (ddd, J = 20.7Σ, 
6.9 Hz, 1H), 2.82 (dd, J =  21.4Σ, 15.5, 5.8 Hz, 1H), 2.64 (dd, J = 22.6Σ, 7.6 Hz, 1H),  
1.36 (s, 9H). 
 
 
H2N
COOH
H
NO
HN
HOOC
H
NO
O
O
HCl
O
O
1) TFA:CH2Cl2
2) 10mM HCl 1.2 eq.
CSE67
C17H15ClN2O4
Mol. Wt.: 346.76
 
2-Fluorenon-9-yl-L-aspartamide: CSE67 / BRL:23 
CH2Cl2 (1.5 mL) and trifluoroacetic-acid (TFA, 1.5 mL, 8.87 mmol, 17.8 eq) was added 
to a round bottom flask followed by N-tBoc protected aspartamide-2-fluoren-9-one 
(0.2044 g, 0.498 mmol) which dissolved immediately and turned a dark orange/brown 
color.  The solution was allowed to stir for 40 min, whereby it was observed that the 
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reaction had completed as determined by TLC.  The solution was then air dried with 
compressed air to remove the remaining TFA and CH2Cl2.  The remaining solid 
(deprotected product and TFA salt) was then mixed thoroughly with 1.1 equivalents of  
0.01 M HCl and sonicated.  The solution was then frozen to -80
◦
 C and placed on the 
lyophilizer to freeze dry and remove all the water and remaining TFA leaving a pure 
yellow/orange powder (0.163 g, 0.47 mmol, 96% yield).  The identity and purity of the 
final product was confirmed by 
1
H, 
13
C  NMR, HRMS & rotational analysis.   
 
1
H-NMR (400 MHz, d6-DMSO at 2.5 ppm) δ 10.79 (s, 1H), 8.43 (b, 2.5H), 7.98 (s, 1H), 
7.68 (m, 3H), 7.55 (m, 2H), 7.29 (dd, J = 14.9Σ, 7.4 Hz, 1H), 4.28 (dd, J = 10.4Σ, 5.2 Hz, 
1H), 3.05 (m, J = 46.0Σ, Hz, 2H); 
 
13
C-NMR (400 MHz, d6-DMSO at 39.5 ppm) δ 193.0, 170.3, 167.7, 144.1, 140.0, 138.7, 
135.5, 134.0, 133.4, 128.7, 124.8, 124.0, 121.7, 120.7, 114.8, 48.6, 36.0; 
 
CHN analysis for C17H15ClN2O4∙2H2O calc. C, 53.34; H, 5.00; N, 7.32; O, 25.08; Cl, 
9.26. Found:  C, 53.29; H, 4.23; N, 6.65; 
 
HRMS m/e calcd. For C17H15N2O4 = 311.1032, found 311.1016; 
 
[ α ]
22
D = + 12
◦
 (c = 0.23, DMSO) 
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DMSO
H
N
O
O
O
O
O
HN
HOOC
H
NO
O
O
2-amino-fluorene
N-tBoc-fluorenyl-L-aspartamide: BRL:24 
Protected aspartate anhydride (0.936 g, 4.35 mmol) was stirred in DMSO (87 mL, to 
make the concentration 0.05 M) and to this 2-aminofluorene (0.684 g, 0.85 eq.-assuming 
85% yield from previous anhydride formation) was added.  The solution was allowed to 
stir for 24 h, when the reaction had reached completion (as determined by the absence of 
2-amino-fluorene via TLC), at 60
◦
 C.  The product in DMSO was then diluted with 
CHCl3 (400 mL) and washed with water, 6 x 250 mL aliquots pH = 2, total of 1.5 L to 
remove DMSO.  Extracted products, observed by TLC, contained primarily the β-amide 
addition product; tBoc protected 2-fluorenyl-aspartamide, but also included small 
amounts of α-amide addition product and starting material tBoc protected aspartate. The 
extracted products were then subsequently concentrated by rotovap to a dry solid and a 
fraction of this dry solid was separated by silica gel (mobile phase = 95% CH2Cl2 / 4% 
MeOH / 1% acetic acid) The β addition product was then collected and concentrated by 
rotovap to afford N-tBoc-2-fluorenyl-aspartamide (0.697g, 1.758 mmol) as a 
white/brown or off-white powder, which was used without further purification. 
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1
H-NMR (400 MHz, d6-DMSO at 2.5 ppm) δ 10.15 (s, 1H), 7.93 (s, 1H), 7.78 (d, J = 8.4 
Hz, 2H), 7.52 (d, J = 7.1 Hz, 2H), 7.33 (dd, J = 14.9Σ, 7.44 Hz, 1H), 7.24 (dd, J = 14.9Σ, 
7.4 Hz, 1H), 7.03 (d, J = 8.4 Hz, 1H), 4.36 (ddd, J =  21.4Σ, 6.9 Hz, 1H), 2.82 (dd, J = 
20.7Σ, 15.2, 5.5 Hz, 1H), 2.86 (dd, J = 22.6Σ, 15.5, 7.1 Hz, 1H), 1.37 (s, 9H). 
 
 
H2N
COOH
H
NO
HN
HOOC
H
NO
O
O
HCl
1) TFA:CH2Cl2
2) 10mM HCl 1.2 eq.
CSE72
C17H17ClN2O3
Mol. Wt.: 332.78
 
 
 
2-Fluorenyl-L-aspartamide: CSE72 / BRL:25 
CH2Cl2 (4 mL) and trifluoroacetic-acid (TFA, 4 mL, 23.65 mmol, 13.45 eq) was added to 
a round bottom flask followed by N-tBoc protected β-fluorenyl-aspartamide (0.697 g, 
1.758 mmol) which dissolved immediately and turned a dark brown color.  The solution 
was allowed to stir for 30 min, whereby it was observed that the reaction had completed, 
determined by TLC.  The solution was then aspirated with compressed air (removes the 
excess TFA and CH2Cl2) and washed with 3 x 50 mL CH2Cl2 and again aspirated until 
dry.  The remaining residue (product and TFA salt) was then suspended in 0.01M HCl 
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(193 mL water, 1.1 eq. HCl) and sonicated.  The solution was then frozen to -80
◦
 C and 
placed on the lyophilizer to freeze dry / remove all the water and remaining TFA leaving 
an off-white residue (0.555 g, 1.67 mmol, 95% yield).  The identity and purity of the final 
product was confirmed by 
1
H, 
13
C NMR, and HRMS.  Specific rotation was also 
calculated. 
 
1
H-NMR (400 MHz, d6-DMSO at 2.5 ppm) δ 10.65 (s, 1H), 8.47 (s, 3 H), 7.95 (s, 1H), 
7.805 (d, J = 3.9 Hz, 1H), 7.78 (d, J = 2.6 Hz, 1H), 7.59 (d, J = 8.4 Hz, 1H), 7.52 (d, J = 
7.8 Hz, 1H), 7.33 (dd, J = 14.2Σ, 7.1 Hz, 1H), 7.24 (dd, J = 14.9Σ, 7.4 Hz, 1H), 4.24 (dd, J 
= 10.4Σ, 5.2 Hz, 1H), 3.87 (s, 2H), 3.12 (dd, J = 22.0Σ, 17.2, 4.9 Hz, 1H), 3.05 ( dd, J = 
22.7Σ, 17.2, 5.5 Hz, 1H); 
 
13
C-NMR (400 MHz, d6-DMSO at 39.5 ppm) δ 170.3, 167.4, 143.7, 142.8, 141.0, 137.9, 
136.5, 126.8, 126.2, 125.0, 120.2, 119.6, 118.0, 116.1, 48.8, 36.5, 36.0; 
 
CHN analysis for C17H19ClN2O3∙H2O calc. C, 58.21; H, 5.46; N, 7.99; O, 18.24; Cl, 
10.11 Found:  C, 59.34; H, 5.02; N, 7.78; 
 
HRMS m/e calcd. For C17H17N2O3 = 297.1239, found 297.1227; 
 
[ α ]
22
D = + 20
◦
 (c = 0.28, DMSO) 
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2-Aminobiphenyl
 
N-tBoc-2-biphenyl-aspartamide: BRL:27 
Protected aspartate anhydride (1.41 g, 6.55 mmol) was stirred in DMSO (131 mL, to 
make the concentration 0.05 M) and to this 2-amino-biphenyl (0.9625 g, 0.85 eq.-
assuming 85% yield from previous anhydride formation) was added.  The solution was 
allowed to stir for 24 hours, when the reaction had reached completion (determined by 
absence of 2-amino-biphenyl by TLC), at ~ 40
◦
 C.  The product in DMSO was then 
diluted with CHCl3 (400 mL) and washed with 6 x 250 mL aliquots of pH 2 brine 
(adjusted 2M HCl) to remove DMSO.  Extracted products, observed by TLC, contained 
primarily the β-amide addition product; N-tBoc protected aspartamide-biphenyl, but also 
included small amounts of α-amide product and starting material protected aspartate. The 
extracted products were then subsequently concentrated by rotovap to a dry solid and a 
fraction of this dry solid was separated by silica gel (mobile phase = 94% CH2Cl2 / 5% 
MeOH / 1% acetic acid (Rf = 0.2)). The β addition product was then collected and 
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concentrated by rotovap to afford N-tBoc-2-biphenyl-aspartamide (0.460 g, 1.197 mmol), 
as a light brown residue and used without further purification.  
 
1
H-NMR (400 MHz, d6-DMSO at 2.5 ppm) δ 9.3 (s, 1H), 7.53 (d, 1H), 7.25-7.45 (m, 
8H), 6.90 (d, J = 8.4 Hz, 1H), 4.30 (dd, J = 20.7Σ, 6.9 Hz, 1H), 2.65 (dd, J = 20.1Σ, 14.9, 
5.2 Hz, 1H), 2.51 (m, 1H overlap with solvent), 1.39 (s, 9H). 
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H2N
COOH
H
NO
HCl
HN
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H
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O
O
CSE76
1) TFA:CH2Cl2
2) 10mM  HCl 1.2 eq.
C16H17ClN2O3
Mol. Wt.: 320.77  
 
2-Biphenyl-L-aspartamide: BRL:28 
CH2Cl2 (3 mL) and trifluoroacetic-acid (TFA, 3 mL, 17.74 mmol, 14.83 eq) was added to 
a round bottom flask followed by N-tBoc protected aspartamide-biphenyl (0.460 g, 1.197 
mmol) which dissolved immediately and turned a darker almost brown color.  The 
solution was allowed to stir for 40 min. whereby it was observed that the reaction had 
completed as determined by TLC.  The solution was then air dried with compressed air to 
remove the remaining TFA and CH2Cl2.  The remaining solid (deprotected product and 
TFA salt) was then mixed thoroughly with 0.01M HCl (131 mL water, 1.1 eq. HCl) and 
sonicated.  The solution was then frozen to -80
◦
 C and placed on the lyophilizer to freeze 
dry / remove all the water and remaining TFA leaving a pure light-brown powder (0.36 g, 
1.12 mmol, 94% yield).  The identity and purity of the final product was confirmed by 
1
H, 
13
C  NMR, HRMS & rotational analysis.   
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1
H-NMR (400 MHz, d6-DMSO at 2.5 ppm) δ 9.67 (s, 1H), 8.46 (s, 2.5H), 7.27-7.50 (m, 
9H), 4.18 (dd, J = undetectable, 1H), 2.92 (dd, J = 22.0Σ, 16.8, 5.2 Hz, 1H), 2.83 (dd, J = 
22.6Σ, 16.8, 5.8 Hz, 1H); 
 
13
C-NMR (400 MHz, d6-DMSO at 39.5 ppm) δ 170.3, 168.1, 138.6, 136.4, 134.1, 130.4, 
128.9, 128.5, 127.7, 127.4, 126.4, 48.7, 35.0;  
 
CHN analysis for C16H20ClN2O3∙1.25*H2O calc. C, 55.74; H, 5.75; N, 8.12; O, 20.11; Cl, 
10.28. Found:  C, 55.76; H, 4.77; N, 7.45; 
 
HRMS m/e calcd. For C16H17N2O3 = 285.1239, found 285.1263; 
 
[ α ]
 22
D = + 20
◦
 (c = 0.31, DMSO) 
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N-tBoc-phenyl-aspartamide:  BRL:29 
Protected aspartate anhydride (1.29 g, 5.99 mmol) was stirred in DMSO (120 mL, to 
make the concentration 0.05 M) and to this aniline (0.464 mL, 5.08 mmol, 0.85 eq.-
assuming 85% yield from previous anhydride formation) was added.  The solution was 
allowed to stir for 24 hours, when the reaction had reached completion (determined by 
absence of aniline by TLC), at ~ 45
◦
 C.  The product in DMSO was then diluted with 
CHCl3 (400 mL) and washed with 6 x 250 mL aliquots pH = 2 brine (adjusted by 2M 
HCl) to take up the DMSO.  Extracted products, observed by TLC, contained primarily 
the β-amide addition product; N-tBoc protected-phenyl-L-asparagine, but also included 
small amounts of α-amide addition product and starting material N-tBoc protected 
aspartate. The extracted products were then subsequently concentrated by rotovap to a 
dry solid and a fraction of this dry solid was separated by silica gel (mobile phase = 94% 
CH2Cl2 / 5% MeOH / 1% acetic acid). The β addition product was then collected and 
concentrated by rotovap to afford N-tBoc-phenyl-aspartamide (0.249g, 0.808 mmol) as a 
white residue, which was used in the next synthetic step without further purification. 
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1
H-NMR (400 MHz, d6-DMSO at 2.5 ppm) δ 9.96 (s, 1H), 7.57 (d, J = 7.8 Hz, 2H), 7.27 
(dd, J = 15.5Σ, 7.8 Hz, 2H), 7.00-7.07 (m, 2H), 4.35 (dd, J =  21.7Σ, 6.9 Hz, 1H), 2.79 (dd, 
J = 20.7Σ, 15.2, 5.5 Hz, 1H), 2.64 (dd, J = 23.3Σ, 15.5, 7.8 Hz, 1H), 1.36 (s, 9H). 
 
 
 
 
H2N
COOH
H
NO
HCl
HN
HOOC
H
NO
O
O
CSE77
1) TFA:CH2Cl2
2) 10mM  HCl 1.2 eq.
C10H13ClN2O3
Mol. Wt.: 244.67  
 
Phenyl-L-aspartamide: CSE77 / BRL:30 
CH2Cl2 (1.5 mL) and trifluoroacetic-acid (TFA, 1.5 mL, 8.87 mmol, 10.98 eq) were 
added to a round bottom flask followed by N-tBoc protected aspartamide-phenyl (0.249 
g, 0.808 mmol) which dissolved immediately and turned a darker yellow color.  The 
solution was allowed to stir for 45 min, whereby it was observed that the reaction had 
completed as determined by TLC.  The solution was then air dried with compressed air to 
remove the remaining TFA and CH2Cl2.  The remaining solid (deprotected product and 
TFA salt) was then mixed thoroughly with 0.01M HCl (89 mL water, 1.1 eq. HCl) and 
sonicated.  The solution was then frozen to -80
◦
 C and placed on the lyophilizer to freeze 
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dry / remove all the water and remaining TFA leaving a white powder (0.156 g, 0.638 
mmol, 80% yield).  The identity and purity of the final product was confirmed by 
1
H, 
13
C 
NMR, HRMS & rotational analysis.   
1
H-NMR (400 MHz, d6-DMSO at 2.5 ppm) δ 10.58 (s, 1H), 8.34 (s, 3H), 7.62 (d, J = 7.8 
Hz, 2H), 7.27 (dd, J = 15.5Σ, 7.8 Hz, 2H), 7.02 (dd, J = 14.2Σ, 7.1 Hz, 1H), 4.09 (app s, 
1H), 3.08 (d, J = 14.2 Hz, 1H), 2.96 (dd, J = 20.1Σ, 16.2, 3.9 Hz, 1H); 
 
13
C-NMR (400 MHz, d6-DMSO at 39.5 ppm) δ 170.4, 167.8, 139.0, 128.7, 123.3, 119.2, 
49.1, 36.2; 
 
CHN analysis for C10H13ClN2O3 calc. C, 49.09; H, 5.36; N, 11.50; O, 19.70; Cl, 14.55 
 Found:  C, 50.39; H, 5.26; N, 11.41; 
 
HRMS m/e calcd. For C10H13N2O3 = 209.0926, found 209.0923; 
 
[ α ]
22
D = + 22
◦
 (c = 0.23, DMSO) 
 
 
 51 
DMSO
H
N
O
O
O
O
O
HN
HOOC O
HN
O
O
O
2-Amino-9-fluorenone
 
N-tBoc-2-fluoren-9-one-α-amide-aspartate:  BRL:22 
Protected aspartate anhydride (1.379 g, 6.41 mmol) was stirred in DMSO (64 mL, to 
make the final 0.1 M) and to this 2-amino-9-fluorenone (1.132 g, 0.85 eq.-assuming 85% 
yield from previous anhydride formation) was added.  The solution was allowed to stir 
for 48 hours, when the reaction had reached completion (determined by absence of 2-
amino-9-fluorenone by TLC), at ~ 45
◦
 C.  The product in DMSO was then diluted with 
CHCl3 (400 mL) and washed with 6 x 250 mL aliquots of pH 2 brine (adjusted by 2M 
HCl) to remove DMSO.  Extracted products, observed by TLC, contained primarily the 
β-amide addition product; N-tBoc protected aspartamide-9-fluorenone, but also included 
small amounts of α-amide addition product and starting material, N-tBoc protected 
aspartate. The extracted products were then subsequently concentrated by rotovap to a 
dry solid and separated by silica gel (mobile phase = 94% CH2Cl2 / 5% MeOH / 1% 
acetic acid). The α addition bi-product was collected from several columns (from 3 
reaction preparations), combined and then concentrated by rotovap to afford N-tBoc-
fluoren-9-one-α-amide-aspartate ( 0.260 g, 3.56 mmol) as an orange foam which was 
used in the next synthetic step without further purification.   
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1
H-NMR (400 MHz, d6-DMSO at 2.5 ppm) δ 10.33 (s, 1H), 7.96 (s, 1H), 7.69 (m, 3H), 
7.56 (m, 2H), 7.30 (dd, J = 14.9Σ, 7.4 Hz, 1H), 7.25 (d, 7.8 Hz, 1H), 4.43 (dd, J = 20.1Σ, 
6.9 Hz, 1H), 2.72 (dd, J =  22.0Σ, 16.5, 5.5 Hz, 1H), 2.58 (dd, J = 24.6Σ, 8.2 Hz, 1H),  
1.39 (s, 9H). 
 
 
 
H2N
HOOC O
HN
O
HN
HOOC O
HN
O
O
O
HCl
1) TFA:CH2Cl2
2) 10mM  HCl 1.2 eq.
CSE78
C17H15ClN2O4
Mol. Wt.: 346.76
 
2-Fluoren-9-one-α-amide-aspartate:  CSE78 / BRL:31 
CH2Cl2 (1.5 mL) and trifluoroacetic-acid (TFA, 1.5 mL, 8.87 mmol, 14.0 eq) was added 
to a round bottom flask containing N-tBoc protected 9-fluorenone-aspartamide (0.260 g, 
0.633 mmol) which dissolved immediately and turned a dark orange/brown color.  The 
solution was allowed to stir for 40 min, whereby it was observed that the reaction had 
completed as determined by TLC.  The solution was then air dried with compressed air to 
remove the remaining TFA and CH2Cl2.  The remaining solid (deprotected product and 
TFA salt) was then mixed thoroughly with 0.01M HCl (60 mL water, 1.1 eq. HCl) and 
sonicated.  The solution was then frozen to -80
◦
 C and placed on the lyophilizer to freeze 
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dry and remove all the water and remaining TFA leaving an orange powder (0.199 g, 
0.574 mmol, 91% yield).  The identity and purity of the final product was confirmed by 
1
H, 
13
C NMR, HRMS & rotational analysis.   
 
1
H-NMR (400 MHz, d6-DMSO at 2.5 ppm) δ 11.28 (s, 1H), 8.56 (s, 3H), 7.96 (s, 1H), 
7.67-7.77 (m, 3H), 7.55 (m, 2H), 7.29 (dd, J = 14.9Σ, 7.44 Hz, 1H), 4.31 (s, 1H), 3.01 (m, 
J = 47.8 Hz, 2H); 
 
13
C-NMR (400 MHz, d6-DMSO at 39.5 ppm) δ 192.9, 170.8, 166.6, 144.0, 139.5, 139.2, 
135.6, 134.1, 133.4, 128.9, 125.2, 124.0, 121.8, 120.8, 115.0, 49.8, 35.2; 
 
CHN analysis for C17H16ClN2O4∙H2O calc. C, 56.13; H, 4.43; N, 7.70; O, 21.99; Cl, 9.75 
 Found:  C, 56.67; H, 4.23; N, 7.14; 
 
HRMS m/e calcd. For C17H15N2O4 = 311.1032, found 311.1011; 
 
[ α ]
22
D = + 9
◦
 (c = 0.27, DMSO) 
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N-tBoc-2,3-dicholoro-phenyl-aspartamide: BRL:32 
Protected aspartate anhydride (1.61 g, 7.48 mmol) was stirred in DMSO (150 mL, to 
make the concentration 0.05 M) and to this 2-3-dichloroaniline (1.04 g, 6.42 mmol, 0.85 
eq.-assuming 85% yield from previous anhydride formation) was added.  The solution 
was allowed to stir at 55
◦
 C for 58 h until it was observed that the reaction had completed 
(determined TLC).  The product in DMSO was then diluted with CHCl3 (400 mL) and 
washed with 6 x 250 mL aliquots of pH = 2 brine (adjusted by 2M HCl) to remove the 
DMSO.  Extracted products, observed by TLC, contained primarily the β-amide addition 
product; N-tBoc-protected-2-3-dichlorophenyl-L-aspartamide, but also included a 
significant quantity of α-amide addition product and starting material N-tBoc protected 
aspartate, approx. 20% each. The extracted products were then subsequently concentrated 
by rotovap to a dry solid and separated by silica gel (mobile phase = 94% CH2Cl2 / 5% 
MeOH / 1% acetic acid). The β addition product (Rf = 0.2) was collected and 
concentrated by rotovap to afford N-tBoc-2-3-dichloro-phenyl-aspartamide- (0.486g, 
1.29 mmol, 17 % yield) as a yellow/white residue and used in the next synthetic step 
without further purification. 
 55 
 
1
H-NMR (500 MHz, d6-DMSO at 2.5 ppm) δ 9.72 (s, 1H), 7.68 (d, J = 7.83z, 1H), 7.42 
(d, J = 8.1Hz, 1H), 7.32 (dd, J = 16.1Σ, 8.1 Hz, 1H), 7.06 (d, J = 7.8 Hz, 1H), 4.34 (d, J = 
5.6 Hz, 1H), 2.85 (dd, J = 16.6Σ, 13.7, 10.8 Hz, 1Ha), 2.72 (dd, J = 22.0Σ, 14.2, 6.8 Hz, 
1Hb), 1.35 (s, 9H); 
 
13
C-NMR (500 MHz, d6-DMSO at 39.5 ppm) δ 173.5, 169.3, 155.6, 137.3, 132.2, 128.36, 
127.0, 125.2, 124.9, 78.6, 50.7, 38.3, 28.6. 
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1) TFA:CH2Cl2
2) 10mM  HCl 1.2 eq.
C10H11Cl3N2O3
Mol. Wt.: 313.56  
 
2,3-Dicholoro-phenyl-aspartamide: CSE79 / BRL:33 
CH2Cl2 (3 mL) and trifluoroacetic-acid (TFA, 3 mL, 17.74 mmol, 13.75 eq) were added 
to a round bottom flask followed by N-tBoc protected aspartamide-phenyl (0.486 g, 1.29 
mmol) which dissolved immediately and turned a dark yellow/brown color.  The solution 
was allowed to stir for 60 min, whereby it was observed that the reaction had completed 
as determined by TLC.  The solution was then air dried with compressed air to remove 
the remaining TFA and CH2Cl2 and washed 3 x 30 mL CH2Cl2. The remaining residue 
(deprotected product and TFA salt) was then mixed thoroughly with 0.01M HCl (141 mL 
water, 1.1 eq. HCl) and sonicated.  The solution was then frozen to -80
◦
 C and placed on 
the lyophilizer to freeze dry / remove all the water and remaining TFA leaving an off 
white powder (0.3127 g, 0.997 mmol, 77% yield).  The identity and purity of the final 
product was confirmed by 
1
H, 
13
C  NMR, HRMS & rotational analysis.   
 
1
H-NMR (500 MHz, d6-DMSO at 2.5 ppm) δ 10.10 (s, 1H), 8.26 (s, 2.5H), 7.66 (d, J = 
8.1Hz, 1H), 7.46 (d, J = 7.8 Hz, 1H), 7.35 (dd, J = 16.1Σ, 8.1 Hz, 1H), 4.23 (dd, J = 10.3Σ, 
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5.1 Hz, 1H), 3.07 (dd, J = 21.5Σ, 17.5, 13.0 Hz, 1H), 3.00 (dd, J = 22.8Σ, 16.6, 11.7 Hz, 
1H); 
 
13
C-NMR (500 MHz, d6-DMSO at 39.5 ppm) δ 170.6, 168.8, 137.1, 132.3, 128.3, 127.21, 
125.6, 125.3, 49.5, 36.4; 
 
HRMS m/e calcd. For C10H11N2O3Cl2 = 277.0147, found 277.0153; 
 
[ α ]
22
D = + 20
◦
 (c = 0.26, DMSO) 
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fluorene
N-tBoc-2-fluorenyl-7-nitro-aspartamide: BRL:75 
N-tBoc protected aspartate anhydride (0.923 g, 4.29 mmol) was stirred in DMSO (~44 
mL, to make 0.1 M final conc.).  To this was added 0.824mg of 2-amino-7-nitro-fluorene 
(0.85 eq, 3.64mmol) synthesized from 2-nitrofluorene (Saroja G., et al. 2004).  The 
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solution was allowed to stir for 24 h at 40
◦
 C in which the reaction had reached 
completion (determined by absence of 2-amino-7-nitro-fluorene on TLC).  The product in 
DMSO was then diluted with 100 mL water (pH adjusted to ~2, by phosphoric acid) and 
extracted with CHCl3 (3 x 400 mL).  The separated organic solutions were combined and 
then washed with brine adjusted to pH = 2 by addition of conc. H3PO4 (6 x 250 mL 
aliquots) to remove the DMSO.  Extracted products, observed by TLC, contained 
primarily the β amide addition product; N-tBoc protected aspartamide-7-nitro-fluorene, 
but also included small amounts of α amide addition product. The extracted products, in 
chloroform, were then subsequently concentrated by rotovap to a dry solid and separated 
by silica gel (mobile phase = 95% CH2Cl2 / 4% MeOH / 1% acetic acid).  The β addition 
product (Rf = 0.25) was collected from several combined fractions and then concentrated 
by rotovap to afford N-tBoc-7-nitrofluorne-aspartamide (0.260 g, 3.556 mmol) as a 
yellow/orange residue, which was used in the next synthetic step without further 
purification. 
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CSE89
C17H16ClN3O5
Mol. Wt.: 377.78
 
2-Fluorenyl-7-nitro-L-aspartamide: BRL:76 
CH2Cl2 (3 mL) and trifluoroacetic-acid (TFA, 3 mL) 1:1 solution was added to a round 
bottom flask containing N-tBoc protected 7-nitro-2-fluorenyl-aspartamide (0.463 g, 1.05 
mmol) which dissolved immediately and turned a yellow/orange color in solution.  The 
solution was allowed to stir for 1 h where it was observed that the reaction had completed 
as determined by TLC.  The solution was then air dried with compressed air to remove 
the remaining TFA and CH2Cl2.  The residue was washed with 3 x 30 ml CH2Cl2 and 
aspirated until dry.  The remaining solid (deprotected product and TFA salt) was then 
mixed thoroughly with 0.01M HCl (115 mL water, 1.1 eq. HCl) and sonicated.  The 
solution was then frozen to -80
◦
 C and placed on the lyophilizer to freeze dry / remove all 
the water and remaining TFA leaving an orange colored residue (0.372 g, 0.984 mmol, 
94% yield).  The purity and identity of the final product was confirmed by 
1
H, 
13
C NMR, 
HRMS, and rotational analysis. 
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1
H-NMR (400 MHz, d6-DMSO at 2.5 ppm) δ 10.63 (s, 1H), 8.39 (s, 1H), 8.27 (d, J= 7.8 
Hz, 1H), 8.05 (S, 1H), 8.03 (d, J= 3.2 Hz, 1H), 8.00 (d, J = 2.6 Hz, 1H), 7.63  (d, J = 8.4 
Hz, 1H), 4.21 (dd, J = 9.0Σ, 4.5 Hz, 1H), 4.05 (s, 2H), 3.07 (dd, J = 21.4Σ, 17.5, 5.2 Hz, 
1H), 2.97 ( dd, J = 22.6Σ, 17.5, 5.2 Hz, 1H); 
 
13
C-NMR (400 MHz, d6-DMSO at 39.5 ppm) δ 170.3, 167.7, 147.7, 146.2, 145.7, 144.07, 
139.7, 134.3, 123.1, 122.3, 120.3, 119.9, 118.4, 115.6, 48.8, 36.8, 36.2; 
 
HRMS m/e calcd. For C17H16N3O5 = 342.1090, found 342.1099; 
 
[ α ]
22
D = +4.5
◦
 (c = 0.067, methanol, Na
+
 D lamp) 
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C21H23N3O5
Mol. Wt.: 397.42
N-tBoc-2-carbazole-α-amide-L-aspartate: BRL: 102 
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Protected aspartate anhydride (0.978 g, 4.55 mmol) dissolved in 90 mL DMSO.  To this 
was added 0.710 g of 2-amino-carbazole (0.855 eq, 3.90 mmol) synthesized from 
carbazole (KyzioL J.B., LyżnIak A. 1980).  The solution was allowed to stir for 24 h at 
60
◦
 C in which the reaction had reached completion (determined by absence of 2-amino-
carbazole on TLC).  The product in DMSO was then diluted with 100 mL water and pH 
adjusted to ~2 by addition of phosphoric acid. The aqueous solution was extracted with 
CHCl3 (400 mL x 3 times).  The CHCl3 washes were combined and then washed with 
brine adjusted to pH = 2 by addition of H3PO4 conc. in 6 x 250 mL aliquots to remove the 
DMSO. The CHCl3 layer was then concentrated to an off light-brown residue by reduced 
pressure.  TLC revealed the crude residue to be primarily the β-amide addition product 
N-tBoc protected 2-carbazole-β-aspartamide, but also includes a small amount of α-
amide addition product. The crude products were then subsequently separated by silica 
gel (mobile phase = 95% CH2Cl2 / 4% MeOH / 1% acetic acid).  The α addition product 
(Rf = 0.3) was collected from several fractions, combined and then concentrated by 
rotovap to afford N-tBoc-2-carbazole-α-aspartamide (0.106 g, 0.267 mmol)(note: not all 
was isolated) as an off white residue, which was used in the next synthetic step without 
further purification. 
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2-Carbazole-α-amide-L-aspartate: BRL: 104 
2 mL of a 1:1 CH2Cl2 and trifluoroacetic-acid solution added to a round bottom 
containing 30.0 mg of N-tBoc-2-carbazole-α-amide-aspartate.  The residue dissolves 
immediately making a dark brown solution and was allowed to stir for 1 h.  The solution 
was aspirated with compressed air until only a dry residue remained.  The light brown 
residue was then washed 3 x 25 mL CH2Cl2 and dried again.  The residue was then 
resuspended by addition of 3 mL 0.01M HCl (1.2 eq.) and brief sonication.  The mixture 
was then frozen to -80
◦
 C and lyophilized until dry leaving 20.0 mg of pure 2-carbazole-
α-amide-L-aspartate an 88% yield. The identity of the final product was confirmed by 
1
H, 
13
C NMR, HRMS and analyzed by rotational analysis. 
 
1
H-NMR (400 MHz, d6-DMSO at 2.5 ppm) ppm 11.32 (s, 1H), 10.83 (s, 1H), 8.48 (s, 
3H), 8.04 (d, J = 1.9 Hz, 1H), 8.02 (s, 1H), 7.99 (s, 1H), 7.43  (d, J = 7.8 Hz, 1H), 7.28-
7.35 (m, 2H), 7.12 (dd, J = 14.9Σ, 7.8, 7.1 Hz, 1H), 4.31(s, 1H), 3.03 (dd, J = 22.0Σ, 16.8, 
5.2 Hz, 1H), 2.92 ( dd, J = 24.6Σ, 17.5, 7.1 Hz, 1H); 
 
 63 
13
C-NMR (400 MHz, d6-DMSO at 39.5 ppm) ppm 170.9, 166.0, 140.0, 140.0, 136.1, 
125.2, 122.3, 120.4, 119.8, 118.9, 118.7, 111.3, 110.8, 101.7, 49.9, 35.4; 
 
HRMS m/e calcd. For C16H16N3O3 = 298.1192, found 298.1207; 
 
[ α ]
22
D = +19
◦
 (c = 0.10, methanol, Na
+
 D lamp) 
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N-tBoc-2-carbazole-L-aspartamide: BRL: 102 
Protected aspartate anhydride (0.978 g, 4.55 mmol) dissolved in 90 mL DMSO.  To this 
was added 0.710 g of 2-amino-carbazole (0.855 eq, 3.90 mmol) synthesized from 
carbazole (KyzioL J.B., LyżnIak A. 1980).  The solution was allowed to stir for 24 h at 
60
◦
 C.  The reaction had reached completion (determined by absence of 2-amino-
carbazole on TLC).  The product in DMSO was then diluted with 100 mL water and pH 
adjusted to ~2 by addition of phosphoric acid. The aqueous solution was extracted with 
CHCl3 (400 mL x 3 times).  The CHCl3 washes were combined and then rinsed with 
brine adjusted to pH = 2 by addition of conc. H3PO4 in 6 x 250 mL aliquots to remove the 
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DMSO.  The CHCl3 layer was then concentrated to an off light-brown residue by reduced 
pressure.  TLC revealed the crude residue to be primarily the β-amide addition product 
N-tBoc protected 2-carbazole-β-aspartamide, but also includes a small amount of α-
amide addition product. The crude products were then subsequently separated by silica 
gel column (mobile phase = 95% CH2Cl2 / 4% MeOH / 1% acetic acid).  The β addition 
product (Rf = 0.2) was collected from several fractions, combined and then concentrated 
by rotovap to afford N-tBoc-2-carbazole-β-aspartamide (0.300 g, 0.755 mmol) (note: 
only a portion was isolated) as an off light brown residue, which was used for the next 
synthetic step without further purification. 
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1) TFA:CH2Cl2
2) 10mM HCl 1.2 eq.
C16H16ClN3O3
Mol. Wt.: 333.77
 
2-Carbazole-L-aspartamide: BRL: 103 
To a round bottom flask containing 28.0 mg of N-tBoc protected 2-carbazole-β-
aspartamide (0.0705 mmol) was added 2 mL of a 1:1 CH2Cl2 and TFA solution.  The 
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protected aspartamide dissolved immediately creating a vibrant green colored solution 
which was allowed to stir for 1 hour.  The solution was then aspirated with compressed 
air until only a residue remained.  The residue was then washed 3 x 20 mL of CH2Cl2 and  
resuspended in 3 mL of a 0.01 M HCl (1.2 eq) and briefly sonicated to dissolve.  This 
mixture was then frozen to -80
◦
 C and lyophilized until dry leaving 20.0 mg of 2-
carbazole-β-aspartamide (.0600 mmol) at 85% yield a light brown residue. The final 
product was analyzed by 
1
H, 
13
C NMR, HRMS and rotational analysis to confirm identity 
and purity. 
 
1
H-NMR (400 MHz, d6-DMSO at 2.5 ppm) ) δ 11.30 (s, 1H), 10.55 (s, 1H), 8.44 (s, 
2.5H), 7.98-8.01(m, 3H), 7.42 (d, J = 8.4 Hz, 1H), 7.24-7.35 (m, 2H), 7.11  (dd, J = 14.9Σ, 
7.8, 7.1 Hz, 1H), 4.26(s, 1H), 3.13 (dd, J = 22.0Σ, 17.5, 16.8, 5.2 Hz, 1H), 3.04 ( dd, J = 
22.6Σ, 17.5,16.8, 5.8 Hz, 1H); 
 
13
C-NMR (400 MHz, d6-DMSO at 39.5 ppm) δ 170.3, 167.1, 140.1, 140.0, 136.8, 124.8, 
122.4, 120.3, 119.6, 118.6, 118.4, 111.1, 110.7, 101.4, 48.7, 35.9;  
 
HRMS m/e calcd. for C16H16N3O3 = 298.1192,  found 298.1180; 
 
[ α ]
22
D =  -3
◦
 (c = 1.27, methanol, Na
+
 D Lamp) 
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N-tBoc-α-naphthyl-aspartamide: BRL: 228 
Protected aspartate anhydride (1.98 g, 9.2 mmol) was dissolved in DMSO (80 mL).  To 
this was added α-naphthylamine (2.37 g, 0.9 eq., 88% aryl amine).  The solution was 
allowed to stir for 48 hours at ~40
◦
 C or until the reaction had completed (determined by 
TLC in the absence of alpha-naphthylamine with mobile phase 95% CH2Cl2 / 4% MeOH 
/ 1% acetic acid).  The solution was then diluted with CHCl3 (450 mL) and washed with 
brine adjusted to pH = 2 by addition of H3PO4 conc. (4 x 200 mL aliquots) to remove the 
DMSO.  The organic phase was then concentrated, leaving a dark red/purple residue.  
The product were then isolated by silica gel (mobile phase = 95% CH2Cl2 / 4% MeOH / 
1% acetic acid).  The α addition bi-product was collected at Rf = 0.3, concentrated and 
stored.   The β addition product was isolated at Rf = 0.2, concentrated by rotovap to a 
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white (slight purple) residue (1.90 g. recovered, 5.31 mmol) and used in the next 
synthetic step without further purification. 
 
1
H-NMR (500 MHz, d6-DMSO at 2.5 ppm) δ 12.68 (s, 1H), 9.93 (s, 1H), 8.09 (d, J = 9.0 
Hz, 1H), 7.92 (dd, J = 8.8 Σ, 5.4 Hz, 1H), 7.74 (d, J = 8.1 Hz, 1H), 7.64 (d, J = 7.3 Hz, 
1H), 7.52 (dd, J = 7.6Σ, 3.9, 3.7 Hz, 2H), 7.47 (dd, J = 15.6 Σ, 7.8 Hz, 1H), 7.16 (d, J= 8.3 
Hz, 1H), 4.42 (dd, 21.3Σ, 13.7, 6.1 Hz, 2H), 2.95 (dd, J = 20.3Σ, 14.9, 9.5 Hz, 1H), 2.84 ( 
dd, J = 23.0Σ, 14.9, 6.8 Hz, 1H), 1.39 (s, 9H) 
 
13
C-NMR (500 MHz, d6-DMSO at 39.5 ppm) δ 173.8, 169.4, 155.7, 128.5, 128.2, 126.45, 
126.1, 126.0, 125.7, 123.4, 122.1, 78.6, 50.9, 38.3, 28.6 
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1) TFA:CH2Cl2
2) 10mM HCl 1.2 eq.
C14H15ClN2O3
Mol. Wt.: 294.73  
1-Naphthyl-aspartamide: BRL: 229 
CH2Cl2 (4 mL) and trifluoroacetic-acid (TFA, 4 mL) solution 1:1 were added to a round 
bottom flask containing N-tBoc-β-naphthyl-aspartamide (1.14 g, 3.18 mmol) which 
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dissolved immediately and turned a dark red/purple color.  The solution was allowed to 
stir for at additional 45 min. at rt (~22
◦
 C) whereby it was observed that the reaction had 
completed as determined by TLC (mobile phase 90% CH2Cl2 / 9% MeOH / 1% AcOH; 
Rf = 0.01).  The solution was then aspirated until dry by compressed air to remove TFA 
and CH2Cl2.  The remaining solid (deprotected product and TFA salt) was washed with 3 
x 80mL CH2Cl2 and then mixed with 193 mL  0.01M HCl (1.1 eq.) followed by light 
sonication to suspend the solid residue.  The solution was then frozen to -80
◦
 C and 
placed on the lyophilizer to freeze dry / remove all the water and remaining TFA leaving 
a slight purple/white powder (1-naphthyl-aspartamide 0.870 g, 2.95 mmol, 93% yield).  
The final product was analyzed by 
1
H, 
13
C NMR, HRMS and rotational analysis to 
confirm identity and purity. 
 
1
H-NMR (500 MHz, d6-DMSO at 2.5 ppm) δ 10.33 (s, 1H), 8.38 (s, 2.5H), 8.09 (dd, J = 
9.0Σ, 3.7 Hz, 1H), 7.92 (dd, J = 9.3Σ, 5.9 Hz, 1H), 7.77 (d, J = 8.1 Hz, 1H), 7.65 (d, J = 
7.3 Hz, 1H), 7.53 (dd, J = 9.3Σ, 4.4, 3.2 Hz, 2H), 7.48 (dd, J = 15.6 Σ, 7.8 Hz, 1H),  4.28 
(dd, 9.8Σ, 4.9 Hz, 1H), 3.19 (dd, J = 21.8Σ, 16.9, 5.1 Hz, 1H), 3.13 ( dd, J = 22.5Σ, 16.9, 
5.6 Hz, 1H); 
 
13
C-NMR (500 MHz, d6-DMSO at 39.5 ppm) δ 170.7, 168.6, 134.1, 133.5, 128.5, 128.22, 
126.5, 126.3, 126.0, 125.9, 123.4, 122.3, 49.2, 35.9; 
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HRMS m/e calcd. for C14H15N2O3 = 259.1083, found 259.1088; 
 
[ α ]
22
D = + 24
◦
 (c = 0.22, methanol, Na
+
 D lamp) 
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N-tBoc-1-naphthyl -α-amide-L-aspartate: BRL: 228 
Protected aspartate anhydride (1.98 g, 9.22 mmol) was dissolved in DMSO (80 mL).  To 
this was added α-naphthylamine (2.37 g, 0.9 eq., 88% aryl amine).  The solution was 
allowed to stir for 48 h at ~40
◦
 C or until the reaction had completed as determined by 
TLC (mobile phase 95% CH2Cl2 / 4% MeOH / 1% acetic acid).  The solution was then 
diluted with CHCl3 (450 mL) and washed with brine adjusted to pH = 2 by addition of 
H3PO4 conc. (4 x 200 mL aliquots) to remove the DMSO.  The organic phase was then 
concentrated by rotovap leaving a dark red/purple residue.  The products were then 
isolated by silica gel (mobile phase = 95% CH2Cl2 / 4% MeOH / 1% acetic acid).  The β-
addition bi-product was collected at Rf = 0.2, concentrated and stored.  A portion of the 
α-addition product was isolated at Rf = 0.3 and subsequently concentrated by rotovap to a 
red/brown residue (0.230 g, 0.642 mmol.) which was used within the next synthetic step 
without further characterization or purification. 
 
 70 
HCl
HN
HOOC O
HN
O
O
H2N
HOOC O
HN
1) TFA:CH2Cl2
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CSE107
C14H15ClN2O3
Mol. Wt.: 294.73  
1-Naphthyl -α-amide-L-aspartate: BRL: 250 
CH2Cl2 (1.5 mL) and trifluoroacetic-acid (TFA, 1.5 mL) solution 1:1 were added to a 
round bottom flask containing N-tBoc-α-amide-L-aspartate (0.230 g, 0.642 mmol) which 
dissolved immediately and turned a dark red/brown color.  The solution was allowed to 
stir for 1 hour at rt (~21
◦
 C) whereby it was observed that the reaction had completed as 
determined by TLC (mobile phase 90% CH2Cl2 / 9% MeOH / 1% AcOH; Rf = 0.01).  
The solution was then aspirated until dry by compressed air to remove the TFA and 
CH2Cl2.  The remaining residue (deprotected product and TFA salt) was taken up into 30 
mL deionized water using light sonication to suspend residue and washed with 3 x 10 mL 
CH2Cl2.  To the aqueous solution containing the final product 0.385 mL 2 M HCl (1.2 
eq.) was added and was then frozen to -80
◦
 C and placed on the lyophilizer until dry 
leaving a off white solid residue (α-naphtyl-amide-L-aspartate 0.179 g, 0.610 mmol, 95% 
yield).  The final product was analyzed by 
1
H, 
13
C NMR, HRMS and rotational analysis 
to confirm identity and purity. 
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1
H-NMR (500 MHz, d6-DMSO at 2.5 ppm) δ 10.70 (s, 1H), 8.13 (dd, J= 8.8Σ, 5.4, 3.4 
Hz, 1H), 7.94 (dd, J= 9.0Σ, 5.6, 3.4 Hz, 1H), 7.805 (d, J = 8.1 Hz, 1H), 7.64 (d, J = 7.3 
Hz, 1H), 7.53 (m, 26.2 Hz, 3H),  4.47 (dd, 12.0Σ, 6.1, 5.9 Hz, 1H), 3.04 (dd, J = 23.7Σ, 
17.4, 5.9 Hz, 1H), 3.01 ( dd, J = 24.9Σ, 18.1, 7.6 Hz, 1H); 
 
13
C-NMR (500 MHz, d6-DMSO at 39.5 ppm) δ 171.5, 167.8, 134.1, 133.0, 128.5, 128.31, 
126.7, 126.5, 126.4, 126.0, 123.4, 122.4, 50.0, 36.0; 
 
HRMS m/e calcd. For C14H15N2O3 = 259.1083, found 259.1063; 
   
[ α ]
22
D = +5˚ (c = 0.12, methanol, Na
+
 D lamp) 
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N-tBoc-p-chloro-phenyl-L-aspartamide: BRL: 132 
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N-tBoc protected aspartate anhydride (0.932 g, 4.33 mmol) was dissolved in DMSO (90 
mL).  To this was added p-chloroaniline (.522 g, .85 eq., 3.68 mmol).  The solution was 
allowed to stir for 48 h at ~70
◦
 C or until the reaction had completed as determined by 
TLC (mobile phase 95% CH2Cl2 / 4% MeOH / 1% acetic acid).  The solution was then 
diluted with CHCl3 (200 mL) and washed with brine adjusted to pH = 2 by addition of 
H3PO4 conc. (4 x 250 mL aliquots) to remove DMSO.  The organic phase was then 
concentrated, leaving a light brown residue.  The products were isolated by silica gel 
(mobile phase = 95% CH2Cl2 / 4% MeOH / 1% acetic acid).  The α-addition bi-product 
was collected at Rf = 0.2, concentrated and stored for later use.   The β addition product 
was isolated at Rf = 0.15 and subsequently concentrated by rotovap to an off white 
residue (0.663 g. recovered, 1.93 mmol) which was used in the next synthetic step 
without further purification. 
 
1
H-NMR (500 MHz, d6-DMSO at 2.5 ppm) δ 12.34 (s, 5H), 10.12 (s, 1H), 7.60 (d, J = 
8.4 Hz, 2H), 7.34 (d, J = 8.4 Hz, 2H), 7.08 (d, J = 8.4 Hz, 1H), 4.34 (dd, 20.7Σ, 13.6, 7.1 
Hz, 1H), 2.80 (dd, J = 20.7Σ, 15.5, 5.8 Hz, 1H), 2.63 (dd, J = 22.6Σ, 15.5, 7.8 Hz, 1H), 
1.36 (s, 9H) 
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HN
HOOC
H
NO
O
O
Cl
+H3N
COOH
H
NO
Cl
HCl
1) TFA:CH2Cl2
2) 10mM HCl 1.2 eq.
CSE98
C10H12Cl2N2O3
Mol. Wt.: 279.12  
p-Chloro-phenyl-L-aspartamide: BRL: 144 
A solution of 50% trifluoroacetic-acid in CH2Cl2 (4 mL) was added to a round bottom 
flask containing N-tBoc-p-chloro-phenyl-aspartamide (0.114 g, 0.333 mmol) which 
dissolved immediately and turned a dark brown color.  The solution was allowed to stir 
for 1 h at rt (~22
◦
 C) whereby it was observed that the reaction had completed as 
determined by TLC (mobile phase 90% CH2Cl2 / 9% MeOH / 1% AcOH; Rf = 0.01).  
The solution was then aspirated until dry with compressed air to remove TFA and 
CH2Cl2.  The remaining residue (deprotected product and TFA salt) was washed with 4 x 
10 mL CH2Cl2 and taken up into 20 mL 0.01 M HCl using light sonication to resuspend 
the residue.  The solution was then frozen to -80
◦
 C and placed on the lyophilizer until 
dry, leaving a white solid residue (p-chloro-phenyl-aspartamide 0.087 g, .312 mmol, 94% 
yield).  The final product was analyzed by 
1
H, 
13
C NMR, HRMS and rotational analysis 
to confirm identity and purity. 
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1
H-NMR (500 MHz, d6-DMSO at 2.5 ppm) δ 10.69 (s, 1H), 8.39 (s, 2.5H), 7.64 (d, J= 
9.1 Hz, 2H), 7.36 (d, J = 9.1 Hz, 2H), 4.15 (dd, 10.4Σ, 5.2 Hz, 1H), 3.05 (dd, J = 21.4Σ, 
16.8, 4.5 Hz, 1H), 2.95 (dd, J = 22.6Σ, 16.8, 5.2 Hz, 1H); 
 
13
C-NMR (500 MHz, d6-DMSO at 39.5 ppm) δ 170.2, 167.7, 137.9, 128.7, 126.9, 120.74, 
48.8, 36.1; 
 
HRMS m/e calcd. For C10H12N2ClO3 = 243.0536, found 243.0565; 
 
[ α ]
22
D = -5˚ (c = 0.080, methanol, Na
+
 D lamp) 
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N-tBoc-1-naphth-7-ol-aspartamide: BRL: 137 
Protected aspartate anhydride (0.561 g, 2.41 mmol) was dissolved in DMSO (80 mL).  To 
this was added 8-amino-2-naphthol (0.373 g, 0.85eq, 96%).  The solution was allowed to 
stir for 48 h at ~40
◦
 C or until the reaction had completed as determined by TLC (mobile 
phase 90% CH2Cl2 / 9% MeOH / 1% acetic acid).  The solution was then diluted with 
CHCl3 (450 mL) and washed with brine adjusted to pH = 2 by conc. H3PO4 (4 x 200 mL 
aliquots) to remove DMSO.  The organic phase was then concentrated, leaving a dark 
red/brown residue.  The crude product was then separated by silica gel (mobile phase = 
95% CH2Cl2 / 4% MeOH / 1% acetic acid).  The α-addition bi-product was collected at 
Rf = 0.3, concentrated and stored.   Some of the β-addition product was isolated at Rf = 
0.2 and concentrated by rotovap to a light brown residue (0.422 g., 1.13 mmol), which 
was used in the next synthetic step without further purification. 
 
1
H-NMR (500 MHz, d6-DMSO at 2.5 ppm) δ 10.59 (s, 1H), 7.74 (d, J = 9.1 Hz 1H), 7.65 
(d, J = 7.1 Hz, 1H), 7.57 (d, J = 7.8 Hz, 1H), 7.45 (s, 1H), 7.19 (dd, 15.5Σ, 7.8 Hz, 1H), 
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7.10 (dd, J = 10.4Σ, 9.1, 7.1Hz, 1H), 6.58 (d, J = 5.8, 1H), 4.195 (d, J = 5.2 Hz, 1H), 2.87 
(dd, 20.7Σ, 14.9, 5.8 Hz, 1H), 2.70 (dd, J = 20.1Σ, 14.9, 5.2 Hz, 1H), 1.37 (s, 9H) 
 
 
 
 
HN
HOOC
H
NO
O
O
OH
+H3N
COOH
H
NO
OH
HCl
1) TFA:CH2Cl2
2) 10mM HCl 1.2 eq.
C14H15ClN2O4
Mol. Wt.: 310.73
CSE99
 
1-Naphth-7-ol-L-aspartamide: BRL: 232 
A 1:1 solution of CH2Cl2 (2 mL) and trifluoro-acetic-acid (TFA, 2 mL) was added to a 
round bottom flask containing N-tBoc-2-napthol-8-β-aspartamide (0.10 g, 0.267mmol) in 
2 mL CH2Cl2, which dissolved immediately and turned a dark red/brown color.  The 
solution was allowed to stir for 1 hour at rt (~21
◦
 C) whereby it was observed that the 
reaction had completed as determined by TLC (mobile phase 85% CH2Cl2 / 14% MeOH / 
1% AcOH; Rf = 0.01).  The solution was then aspirated until dry with compressed air to 
remove the remaining TFA and CH2Cl2.  The remaining solid (deprotected product and 
TFA salt) was washed with 2 x 50 mL CH2Cl2 and then taken up into 29.4 mL of 0.01M 
HCl (diluted from 160 µL 2M HCl, 1.1 eq.) followed by light sonication to 
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dissolve/suspend remaining solid residue.  The solution was then frozen to -80
◦
 C and 
placed on the lyophilizer to freeze dry / remove all the water and remaining TFA leaving 
a dark red/brown solid (1-naphth-7-ol-L-aspartamide, 0.075 g, 90% yield).  The final 
product was analyzed by 
1
H, 
13
C NMR, HRMS and rotational analysis to confirm identity 
and purity. 
 
1
H-NMR (500 MHz, d6-DMSO at 2.5 ppm) δ 10.17 (s, 1H), 9.92 (s, 1H), 8.44 (s, 2.5H), 
7.77 (d, J= 8.4 Hz, 1H), 7.64 (d, J = 7.8 Hz, 1H), 7.52 (d, J = 7.8 Hz, 1H), 7.31 (s, 1H), 
7.23 (dd, J = 15.5Σ, 7.76, 1H), 7.15 (dd, J = 10.4 Σ, 8.4, 6.5 Hz, 1H),  4.26 (dd, 9.1Σ, 4.5 
Hz, 1H), 3.195 (dd, J = 22.0Σ, 17.5, 12.3 Hz, 1H), 3.15 ( dd, J = 22.6Σ, 16.8, 11.0 Hz, 
1H); 
 
13
C-NMR (500 MHz, d6-DMSO at 39.5 ppm) δ 170.3, 168.1, 155.6, 131.4, 129.7, 128.42, 
125.5, 122.4, 121.9, 118.7, 104.5, 48.9, 35.4; 
 
HRMS m/e calcd. For C14H15N2O4 = 275.1032, found 275.1030; 
 
[ α ]
22
D = +18 
◦
 (c = 0.29, methanol, Na
+
 D lamp) 
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N-tBoc-1-naphth-7-ol-α-amide-aspartate: BRL: 137 
Protected aspartate anhydride (0.561 g, 2.41 mmol) was dissolved in DMSO (80 mL).  To 
this was added 8-amino-2-naphthol (0.373 g, 0.85eq, 96%).  The solution was allowed to 
stir for 48 h at ~40
◦
 C or until the reaction had completed as determined by TLC (mobile 
phase 90% CH2Cl2 / 9% MeOH / 1% acetic acid).  The solution was then diluted with 
CHCl3 (450 mL) and washed with brine adjusted to pH = 2 by conc. H3PO4 (4 x 200 mL 
aliquots) to remove DMSO.  The organic phase was then concentrated, leaving a dark 
red/brown residue.  The crude product was then separated by silica gel (mobile phase = 
95% CH2Cl2 / 4% MeOH / 1% acetic acid).  The β-addition bi-product was collected at 
Rf = 0.2, concentrated and stored.   The α-addition product was isolated at Rf = 0.3 and 
concentrated by rotovap to a light brown residue (0.040 g., 0.107 mmol).  The isolated 
product was used in the next synthetic step without further purification or 
characterization. 
 
1
H-NMR (500 MHz, d6-DMSO at 2.5 ppm) δ 9.75 (s, 1H), 7.76 (d, J = 9.1 Hz 1H), 7.63 
(d, J = 7.8 Hz, 1H), 7.50 (d, J = 7.8 Hz, 1H), 7.24 (m, 3H), 7.11 (d, J = 8.4 Hz, 1H), 4.59 
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(d, J = 5.2 Hz, 1H), 2.80 (dd, 19.4Σ, 15.5, 3.9 Hz, 1H), 2.65 (dd, J = 24.6Σ, 15.5, 6.5 Hz, 
1H), 1.41 (s, 9H) 
 
 
HCl
HN
HOOC O
HN
O
O
HO
H2N
HOOC O
HN
HO
1) TFA:CH2Cl2
2) 10mM HCl 1.2 eq.
C14H15ClN2O4
Mol. Wt.: 310.73
CSE101
 
1-Naphth-7-ol-α-amide-aspartate: BRL: 147 
A 50 % solution of trifluoro-acetic-acid in CH2Cl2 (3 mL) was added to a round bottom 
flask containing N-tBoc-1-naphth-7-ol-α-amide-aspartate (0.040 g, 0.107 mmol), which 
dissolved immediately and turned a dark red/brown color.  The solution was allowed to 
stir for 1 h at rt (~21
◦
 C) whereby it was observed that the reaction had completed as 
determined by TLC (mobile phase 85% CH2Cl2 / 14% MeOH / 1% AcOH; Rf = 0.01).  
The solution was then aspirated with compressed air until dry to remove TFA and 
CH2Cl2.  The remaining solid (deprotected product and TFA salt) was washed with 2 x 60 
mL CH2Cl2 and then taken up into 20 mL deionized water followed by the addition of 64 
µL 2 M HCl (1.2 eq.) and light sonication to dissolve / resuspend the solid residue.  The 
solution was then frozen to -80
◦
 C and placed on the lyophilizer to freeze dry leaving a 
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dark red/brown solid (1-naphth-7-ol-α-amide-aspartate, 0.031 g, 92% yield).  The final 
product was analyzed by 
1
H, 
13
C NMR, HRMS and rotational analysis to confirm identity 
and purity.  
 
1
H-NMR (500 MHz, d6-DMSO at 2.5 ppm) δ 10.33 (s, 1H), 9.88 (s, 1H), 8.41 (s, 2.5H), 
7.79 (d, J= 8.8Hz, 1H), 7.68 (d, J = 7.8 Hz, 1H), 7.51 (d, J = 7.1 Hz, 1H), 7.28 (s, 2H), 
7.24 (d, 7.6, 1H), 7.14 (d, 8.3 Hz, 1H),  4.44 (s, 1H), 3.07 (dd, J = 20.8Σ, 17.4, 3.4 Hz, 
1H), 2.96 (dd, J = 24.9Σ, 17.1, 7.8 Hz, 1H); 
 
13
C-NMR (500 MHz, d6-DMSO at 39.5 ppm) δ 171.4, 167.5, 156.1, 131.2, 130.2, 130.2, 
128.8, 126.4, 122.9, 122.4, 119.2, 104.8, 49.9, 36.1; 
 
HRMS m/e calcd. C14H15N2O4 = 275.1032, found 275.1018; 
 
[ α ]
22
D = -5 
◦
 (c = 0.11, methanol, Na
+
 D lamp) 
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N-tBoc-p-chloro-phenyl-α-amide-aspartate: BRL: 132 
Protected aspartate anhydride (0.932 g, 4.33 mmol) was dissolved in DMSO (90 mL).  To 
this was added p-chloroaniline (0.522 g, 0.85 eq., 3.68 mmol).  The solution was allowed 
to stir for 48 h at ~70
◦
 C or until the reaction had completed as determined by TLC.  The 
solution was then diluted with CHCl3 (200 mL) and washed with brine adjusted to pH  2 
by conc. H3PO4 (4 x 250 mL aliquots) to remove DMSO.  The organic phase was then 
concentrated, leaving a light brown residue.  The products were then isolated by silica gel 
(mobile phase = 95% CH2Cl2 / 4% MeOH / 1% acetic acid).  The β-addition bi-product 
was collected at Rf = 0.15, concentrated and stored for later use.   The α-addition product 
was isolated at Rf  = 0.2 and subsequently concentrated by rotovap to a white residue 
(0.120 g recovered, 0.350 mmol), which was used in the next synthetic step without 
further purification. 
 
1
H-NMR (500 MHz, d6-DMSO at 2.5 ppm) δ 10.15 (s, 1H), 7.62 (d, J = 9.1 Hz, 2H), 7.35 
(d, J = 9.1 Hz, 2H), 7.21 (d, J = 7.8 Hz, 1H), 4.40 (dd, 20.1Σ, 12.9, 7.1 Hz, 1H), 2.66 (dd, 
J = 21.4Σ, 16.2, 5.8 Hz, 1H), 2.51 (dd, overlap with DMSO, 1H), 1.37 (s, 9H) 
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HCl
HN
HOOC O
HN
O
O
Cl +H3N
HOOC O
HN Cl
1) TFA:CH2Cl2
2) 10mM HCl 1.2 eq.
CSE100
C10H12Cl2N2O3
Mol. Wt.: 279.12
 
p-Chloro-phenyl-α-amide-aspartate: BRL: 146 
A solution of 50% trifluoroacetic-acid in CH2Cl2 (4 mL) was added to a round bottom 
flask containing N-tBoc-p-chloro-phenyl-α-amide-aspartate (0.120 g, 0.333 mmol), 
which dissolved immediately and turned a dark brown color.  The solution was allowed 
to stir for 1 h at rt (~21
◦
 C) whereby it was observed that the reaction had completed as 
determined by TLC (mobile phase 90% CH2Cl2 / 9% MeOH / 1% AcOH; Rf = 0.01).  
The solution was then aspirated with compressed air until dry to remove the TFA and 
CH2Cl2.  The remaining residue (deprotected product and TFA salt) was washed with 
CH2Cl2 (3 x 10 mL) and then taken up into 20 mL deionized water using light sonication 
to suspend the residue where 0.210 mL 2 M HCl (1.2 eq.) was added.  The solution was 
then frozen to -80
◦
 C and placed on the lyophilizer until dry, leaving a white solid (p-
chloro-phenyl-α-amide-aspartate 0.094 g, 0.336 mmol, 96% yield).  The final product 
was analyzed by 
1
H, 
13
C NMR, HRMS and rotational analysis to confirm identity and 
purity. 
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1
H-NMR (500 MHz, d6-DMSO at 2.5 ppm) δ 10.95 (s, 1H), 8.62 (s, 2.0H), 7.64 (d, J = 
8.8 Hz, 2H), 7.40 (d, J = 8.6 Hz, 2H), 4.24 (dd, 12.7Σ, 6.6 Hz, 1H), 2.96 (dd, J = 22.7Σ, 
17.6, 5.4 Hz, 1H), 2.88 (dd, J = 24.9Σ, 17.4, 7.3 Hz, 1H); 
 
13
C-NMR (500 MHz, d6-DMSO at 39.5 ppm) δ 175.9, 171.6, 142.4, 134.0, 132.8, 126.2, 
55.0, 40.4; 
 
HRMS m/e calcd. For C10H12ClN2O3 = 243.0536,  found 243.0548; 
 
[ α ]
22
D = +16 
◦
 (c = 0.12, methanol, Na
+
 D lamp) 
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N-tBoc-2,3-dimethyl-phenyl-aspartamide: BRL: 236 
Protected aspartate anhydride (1.846 g, 8.58 mmol) was dissolved in DMSO (120 mL).  
To this was added 2,3-dimethylaniline (0.954 mL, 0.9 eq., 7.72 mmol).  The solution was 
allowed to stir for 48 h at ~ 40
◦
 C or until the reaction had completed as determined by 
TLC.  The solution was then diluted with CHCl3 (200 mL) and washed with brine 
adjusted to pH = 2 by addition of conc. H3PO4 (6 x 200 mL aliquots) to remove DMSO.  
The organic phase was then concentrated, leaving a light yellow residue.  The products 
were then isolated by silica gel (mobile phase = 95% CH2Cl2 / 4% MeOH / 1% acetic 
acid).  The α-addition bi-product was collected at Rf = 0.3, concentrated and stored for 
later use.  The β-addition product was isolated at Rf = 0.2 and subsequently concentrated 
by rotovap to a white solid (0.450 g. recovered, 1.34 mmol), N-tBoc-2,3-dimethyl-
phenyl-aspartamide.  The product was used without further purification in the next 
synthetic step. 
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1
H-NMR (500 MHz, d6-DMSO at 2.5 ppm) δ 12.62 (b, 2.5H), 9.35 (s, 1H), 7.03 (m, J = 
64.6 Hz, 3 H), 4.34 (dd, 21.5Σ, 13.9, 7.8 Hz, 1H), 2.76 (dd, J = 20.5Σ, 14.9, 5.6 Hz, 1H), 
2.64 (dd, J = 22.7Σ, 14.7, 7.8 Hz, 1H), 2.22 (s, 3H), 2.03 (s, 3H), 1.36 (s, 9H); 
 
13
C-NMR (500 MHz, d6-DMSO at 39.5 ppm) δ 173.8, 168.6, 155.6, 137.3, 136.4, 131.6, 
127.3, 125.5, 123.9, 78.6, 50.9, 38.1, 28.6, 20.6, 14.4 
 
 
 
HN
HOOC
H
NO
O
O +H3N
COOH
H
NOHCl
1) TFA:CH2Cl2
2) 10mM HCl 1.2 eq.
CSE105
C12H17ClN2O3
Mol. Wt.: 272.73  
2,3-Dimethyl-phenyl-aspartamide: BRL: 237 
A solution of 50% trifluoroacetic-acid in CH2Cl2 (6 mL) was added to a round bottom 
flask containing N-tBoc-2,3-dimethyl-phenyl-β-aspartamide (0.450 g, 1.34 mmol) which 
dissolved immediately and turned a dark yellow color.  The solution was allowed to stir 
for 1 h at rt (~21
◦
 C) whereby it was observed that the reaction had completed as 
determined by TLC (mobile phase 90% CH2Cl2 / 9% MeOH / 1% AcOH; Rf = 0.01).  
The solution was then aspirated with compressed air until dry to remove all TFA and 
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CH2Cl2.  The remaining residue (deprotected product and TFA salt) was washed with 3 x 
60 mL CH2Cl2 and then taken up into 80 mL deionized water using light sonication to 
suspend the residue followed by addition of 0.803 mL 2.0 M HCl (1.2 eq.).  The solution 
was then frozen to -80
◦
 C and placed on the lyophilizer until dry, leaving a white residue 
(2,3-dimethyl-phenyl-β-aspartamide 0.347 g, 1.27 mmol, 95% yield).  The final product 
was analyzed by 
1
H, 
13
C NMR, HRMS and rotational analysis to confirm identity and 
purity. 
 
1
H-NMR (500 MHz, d6-DMSO at 2.5 ppm) δ 9.87 (s, 1H), 8.49 (s, 2.5H), 7.10 (d, J = 7.6 
Hz, 1H), 7.00 (m, J = 28.1 Hz, 2H), 4.20 (d, 4.2 Hz, 1H), 3.08 (dd, J = 22.0Σ, 16.6, 5.4 
Hz, 1H), 3.02 (dd, J = 22.0Σ, 16.6, 5.4 Hz, 1H), 2.21 (s, 3H), 2.05 (s, 3H); 
 
13
C-NMR (500 MHz, d6-DMSO at 39.5 ppm) δ 170.7, 167.9, 137.4, 136.1, 131.7, 127.5, 
125.5, 124.1, 49.2, 35.5, 20.6, 14.6; 
 
HRMS m/e calcd. For C12H17N2O3 = 237.1239, found 237.1252 
 
[ α ]
22
D = -2 
◦
 (c = 0.17, methanol, Na
+
 D lamp) 
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N-tBoc-2,3-dimethyl-phenyl-α-amide-aspartate: BRL: 236 
Protected aspartate anhydride (1.846g, 8.58 mmol) was dissolved in DMSO (120 mL).  
To this was added 2,3-dimethylaniline (0.954 mL, 0.9 eq., 7.72 mmol).  The solution was 
allowed to stir for 48 h at ~40
◦
 C or until the reaction had reached completion as 
determined by TLC.  The solution was then diluted with CHCl3 (200 mL) and washed 
with brine adjusted to pH ~2 by addition of conc. H3PO4 (6 x 200 mL aliquots) to remove 
DMSO.  The organic phase was then concentrated leaving a light yellow residue.  The 
products were then isolated by silica gel (mobile phase = 95% CH2Cl2 / 4% MeOH / 1% 
acetic acid).  The β-addition bi-product was collected at Rf = 0.2, concentrated and stored 
for later use.   The α-addition product was isolated at Rf = 0.3 and subsequently 
concentrated by rotovap to a white residue (0.300 g. recovered, 0.892 mmol), which was 
used in the next synthetic step without further purification. 
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HCl
HN
HOOC O
HN
O
O
+H3N
HOOC O
HN
1) TFA:CH2Cl2
2) 10mM HCl 1.2 eq.
CSE106
C12H17ClN2O3
Mol. Wt.: 272.73  
2,3-Dimethyl-phenyl-α-amide-aspartate: BRL: 248 
A solution of 50% trifluoroacetic-acid in CH2Cl2 (6 mL) was added to a round bottom 
flask containing N-tBoc-2,3-dimethyl-phenyl-α-amide-aspartate (0.300 g, 0.892 mmol) 
which dissolved immediately and turned a dark yellow color.  The solution was allowed 
to stir for 1 h at rt (~21
◦
 C) whereby it was observed that the reaction had completed as 
determined by TLC (mobile phase 90% CH2Cl2 / 9% MeOH / 1% AcOH; Rf = 0.01).  
The solution was then aspirated with compressed air until dry to remove the TFA and 
CH2Cl2.  The remaining residue (deprotected product and TFA salt) was washed with 3 x 
20 mL CH2Cl2 and then taken up into 40 mL deionized water using light sonication to 
suspend the residue followed by addition of 0.535 mL 2.0 M HCl (1.2 eq.).  The solution 
was then frozen to -80
◦
 C and placed on the lyophilizer until dry, leaving a white solid 
(2,3-dimethyl-phenyl-α-amide-aspartate, 0.234 g, 0.856 mmol, 96% yield).  The final 
product was analyzed by 
1
H, 
13
C NMR, HRMS and rotational analysis to confirm identity 
and purity. 
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1
H-NMR (500 MHz, d6-DMSO at 2.5 ppm) δ 10.07 (s, 1H), 8.45 (s, 2.5H), 7.11 (d, J = 
7.3 Hz, 1H), 7.05 (m, J = 24.4 Hz, 2H), 4.30 (dd, J = 11.2Σ, 5.6 Hz, 1H), 2.98 (dd, J = 
22.2Σ, 16.6, 5.6 Hz, 1H), 2.93 (dd, J = 23.7Σ, 16.6, 5.9 Hz, 1H), 2.23 (s, 3H), 2.06 (s, 3H); 
 
13C-NMR (500 MHz, d-DMSO at 39.5 ppm) ppm 171.31, 166.93, 137.62, 135.43, 
131.93, 127.96, 125.73, 123.89, 49.72, 35.88, 20.56, 14.42; 
 
HRMS m/e calcd. For C12H17N2O3 = 237.1239, found 237.1222; 
 
[ α ]
22
D= -2 
◦
 (c = 0.14, methanol, Na
+
 D lamp) 
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2,3-dichloroaniline
 
N-tBoc-2,3-dichloro-phenyl-α-amide-aspartate: BRL: 227 
N-tBoc protected aspartate anhydride (1.855g, 8.618 mmol) was dissolved in DMSO 
(120 mL).  To this was added 2,3-dichloroaniline (1.268 g, 0.9 eq., 7.75 mmol).  The 
solution was allowed to stir for 48 h at ~65
◦
 C or until the reaction had completed as 
determined by TLC.  The solution was then diluted with CHCl3 (200 mL) and washed 
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with brine acidified to pH = 2 by addition of conc. H3PO4 (6 x 200 mL aliquots) to take 
up the DMSO.  The organic phase was then concentrated leaving a light yellow residue.  
The products were then isolated by silica gel (mobile phase = 95% CH2Cl2 / 4% MeOH / 
1% acetic acid).  The β-addition bi-product was collected at Rf = 0.2, concentrated and 
stored for later use.   The α-addition product was isolated at Rf = 0.3 and subsequently 
concentrated by rotovap to a white residue (0.200 g. recovered, 0.530 mmol), N-tBoc-
2,3-dichloro-phenyl-α-amide-aspartate.  The product was used in the next synthetic step 
without further purification. 
 
1
H-NMR (500 MHz, d6-DMSO at 2.5 ppm) δ 12.39 (b, 0.5H), 9.52 (s, 1H), 7.84 (d, J = 
8.1 Hz, 1H), 7.44 (dd, J = 18.1Σ, 9.1 Hz, 1H), 7.35 (dd, J = 16.1Σ, 8.1 Hz, 1H), 4.48 (dd, 
20.5Σ, 13.4, 7.1 Hz, 1H), 2.76 (dd, J = 22.2Σ, 16.6, 5.6 Hz, 1H), 2.58 (dd, J = 24.7Σ, 16.8, 
8.1 Hz, 1H), 1.39 (s, 9H). 
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HCl
HN
HOOC O
HN
O
O Cl Cl
+H3N
HOOC O
HN
Cl Cl
1) TFA:CH2Cl2
2) 10mM HCl 1.2 eq.
CSE108
C10H11Cl3N2O3
Mol. Wt.: 313.56  
2,3-Dichloro-phenyl-α-amide-aspartate: BRL: 252 
A solution of 50% trifluoroacetic-acid in CH2Cl2 (6 mL) was added to a round bottom 
flask containing N-tBoc-2,3-dichloroaniline-α-aspartamide (0.200 g, 0.530 mmol) which 
dissolved immediately and turned a dark brown color.  The solution was allowed to stir 
for 1 h at rt (~21
◦
 C) whereby it was observed that the reaction had completed as 
determined by TLC (mobile phase 90% CH2Cl2 / 9% MeOH / 1% AcOH; Rf = 0.01).  
The solution was then aspirated with compressed air until dry to remove the remaining 
TFA and CH2Cl2.  The remaining residue (deprotected product and TFA salt) was washed 
with 3 x 10 mL CH2Cl2 and then taken up into 20 mL deionized water using light 
sonication to suspend the residue followed by addition of  0.318 mL 2.0 M HCl (1.2 eq.).  
The solution was then frozen to -80
◦
 C and placed on the lyophilizer until dry, leaving a 
white residue (2,3-dichloro-phenyl-α-amide-aspartate 0.153 g, 0.488 mmol, 92% yield).  
The final product was analyzed by 
1
H, 
13
C NMR, HRMS and rotational analysis to 
confirm identity and purity. 
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1
H-NMR (500 MHz, d6-DMSO at 2.5 ppm) δ 10.49 (s, 1H), 8.52 (s, 2.5H), 7.61 (d, J = 
8.1 Hz, 1H), 7.51 (d, J = 7.8 Hz, 1H), 7.38 (dd, J = 16.4Σ, 8.3 Hz, 1H ), 4.39 (d, J = 2.7 
Hz, 1H), 2.98 (m, J = 44.5 Hz, 2H); 
 
13
C-NMR (500 MHz, d6-DMSO at 39.5 ppm) δ 171.2, 167.5, 136.3, 132.5, 128.6, 128.0, 
126.3, 125.5, 49.8, 35.8; 
 
HRMS m/e calcd. For C10H11Cl2N2O3 = 277.0147, found 277.0118; 
 
[ α ]
22
D = -3 
◦ 
(c = 0.11, methanol, Na
+
 D lamp) 
 
 
 
HN
HOOC O
HN
O
OH
N
O
O
O
O
O
DMSO
2-biphenylamine
 
N-tBoc-1-biphenyl-α-amide-aspartate: BRL: 27 
Protected aspartate anhydride (1.41g, 6.56 mmol) was dissolved into DMSO (120 mL).  
To this was added 2-aminobiphenyl (0.963 g, 0.85 eq., 5.58 mmol).  The solution was 
allowed to stir for 24 h at ~40
◦
 C or until the reaction had completed as determined by 
TLC (95% CH2Cl2 / 4% MeOH / 1% acetic acid).  The solution was then diluted with 
CHCl3 (200 mL) and washed with brine adjusted to pH = 2 by addition of conc. H3PO4, 
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(4 x 250 mL aliquots) to remove DMSO.  The organic phase was then concentrated, 
leaving a light brown residue.  The products were then isolated by silica gel (mobile 
phase = 94% CH2Cl2 / 5% MeOH / 1% acetic acid).  The β-addition bi-product was 
collected at Rf = 0.2, concentrated and stored for later use.   The α-addition product was 
isolated at Rf = 0.3 and concentrated in-vacuo to a light/brown residue (0.270 g. 
recovered, 0.702 mmol) N-tBoc-1-biphenyl-α-amide-aspartate, which was used in the 
next synthetic step without further purification. 
 
1
H-NMR (400 MHz, d6-DMSO at 2.5 ppm) δ 9.10 (s, 1H), 7.75 (d, J= 7.8 Hz, 1H), 7.43 
(d, J = 6.8 Hz, 2H), 7.35 (m, J = 77.5Σ Hz, 4H), 7.26 (m, 35.5Σ Hz, 2H), 7.10 (d, 7.6 Hz, 
1H), 4.28 (dd, 20.0Σ, 12.7, 7.3 Hz, 1H), 2.58 (dd, J = 21.0Σ, 16.6, 4.6 Hz, 1H), 2.44 (dd, J 
= 25.4Σ, 17.1, 9.0 Hz, 1H), 1.32(s,9H). 
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HCl
HN
HOOC O
HN
O
O
+H3N
HOOC O
HN
1) TFA:CH2Cl2
2) 10mM HCl 1.2 eq.
CSE114
C16H17ClN2O3
Mol. Wt.: 320.77  
1-Biphenyl-α-amide-aspartate: BRL: 276 
To 0.270 g (0.702 mmol) of N-tBoc-1-biphenyl-α-amide-aspartate in a round bottom 
flask was added 6 mL of 50% TFA in CH2Cl2, which dissolved immediately and turned a 
dark yellow color.  The solution was allowed to stir for 1 h at rt (~21
◦
 C) whereby it was 
observed that the reaction had completed as determined by TLC (90% CH2Cl2 / 9% 
MeOH / 1% AcOH; Rf = 0.01).  The solution was then aspirated with compressed air 
until dry to remove TFA and CH2Cl2.  The remaining residue (deprotected product and 
TFA salt) was washed with 3 x 20 mL CH2Cl2 and then taken up into 20 mL dionized 
water using light sonication to suspend the residue and 0.421 mL (1.2 eq.) of  2 M HCl 
was added.  The mixture was then frozen to -80
◦
 C and lyophilized until dry, leaving a 
white residue (1-biphenyl-α-amide-aspartate 0.203 g, 0.632 mmol, 90% yield).  The final 
product was analyzed by 
1
H, 
13
C NMR, HRMS and rotational analysis to confirm identity 
and determine purity. 
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1
H-NMR (500 MHz, d
6
-DMSO at 2.5 ppm) δ 9.94 (s, 1H), 8.33 (s, 2.5H), 7.41 (m, J = 
80.7Σ Hz, 9H), 4.10 (dd, J = 11.5Σ, 7.1, 4.4 Hz, 1H), 2.74 (dd, J = 21.8Σ, 17.8, 4.2 Hz, 
1H), 2.67 (dd, J = 25.4Σ, 17.6, 7.8 Hz, 1H); 
 
13
C-NMR (500 MHz, d6-DMSO at 39.5 ppm) δ 171.3, 167.2, 138.9, 137.1, 133.9, 130.89, 
129.3, 128.9, 128.3, 127.9, 127.2, 127.1, 49.6, 35.4; 
 
HRMS m/e calcd. For C16H17N2O3 = 285.1239, found 285.1263; 
 
[ α ]
22
D = -11
 ◦
 (c = 0.12, methanol, Na
+
 D lamp); 
 
 
 
 
 
DMSO
H
N
O O
O
O
O
HN
HOOC
H
N
O
O
O
OH
8-amino-2-naphthol
 
N-tBoc-1-naphth-7-ol-glutamide: BRL: 153 
Protected glutamate anhydride (2.02 g, 8.17mmol) derived from N-tBoc-L-glutamate by 
reflux in acetic anhydride [Huang et al. 1997] was dissolved into 100 mL DMSO.  To 
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this was added 8-amino-2-naphthol (1.300 g, 1 eq., 96%).  The mixture was allowed to 
stir for 48 h at ~40
◦
 C or until the reaction had completed as determined by TLC (95% 
CH2Cl2 / 4% MeOH / 1% acetic acid; Rf = 0.25).  The solution was then diluted with 
CHCl3 (200 mL) and washed with brine adjusted to pH = 2 by addition of conc H3PO4, (4 
x 250 mL aliquots) to remove DMSO.  The organic phase was concentrated, leaving a 
dark red/brown crude residue and separated by silica gel (95% CH2Cl2 / 4% MeOH / 1% 
acetic acid).  The product, N-tBoc-1-naphth-7-ol-glutamide, was isolated at Rf = 0.25 and 
subsequently concentrated by rotovap to a dark red brown oil and used without further 
purification. 
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HN
HOOC
H
N
O
O
O
OH
+H3N COOH
H
NO
OH
HCl
1) TFA:CH2Cl2
2) 10mM HCl 1.2 eq.
CSE102
C15H17ClN2O4
Mol. Wt.: 324.76  
 
1-Naphth-7-ol-glutamide: BRL:  234 
A 50 % solution of TFA in CH2Cl2 (6 mL) was added to a round bottom flask containing 
0.520 g (1.34 mmol) of N-tBoc-8-napthol-2-glutamide which dissolved immediately and 
turned a dark red/brown color.  The mixture was allowed to stir for at additional 45 min. 
at room temp (~21
◦
 C) whereby it was observed that the reaction had completed as 
determined by TLC (90% CH2Cl2 / 9% MeOH / 1% AcOH; Rf = 0.01).  The solution was 
then aspirated with compressed air until dry to remove TFA and CH2Cl2.  The remaining 
solid (deprotected product and TFA salt) was washed with 3 x 80 mL CH2Cl2 and then 
mixed with 147 mL 0.01 M HCl (737 µL of 2.0 M HCl, 1.1 eq.) followed by light 
sonication to suspend the residue.  The solution was then frozen to -80
◦
 C and placed on 
the lyophilizer to dry / remove all the water and remaining TFA leaving a dark red 
residue (8-naphthol-2-glutamide).  The final product was analyzed by 
1
H, 
13
C NMR, and 
rotational analysis to confirm identity and determine purity. 
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1
H-NMR (500 MHz, d6-DMSO at 2.5 ppm) δ 9.95 (s, 1H), 8.58 (s, 2.5H), 7.74 (d, J = 8.8 
Hz, 1H), 7.61 (d, J= 8.1 Hz, 1H), 7.44 (d, J = 7.1 Hz, 1H), 7.24 (s, 1H), 7.20 (dd, J = 
15.2Σ, 7.6, 1H), 7.12 (d, J = 8.3 Hz 1H), 3.96 (dd, J = 15.4 Σ, 5.2 Hz, 1H),  2.73 (m, 30.8Σ, 
7.8, 7.6 Hz, 1H), 2.62 (m, J = 30.3Σ, 7.8, 7.6, 7.1, Hz, 1H), 2.16 ( m, J = 6.6 Hz, 2H); 
 
13
C-NMR (500 MHz, d6-DMSO at 39.5 ppm) δ 171.2, 170.9, 155.9, 132.2, 130.5, 130.1, 
128.8, 125.9, 123.2, 122.4, 119.0, 104.9, 52.0, 31.6, 26.5; 
 
CHN analysis for C15H17ClN2O4∙ 5H2O calc. C, 43.43; H, 6.56; N, 6.75; O, 34.71; Cl, 
8.55 Found:  C, 41.83; H, 6.17; N, 5.29; 
  
[ α ]
22
D = + 10
◦
 (c = 0.50, methanol, Na
+
 D lamp). 
 
 
 
DMSO
HN
HOOC O
HN
O
O NO2
H
N
O
O
O
O
O
2-Amino-7-nitro-fluorene
 
 
N-tBoc-7-nitro-fluorenyl-1-α-amide-aspartate: BRL: 75 
Aspartate anhydride, 0.923 g (4.29 mmol), was dissolved into 44 mL DMSO (0.1 M final 
conc.).  To this was added 0.824mg of 2-amino-7-nitrofluorene (0.85 eq, 3.64mmol) 
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synthesized from 2-nitrofluorene (Saroja G., et al. 2004).  The solution was allowed to 
stir for 24 h at 40
◦
 C in which the reaction had reached completion as determined by 
TLC.  The reaction crude in DMSO was then diluted with 100 mL water (pH = 2, 
adjusted by addition of conc. H3PO4) and extracted with CHCl3 (3 x 400 mL).  The 
separated organic layers were combined and washed with brine at pH = 2 adjusted by 
H3PO4 6 x 250 mL aliquots to remove DMSO.  The organic phase was dried over Na2SO4 
and concentrated to an oil.  The product was then isolated by silica gel (mobile phase = 
95% CH2Cl2 / 4% MeOH / 1% acetic acid).  The α-addition product (Rf = 0.5) was 
collected from several combined fractions and concentrated to a yellow solid residue, 
0.100 g (0.226 mmol) of N-tBoc-7-nitro-fluorenyl-1-α-amide-aspartate, which was used 
in the next synthetic step without further purification. 
 
 
 
+H3N
HOOC O
HN
NO2
HCl
HN
HOOC O
HN
O
O NO2
1) TFA:CH2Cl2
2) 10mM  HCl 1.2 eq.
CSE129
C17H16ClN3O5
Mol. Wt.: 377.78
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7-Nitro-fluorenyl-2-α-amide-aspartate: BRL: 299 
To 0.100 g of N-tBoc-7-nitro-fluorenyl-2-α-amide-aspartate was added 6 mL of 50% 
TFA in CH2Cl2 (% vol) which dissolved immediately and turned a dark orange color.  
The solution was allowed to stir for 60 min whereby it was observed that the reaction had 
completed as determined by TLC.  The solution was then aspirated until dry with 
compressed air to remove the TFA and CH2Cl2. The remaining solid (deprotected product 
and TFA salt) was then suspended by addition of 1.2 eq. 0.01M HCl and light sonicatio.  
and frozen to -80
◦
C.  One frozen the sample was placed on the lyophilizer until dry, 
removing all remaining TFA and leaving an orange solid residue.  The residue was then 
washed 3 x 30 mL of CH2Cl2, leaving 0.075 g of 7-nitro-fluorenyl-2-α-amide-aspartate 
(an 88% yield).  The final product was confirmed by 
1
H, 
13
C NMR, HRMS and rotational 
analysis.   
 
1
H-NMR (500 MHz, d6-DMSO at 2.5 ppm) δ 11.01 (s, 1H), 8.41 (s, 1H), 8.27 (dd, J = 
10.0Σ, 8.7, 1.5 Hz, 1H), 8.06 (dd, J = 16.9Σ, 8.6 Hz, 1H), 8.02 (s, 1H), 7.69 (d, J = 8.3 Hz, 
1H), 4.29 (dd, J = 12.7Σ, 6.8 Hz, 1H), 4.08 (s, 2H), 3.00 (dd, J = 22.5Σ, 17.4, 5.1 Hz, 1H), 
2.97 ( dd, J = 24.7Σ, 17.1, 7.6 Hz, 1H); 
 
13
C-NMR (500 MHz, d6-DMSO at 39.5 ppm) δ 171.2, 166.9, 147.9, 146.7, 146.2, 144.6, 
139.6, 135.3, 123.5, 122.8, 120.8, 120.5, 119.1, 116.6, 50.3, 37.2, 35.8; 
 
 101 
HRMS m/e calcd. For C17H16N3O5 = 342.1090, found 342.1087; 
 
[ α ]
22
D = + 29
◦
 (c = 0.12, methanol, Na
+
 D lamp). 
 
 
 
DMSO
H
N
O
O
O
O
O
HN
HOOC O
HN
O
O
2-amino-fluorene
 
 
N-tBoc-2-fluorenyl-α-amide-aspartate: BRL: 25 
Aspartate anhydride, 0.936 g (4.35 mmol) was dissolved into 87 mL DMSO (0.05 M 
final conc).  To this was added 0.684 g of 2-amino-fluorene (0.85 eq., 98%, 3.77mmol).  
The solution was allowed to stir for 24 h at rt in which the reaction had reached 
completion as determined TLC.  The product in DMSO was then diluted with 100 mL 
water pH = 2 adjusted by H3PO4 conc and extracted with 3 x 400 mL CHCl3.  The 
organic layers were combined and washed with 6 x 250 mL aliquots brine, adjusted to pH 
= 2 by addition of H3PO4 conc, to remove DMSO.  The organic layer was then dried over 
Na2SO4 and concentrated by rotovap to a crude residue and subsequently separated by 
silica gel (95% CH2Cl2 / 4% MeOH / 1% acetic acid).  The α-addition product (Rf = 0.3) 
was collected from several combined fractions and concentrated in-vacuo leaving N-
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tBoc-2-fluorenyl-α-amide-aspartate as an off white solid which was used in the next 
synthetic step without further purification. 
 
 
+H3N
HOOC O
HN
HN
HOOC O
HN
O
O
HCl
1) TFA:CH2Cl2
2) 10mM  HCl 1.2 eq.
CSE97
C17H17ClN2O3
Mol. Wt.: 332.78
 
2-fluorenyl-α-amide-aspartate: BRL: 130 
To 0.305 g of N-tBoc-2-fluorenyl-α-amide-aspartate was added 6 mL of a 50% TFA in 
CH2Cl2 (%vol) solution which turned dark brown and dissolved immediately.  The 
solution was allowed to stir for 60 min where it was observed that the reaction had 
completed (determined by absence of starting material on TLC).  The solution was then 
aspirated until dry to remove TFA and CH2Cl2.  To the remaining solid (deprotected 
product and TFA salt) was added 1.2 eq. of a 0.01M HCl solution followed by 
resuspension of the residue via sonication.  The solution was then frozen to -80
◦
C and 
placed on the lyophilizer until dry, removing all remaining TFA and leaving an orange 
solid residue. The residue was washed with CH2Cl2 (3 x 30mL), leaving 0.241 g of 2-
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fluorenyl-α-amide-aspartate (a 94% yield).  The final product was confirmed by 
1
H, 
13
C 
NMR, HRMS and rotational analysis.   
 
1
H-NMR (500 MHz, d6-DMSO at 2.5 ppm) δ 10.67 (s, 1H), 7.90 (s, 1H), 7.86 (d, J = 8.4 
Hz, 1H), 7.83 (d, J = 7.1 Hz, 1H), 7.56 (dd, J = 15.5Σ, 7.1 Hz, 1H), 7.36 (dd, J = 14.2Σ, 
7.1 Hz, 1H), 7.28 (dd, J = 14.9Σ, 7.1 Hz, 1H), 4.26 (dd, J = 12.3Σ, 5.2 Hz, 1H), 3.92 (s, 
2H), 2.99 (dd, J = 22.0Σ, 17.5, 4.5 Hz, 1H), 2.87 ( dd, J = 25.2Σ, 17.5, 7.8 Hz, 1H); 
 
13
C-NMR (500 MHz, d6-DMSO at 39.5 ppm) δ 170.9, 166.2, 143.9, 142.9, 140.8, 137.23, 
137.1, 126.8, 126.4, 125.1, 120.3, 119.7, 118.3, 116.4, 49.9, 36.6, 35.5; 
 
HRMS m/e calcd. For C17H17N2O3 = 297.1239, found 297.1226; 
 
[ α ]
22
D = + 21
◦
 (c = 0.13, methanol, Na
+
 D lamp). 
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Abstract 
Hydroxy-L-proline represents an excellent molecular scaffold for the synthesis of diverse 
multifunctionalized unnatural amino acids with distinctive three dimensional 
configurations for probing the structure of a biological target.  The conformationally 
restricted proline ring makes it ideal to construct high potency inhibitors of amino acid 
transport and for computational modeling of the synthetic products.  We have synthesized 
a series of hydroxy-L-proline derivatives for activity screening at the ASCT neutral 
amino acid transporters.  A number of these synthetic prolinols were identified as non 
substrate inhibitors of low micro molar, and nano molar affinity towards the neutral 
amino acid transporters ASCT1 and ASCT2 by electrophysiological recordings.  The 
synthetic compounds (active and inactive) were computationally docked into an ASCT2 
seeded crystal homology model and analyzed with respect to structure / activity.  In a 
ligand binding domain where there exists multiple hydrophobic pockets and a multitude 
of plausible polar interactions, starting with a conformationally restricted molecular 
scaffold has helped to focus our attention along a clear path to finding an inhibitor of high 
potency for our target.  This biologically oriented synthetic approach has proved 
invaluable for the development of this project and will continue to provide insight and 
generate new ideas geared towards designing next generation inhibitors for our target 
amino acid transporters.   
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1.  INTRODUCTION 
The neutral amino-acid transporter ASCT2 (alanine serine cysteine transporter 
subtype 2; gene SLC1A5) is known to transport amino acids alanine, serine, cysteine, 
threonine, asparagine, and glutamine in or out of a cell in a sodium dependent obligate 
exchange process [Utsunomiya-Tate et al. 1996; Broer et al. 1999].  Similarly, the sister 
transporter ASCT1 (gene SLC1A4) transports serine, cysteine, alanine and to a lesser 
extent threonine [Arriza et al. 1993; Zerangue et al. 1996].  Both transporters are 
understood to exist within the same family of solute carrier 1, Na
+
 dependant, membrane 
spanning, amino acid transporters as does the excitatory amino acid transporters subtypes 
1-5 (EAATs 1-5)); substantially differing between the amino acids transported (neutral 
verses acidic) and net ion flux during transport.  The ASC transporters are included 
within a superfamily of solute transporters for which there is a homolog crystal structure, 
GltPh, a sodium dependant L-aspartate transporter isolated from Pyrococcus horiksohii 
[Yernool et al. 2004].  The homology between the ASC and the EAAT transporters can 
be exemplified by an alignment of their primary sequence, suggesting approximately 40-
44% homology [Y. Kanai et al. 1995].  Site-directed mutagenesis of a highly conserved 
arginine Arg479 in GLAST-1 (rat equivalent to human EAAT-1) or of Arg447 in EAAC-
1 (rabbit homologue of human EAAT-3) to a threonine and cysteine, respectively, have 
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shown that this arginine residue is necessary for transport of acidic amino acids aspartate 
or glutamate [Conradt et al. 1995;  Bendahan et al. 2000].  Interestingly, the mutation of 
arginine 447 for a cysteine in EAAC-1 increased the affinity and transport of the neutral 
amino acids serine, alanine and cysteine.  The equivalent residue in hASCT1 and 
mASCT2 by position and sequence alignment contains a threonine at residue 459 and 
cysteine at residue 479, respectively [Arriza et al. 1993; Utsunomiya-Tate et al. 1996].  
This suggested that this residue at 447 in GLAST-1, 479 in EAAC-1 and equivalent in 
the ASC transporters is solely responsible for discriminating in-between neutral and 
acidic amino acids transported by this family.  Conceptually, this presents a unique 
opportunity to construct inhibitors of the ASC transporters based off of similar structural 
and functional pharmacophore models developed from the numerous and well 
characterized EAAT inhibitors. 
There are a number of well known classes of synthetic EAAT inhibitors 
including, in particular, the pyrrolidine dicarboxylates and Nβ-aryl-aspartamides.  The 
synthetic compound L-trans-2,4-PDC (pyrrolidine-dicarboxylate) I was identified as a 
potent substrate inhibitor of the EAAT transporters by a group investigating radiolabeled 
glutamate uptake in synaptosomes [R. J. Bridges; et al. 1990].   
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Figure 1.  EAAT inhibitors:  2,4-PDC I, β-fluorenyl-L-aspartamide II, β-threo-
benzyloxy-L-aspartate (TBOA) III, L-β-threo-benzylaspartate IV. 
 
Importantly, it was observed that addition of a methyl group to the ring of L-trans-2,4-
PDC to make 2,4-methyl-PDC changed the transport properties of this compound from a 
substrate to a non-substrate inhibitor of the EAATs, and similarly an isopropyl derivative 
of kainite, dihydrokainate [Koch et al. 1999].  This observation has been consistent with 
the next generation EAAT inhibitors, namely the high potency (IC50 ≈ 0.020, 0.200 µM; 
EAAT-3 & EAAT-1) 2-fluorenyl-L-aspartamide II [Dunlop et al. 2007] and other 
derivatives of Nβ-aryl-aspartamides [Greenfield et al. 2005], which have led to the 
identification of a relatively large hydrophobic pocket.  Additionally, there has been 
considerable effort to create selective inhibitors of the EAATs through discovery of 
analogs of TBOA (L-threo-beta-benzyloxyaspartate) III and threo-benzyl-L-aspartate IV 
by extension of the benzyloxy and benzyl groups [Shimamoto et al. 1998; Esslinger et al. 
2005].  Similarly, a hydrophobic pocket near the ligand binding domain of the ASC 
transporters may also exist that could be exploited to develop high potency and/or 
selective inhibitors.  Lending support to this credence is the activity of benzyl-L-serine, 
and benzyl-L-cysteine, of which resemble TBOA minus the beta carboxylic acid.  Both 
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of these compounds act as non-substrate inhibitors of ASCT2, although with a 
considerably low affinity, Ki ≈ 780 µM for benzyl-L-cysteine and 900 µM for benzyl-L-
serine [Grewer et al. 2004].   Furthermore, our lab has observed that Nγ-aryl-glutamine 
analogs are capable of inhibiting ASCT2 mediated uptake of L-glutamine and thus also 
supporting the existence of a large hydrophobic pocket [Esslinger et al. 2005].   
 
ASCT2, particularly, has been suggested to play an important physiologic role by 
the shuttling of glutamine which itself may facilitate or regulate various physiological 
processes such as cell growth, proliferation, and possibly even glutamatergic 
neurotransmission via the glutamate / glutamine cycle.  Recently ASCT2 transport has 
garnered attention because of its link to the, though somewhat unclear, regulation of the 
mammalian-target-of-rapamycin (mTOR), a serine/threonine protein kinase that is 
implicated in the regulation of cell growth and survival [Fuchs et al. 2007, Nicklin, et al. 
2009].  Although the involvement of ASCT2 in growth and proliferation of certain tumor 
cell lines has been initially investigated [Fuchs et al. 2005 ]; the physiological 
significance, the contribution to the glutamate / glutamine cycle and function of both 
ASC transporters in mammalian tissues, like those in the central nervous system,  is 
poorly understood.  This may be a owing to the absence of potent and/or selective 
inhibitors to act as pharmacologic tools for probing of ASC transporter function.  Thus 
far, there has been little progress in developing inhibitors to study the ASC transport 
system.  This might be explained by the lower affinity the ASC transporters have for their 
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endogenous substrates; 24-400 µM for preferred substrates of ASCT(1 & 2) 
[Utsunomiya-Tate et al. 1996; Broer et al. 1999] relative to transporters such as the 
serotonin transporters.  Additionally, the activity of the first ASCT2 inhibitors, benzyl 
cysteine and L-γ-glutamyl-p-nitroanilide (Ki > 800; data not shown), as leads have a 
discouragingly low affinity.  Recently, it was reported that trans-4-hydroxy-L-proline is a 
high affinity, or preferred substrate transported by ASCT1 [Pinilla-Tenas et al. 2003].  
The proline ring itself is particularly useful as a scaffold for creating molecules with 
multiple stereocenters with unique spatial arrangement.  We were also drawn to the idea 
that the conformationally restrained ring of hydroxy-proline derivatives when combined 
with computational modeling would help to establish the fundamental molecular 
interactions that take place between ligand and ASCT transporter.  Here we report the 
synthesis, activity and computational docking of a unique series of hydroxy-L-proline 
derivatives, or prolinols, as inhibitors of the neutral amino acid transporters hASCT1 and 
mASCT2 measured by electrophysiological recordings of blocking a Na
+
-dependant 
anion leak.  
 
2. Methods 
2.1. Chemicals and Reagents 
L-[
3
H]-alanine and L-[
3
H]-glutamine was purchased from Dupont NEN (Boston, 
MA).  Trans-4-hydroxy-L-proline, trans-3-hydroxy-L-proline, and benzyl alcohols were 
obtained from Acros Organics (Morris Plains, NJ).  LC-MS grade acetonitrile for HPLC 
 
 
111 
was obtained from EMD Chemicals USA.  The synthesis of all hydroxy-L-proline 
derivatives were synthesized by Brent R. Lyda under the mentorship of Dr. Sean 
Esslinger.  Separation of regioisomers and isolation of final products were performed on 
a HPLC C18, 250mm x 21.2mm, 10µ column using a Waters 486 Tunable Detector, and 
a Milton Roy pump.  Full experimental details are reported in the experimental section.  
All other chemical reagents were purchased from Acros Organics (Morris Plains, NJ).  
All solvents were purchases from VWR International (Radnor, PA). 
2.3. Radiolabeled Uptake in Xenopus lavies oocytes 
Briefly, uptake in oocytes was performed in 12 well plates, 3-5 oocytes / well x 3 
wells, with 10 minute incubations at 2 minute intervals / row, and 50 µl of L-glutamine in 
each well.  Oocytes were injected with 50.6 ng of mASCT2 RNA.  L-Glutamine 10 µM 
with 3 µl/ml L-[
3
H]-glutamine in Nd96 buffer at pH 7.4+/-0.05 was used for each 
experiment.  After 10 minutes, eggs were vortexed and lysed by addition of 2 M NaOH 
(1 mL) and placed in scintillation vials for quantification by a radioscintillation counter.   
Oocytes were preloaded for 20 minutes with 100 µM L-alanine (4 µL/mL· L-
[
3
H]-alanine) in Nd96 buffer at pH 7.4+/-0.05.  The experiment was done in 12 well 
plates, with 3-5 oocytes / well and totaling with 3 wells.  Radiolabeled L-[
3
H]-alanine 
exchange was performed over a course of 20 minutes with 1 mM of substrates (L-
glutamine, or L-alanine) or 1 mM trans-3-hydroxy-L-proline in 2 mL Nd96 buffer.    10 
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µL samples were taken at 1 min intervals and placed into scintillation vial for 
quantification.   
2.4. ASCT Expression and Electrophysiological Recordings in Xenopus lavies 
oocytes. 
Human ASCT1 and murine ASCT2 cRNA were microinjected in stage V-VI 
oocytes.  Uncoupled anion currents associated with the transport of substrate were 
recorded 3-5 days later as previously described (Zerangue & Kavanaugh, 1996).  
Recording solution contained 50 mM NaCl, 50 mM NaSCN, 2 mM KCl, 1 mM MgCl2, 
1.8 mM CaCl2, and 5 mM HEPES (pH7.4).  Using two-electrode voltage clamp (TEVC), 
oocytes were held at -20 mV.  Under these recording conditions, transport of substrates 
results in an outward anion current carried by SCN-, or nontransported inhibitors block 
an anion leak conductance (inward current) (Grewer & Grabsch, 2004).  These currents 
also exist in the related excitatory amino acid transporters (EAATs 1-5; Wadiche et al., 
1995).  Microelectrodes were filled with 3M KCl and had resistances from 1 to 3 MΩ.  
Recordings were performed at 22 °C with a Geneclamp 500 amplifier connected to a 
PowerLab 2/26 (AD instruments).  The digital output was interfaced to a MacBook Pro 
(Macintosh) using Chart v7.1.2 software.  The currents were low-pass filtered at 10 Hz 
and aquired at 20 Hz. Data was analyzed offline and modeling and fitting of substrate 
concentration-dependence of the currents was performed with Kaleidagraph software (v 
4.04).  The concentration dependent percent block of the anion leak or substrate 
activation of the anion current were fit with the Michaelis-Menten equation (Ianion =  Imax 
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x [Drug]/(Km +[Drug])) to define the Ki of inhibition or the apparent affinity (Km) of 
transport, respectively.    
 
2.5. Computational Docking 
Mouse ASCT2 primary sequence obtained from GenBank, 
http://www.ncbi.nlm.nih.gov was aligned with the Protein Data Bank (PDB) sequences 
for an archaeal homologue GltPh, 2NWW.pdb; [Boudker et al., 2007]. The ASCT2 
homology model was constructed by threading the aligned sequence along 2NWW 
coordinates using the T-Coffee – Fasta alignment, SCWRL – server (http://www 
1.jcsg.org/scripts/prod/scwrl/serve.cgi).  The resulting model was optimized through local 
energy minimizations of regions with high steric and electrostatic interference using the 
AMBER7 force field in the SYBYL.  Energy minimized prolinols using SYBYL were 
docked using GOLD into the ASCT2 model.  Each of the top ten poses for each of three 
separate docking experiments was evaluated for their capacity to dock with ASCT2 
residues C479 and D476 or ASCT1 residues T459 and D456.  The top GOLDScore poses 
and lowest predicted –ΔG molecules were incorporated into the homology model and 
visualized by The PyMOL Molecular Graphics System, Version 1.3, Schrödinger, LLC. 
 
3.  Results 
3.1.  Trans-3-hydroxy-L-Proline and trans-4-hydroxy-L-Proline are high affinity 
substrates of ASCT-1 and ASCT-2 transport.   
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We first set out to identify a synthetically useful molecular scaffold that was 
commercially available and itself binds to the ASC transporters as a substrate or 
nonsubstrate (transported or not transported).  The hydroxy-L-prolines, trans-3-hydroxy-
L-proline (3-HP), trans-4-hydroxy-L-proline (4-HP) and cis-4-hydroxy-L-proline were 
screened as potential inhibitors by radio labeled L-[
3
H]-glutamine uptake in Xenopus 
lavies oocytes expressing mouse ASCT2.  Consistently, trans-3-hydroxy-L-proline, and 
trans-4-hydroxy-L-proline dose dependently inhibited 10 µM L-glutamine uptake (IC50 ≈ 
49 +/-23 µM, n(6); IC50 ≈ 85 +/-35, n(4); 3-HP and 4-HP, respectively, fit by non-linear 
regression) whereas cis-4-hydroxy-L-proline and L-proline did not (data not shown).   
Knowing that ASCT2 is an obligate exchanger of one neutral amino acid substrate for 
another, we conducted an experiment to determine if exchange was taking place in the 
presence of the trans-3-hydroxy-proline.  ASCT2 expressing oocytes preloaded for 20 
minutes in Nd96 buffer containing L-alanine (100 µM; 4 µL/mL· L-[
3
H]-alanine) was 
used to determine over a course of 20 minutes whether trans-3-hydroxy-L-proline is a 
substrate or a non-substrate inhibitor of ASCT2.  The uninjected oocytes served as a 
control for nonspecific efflux or radiolabeled alanine “leak”.  It was observed that 3-HP 
induces efflux of radio labeled L-alanine comparatively with the efflux observed by 
known preferred substrates, L-glutamine and L-alanine, thus suggesting that 3-HP is a 
substrate of ASCT2 (Figure 2).  
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Figure 2.  L-[
3
H]-alanine efflux over 20 minute time course in presence of trans-3-
hydroxy-L-proline (square), L-alanine (circle), or L-glutamine (diamond) and water 
injected oocytes (triangle).   Uninjected preloaded oocyte controls exhibit no discernable 
radioligand leak or nonspecific efflux.   
 
Trans-3-hydroxy-L-proline and trans-4-hydroxy-L-proline were evaluated as 
substrates of ASCT1 and ASCT2 by two-electrode voltage clamp recordings of a 
substrate induced 
-
SCN anion current, a technique we have found to be most reliable in 
screening for inhibitors and for characterizing the transport kinetics of the ASC 
transporters [Bröer et al. 2000; Grewer and Grabsch 2004].  A dose response with 3-HP 
or 4-HP in oocytes expressing in both ASC transporters reveals a standard and saturable 
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dose response curve (Figure 3).  Using non-linear regression best fit to Michaelis-
Menten equation we calculated the Km of both substrates, 3-HP Km = 14 +/-1.8 µM, and 
4-HP Km = 17.1 +/-0.8 µM compared to the ASCT1 substrate L-alanine Km 40 +/-1.8 
µM (Figure 3, A).  The Km found for 4-HP has been reported previously and our finding 
is in close agreement 33.2 ± 4.3µM [Pinilla-Tenas et al. 2003].   The Km of 3-HP, 4-HP 
and endogenous substrate L-glutamine transported by ASCT2 were calculated in the 
same manner 3-HP Km = 28.6 +/-6.4 µM; 4-HP Km = 76.3 +/-11.0 µM, Gln Km = 47.4 +/-
4.6 µM (Figure 3, B).  These calculated Km values for both 3-HP and 4-HP at ASCT-2 
are also in close agreement with the IC50 values we found by radio-labeled uptake.  
Additionally, our calculated Km of 47.4 µM for glutamine is also in very good agreement 
with that found in previous publications, 24 µM and 70 µM [Utsunomiya-Tate et al. 
1996; Bröer et al. 1999].   
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Figure 3. A. hASCT1 dose response curve for substrate activated anion currents using 
two-electrode voltage clamp of Xenopus lavies oocytes (-20mV). Currents are normalized 
to the maximum current estimated for Alanine  B. mASCT2 dose response curve for 
substrate activated anion currents using two-electrode voltage clamp of Xenopus lavies 
oocytes (-20mV).  Currents are normalized to the maximum current estimated for 
glutamine. Extracellular solutions contained 50 mM NaSCN, a highly permeable ion to 
the transporters anion channel.  Dose reponse curves were fit to Michaelis-Mention 
equation to find Km. 
 
Although the represented graphs show a difference in substrate elicited currents, it is 
important to understand that the Imax, maximum current, recorded by 3-HP or 4-HP are 
normalized to maximal current recorded for alanine or glutamine (ASCT1 and ASCT2) 
within our setup and is not representative of Vmax, the maximal rate at which the 
substrates are transported.  This can be explained by an amino acid exchange process that 
is stoichiometrically uncoupled to the anion current, which has been observed in both 
ASCT1 and ASCT2 [Zerangue and Kavanaugh 1996; Bröer et al 2000].  Therefore, in 
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considering both the current recordings and radiolabeled uptake data it can be concluded 
that both 3-HP and 4-HP are substrates of the ASC transporters.  With the exception of 
trans-4-hydroxy-L-proline acting at ASCT1; this is, to the best of our knowledge, the 
first time these naturally occurring amino acids as substrates of ASCT1 and ASCT2 have 
been reported.  Importantly, L-proline induces little substrate like current when applied to 
ASCT1 or ASCT2 at 300 µM (data not shown).  This is consistent with previous 
radiolabeled uptake studies showing L-proline to have a Km of 704 +/-86 µM at ASCT1 
[Pinilla-Tenas et al. 2003] and minimal inhibition of ASCT2 mediated radio-labeled L-
alanine uptake [Utsunomiya-Tate et al. 2006; Kekuda et al. 1996], and no inhibition of 
radio-labeled glutamine uptake detected within our uptake experiments.  This indicates 
that the ASC transporters may have a preference for binding amino acids with a beta or 
gamma positioned alcohol group, likely as a hydrogen bond acceptor and / or donor. 
 
3.2. Synthetic hydroxy-proline derivatives. 
A series of stereochemically distinct substituted hydroxy-L-proline derivatives 
(Figure 4) was synthesized and isolated to be evaluated as non-substrate inhibitors of 
ASCT1 and ASCT2.  Amongst the prolinols produced and isolated included regioisomers 
of phenyl, methyl or phenol-ether substituted hydroxy-L-prolines (compounds CSE -103, 
104, 109, 110, 117, 118) derived from protected 3,4-epoxy-proline under basic 
conditions.  Also included in the series was cis-4-methyl-trans-4-hydroxy-L-proline 
(CSE95) and cis-4-hydroxy-trans-4-methyl-L-proline (CSE96) synthesized from 
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protected-4-keto-proline under basic condition.  Lastly, various benzyl or alkyl ether 
substituted L-prolinols of both first (CSE-113, 115, 121, 122, 124, 127) and third 
generation (CSE-130, 131, 132) were produced under acidic conditions from protected 
cis or trans 3,4-epoxy-prolines.  This stereochemically diverse series was then tested for 
inhibitor activity against ASCT1 and ASCT2 to probe for activity and thereby guide the 
discovery of novel pharmacologic lead inhibitors.  Refer to the experimental procedures 
section for full experimental details, procedures and synthetic schemes.   
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Figure 4:  Synthesized substituted prolinols for biological testing as inhibitors of the 
ASC transporters.  
 
3.3.  Non-substrate inhibitors of ASC transporters block leak current. 
In screening the synthesized prolinols at ASCT1 and ASCT2 by 
electrophysiological methods it was critical to determine whether this class of compounds 
in particular displayed substrate or non-substrate like activity.  It has been shown that 
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non-substrate inhibitors of ASCT2 when applied alone will produce what appears as an 
inward current that is opposite of a substrate induced current, the effect of inhibiting a 
tonic anion conductance [Grewer et al. 2004].  Our results confirm this in ASCT2 
showing block of a tonic anion conductance by synthetic prolinol CSE121 at 300 µM 
relative to 300 µM of glutamine, a substrate, when individually applied (Figure 5, B).  
The anion leak is also present in ASCT1 as seen when applying synthetic prolinol 
CSE122 relative to the substrate alanine (Figure 5, A).  Interestingly, we observed a very 
robust inward current at ASCT2 when applying inhibitors such as CSE 121 at 300 µM, 
which is much less pronounced in ASCT1.  These results suggest that the synthesized 
prolinols act as non-substrate inhibitors. 
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Figure 5. Hydroxy proline derivative CSE 121 (300μM) and CSE 122 (300μM) block a 
leak current in mASCT2 and hASCT1, opposite the current induced by substrate (-
20mV). A. Inset: The current and voltage relationship for hASCT1 currents activated by 
Ala or blocked by CSE 122 resolved by subtracting away voltage jumps in Ringer 
solution. B. Inset: The current and voltage relationship for mASCT2 currents activated by 
Gln or blocked by CSE 121 resolved by subtracting away voltage jumps in Ringer 
solution. 
 
 
3.4.  System ASC Transporters are inhibited by 4-cis-ether substituted-trans-3-
hydroxy-L-prolines. 
Next we wanted to determine the affinity of what seemed to be the more robust 
prolinol inhibitors identified in our screening.  Application of selected prolinol non-
substrate inhibitors to oocytes expressing ASCT2 or ASCT1 showed block of the inward 
anion current that was concentration dependant and saturable (Figure 6, B Inset).   
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Figure 6. The leak current in hASCT1 and mASCT2 has a saturable block revealed by 
increasing concentrations of CSE 131 (down triangle), CSE 130 (diamond), CSE 122 
(square), CSE 121 (up triangle), CSE 118 (wedge), and CSE 115 (circles). The 50% 
block is considered to be the Ki for binding of a non-transportable substrate. B. Inset: A 
representative trace showing the dose relationship for the mASCT2 leak current blocked 
by CSE 121. 
 
The resulting dose response (Figure 6, A and B) recorded at ASCT1 and ASCT2 when 
applying a particular synthetic prolinol was fitted to Michaelis-Menten by non-linear 
regression to determine the apparent Km or actual Ki ≈ Kd.  Actual and estimated Ki’s are 
reported in Table 1.   
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CSE 
# 
 
 
Ki(µM) 
ACST1 
Ki (µM) 
ASCT2 
cis-hydroxy-L-
proline 
H2N
OH
O
O-
 
805 
+/- 148 
872 
+/- 201 
CSE95 
H2N
O
O-
OH
 
no detectable block 
of anion 
conductance  
926 
+/- 252 
CSE96 
H2N
HO
O
O-
 
no detectable block 
of anion 
conductance  
1077 
+/- 322 
CSE103 
H2N
OH
O
O-
 
332 
+/- 74 
1128 
+/- 318 
CSE104 
H2N
O
O-
OH
 
≈600 ≈600 
CSE109 
H2N
OH
O
O-
 
564 
+/- 149 
922 
+/- 316 
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CSE110 
H2N
O
O-
OH
 
1050 
+/- 110 
1149 
+/- 283 
CSE113 
H2N
O
OH
O
-O  
493 
+/- 61 
828 
+/- 248 
CSE115 
H2N
O
OH
O
O-
 
214* 
+/- 32 
235* 
+/- 69 
CSE117 
H2N
OH
O
O
O-
 
594 
+/- 191 
502 
+/- 110 
CSE118 
H2N
O
OH
O
O-
 
150 
+/- 43 
141* 
+/- 20 
CSE121 
H2N
O
OH
O
-O  
39* 
+/- 5 
 
69* 
+/- 7 
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CSE122 
H2N
O
OH
O
O-
 
237* 
+/-40 
 
268* 
+/- 70 
CSE124 
H2N
O
OH
O
O-
 
481 
+/- 77 
600 
+/- 176 
CSE127 
H2N
O
OH
O
O-
 
505 
+/- 105 
≈400 
CSE128 
H2N
O
OH
O
O-
 
≈150 ≈150 
Table 1:  Actual * or estimated Ki in µM derived from inhibition of tonic anion leak by 
first and second generation prolinols in Xenopus oocytes expressing human ASCT1 or 
mouse ASCT2. 
 
The first generation of these synthesized substituted hydroxy-proline derivatives 
showed modest activity.  One prolinol (CSE115) stood out amongst the various phenyl 
and methyl substituted trans-hydroxy-L-prolines (CSE-95, 96, 103, 104, 109, 110) and 
the substituted cis-hydroxy-L-prolines (CSE-113, 124, and cis-hydroxy-L-proline) in our 
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screening.   A dose response using cis-4-methoxy-trans-3-hydroxy-L-proline (CSE115) 
at both transporters gave the corresponding Ki of 214 +/-32 at ASCT1 and Ki of 235 +/-
69 at ASCT2.  After assessment of this first series we decided to pursue a second series 
of ether substituted trans-hydroxy-L-prolines more focused on prolinols with a 3 
positioned alcohol, this included CSE-117, 118, 121, 122, and 128.   The isopropoxy-cis-
hydroxy-L-proline CSE127 was also made in this series because we felt it was prudent to 
expand just beyond the addition of a methoxy group before ruling out this class of 
prolinols as potential leads.   
 Measuring the blocked anion leak with the second generation of prolinols 
revealed that addition of a phenoxy or benzyloxy at the four carbon of the proline ring, 
CSE118 and CSE121, increases potency relative to the 4-methoxy substituent CSE115.  
However, no real improvement in affinity was gained by the isopropoxy extension from 
the methoxy group for cis- or trans-hydroxy-L-prolines.  Most encouraging was the 
benzyloxy product, trans-3-hydroxy-cis-4-benzyloxy-L-proline CSE121, which provided 
a 5 and 3 fold increase in potency at ASCT1 and ASCT2 respectively.  This is well 
within the affinity these transporters exhibit for their preferred substrates, an affinity that 
has not yet been achieved by any non-substrate inhibitor of the ASC transporters to date.  
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CSE130 
H2N
O
OH
O
O-
O
 
13* 
+/- 2 
10* 
+/- 2 
CSE131 
H2N
O
OH
O
-O  
0.31* 
+/- 0.04 
0.24* 
+/- 0.04 
CSE132 
H2N
O
OH
O
O-
 
≈10 ≈10 
Table 2:  Actual Ki’s * of third generation prolinols as lead inhibitors of ASCT1 and 
ASCT2, calculated from measured dose response of blocked anion conductance.  
 
  The next step in developing this class of inhibitors was clearly to expand upon the 
benzyl-ether of 4-cis-benzyloxy-trans-3-hydroxy-L-proline (CSE121).  The third 
generation of prolinols that were synthesized included the addition of a biphenyl, naphtyl, 
and diphenyl ether group, Table 2 CSE-130, 131, and 132.  These additions markedly 
improved the potency of these prolinols at the ASC transporters.  Like the other prolinols 
derivatives, the new inhibitors obeyed Michaelis-Menten kinetics displaying block of the 
anion leak conductance that was dose dependent and saturable.  The corresponding Ki 
values obtained are a leap from that of the second and first generation prolinols.  
Strikingly, the addition of a phenyl group para to the methoxybenzyl of CSE 121 
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afforded a 290-fold improvement in potency at ASCT2.  This is also a significant leap, 
40-fold, in potency over that of the naphthyl and 3-diphenyl ether prolinols (CSE 132, 
and 130).  This result may indicate that the hydrophobic pocket of these transporters, of 
which we are probing, is somewhat narrow.  The new lead inhibitor (2S, 3R, 4R)-3-
hydroxy-4-O-methyl-p-biphenyl-proline (CSE131) was found to have a Ki of 0.24 µM at 
ASCT2 and 0.31 µM at ASCT1.  Unfortunately, this last series did not pull out any 
selectivity between ASCT1 and ASCT2 as we were hoping.   
 
3.5 Computational docking predicts ligand transporter interaction and hydrophobic 
pockets. 
 In addition to the biological screening of the prolinol series we obtained a crystal 
homology model (GltPh) of human ASCT2 from the Protein Data Bank.  The synthesized 
prolinols CSE 113, 121, 128, 130, 131, and 132 (Figure 4) were docked using GOLD 
into the ASCT2 homology model based upon the open, ligand accessible, form of GltPh 
with bound TBOA [Boudker et al. 2007].    The top computer generated posses, scored 
via ChemScore, of three separate docking experiments were evaluated by the presentation 
of reasonable intermolecular interactions between the docked hydroxy-proline derivatives 
and residues C479 and D476 of ASCT2.  Importantly, both of these residues are the 
equivalent residues in the putative ligand binding site of EAAT 1 and 3 that were 
identified by site directed mutagenesis as functionally critical residues for binding and 
transport of endogenous substrates [Conradt et al. 1995;  Bendahan et al. 2000; Teichman 
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and Kanner 2007].  The docking experiments were run with one constraint (ChemScore 
constraint weight = 5.0) to favor an interaction with aspartate residue D476 of ASCT2.  
Without the constraint the docked poses would otherwise interact entirely with the 
carbon- peptide backbone and hydrophobic regions of the transporter which would 
suggest that binding is purely allosteric, which is inaccurate.  Essentially, with the 
constraint the GOLD will avoid this improper docking which coincidently also favors 
docked poses of inactive prolinols over active. 
 Prolinol CSE121 docked into the ASCT2 homology model by aligning with its 
secondary amine to the β carboxylic acid of Asp476 at 2.2Ǻ and to the nearby Thr480. 
(Figure 7).  Additionally, the trans-3-hydroxyl group of the prolinol (CSE121) aligned at 
2.7 Ǻ to the sulfhydryl group of Cys479; and finally, the α-carboxylic acid of the prolinol 
aligned with the nearby Asn483 and serine peptide amide from the HP1 loop.  
Consequently, the orientation that the prolinol CSE121 adopts in order to interact with 
these critical residues places the benzylether group down towards the intracellular 
spanning side of helix transmembrane seven (TM7a; teal) or slightly under the HP2 loop 
(red).   
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Figure 7: CSE121 (purple) docked into a mouse ASCT2 homology model. Shows 
intermolecular interactions between the prolinol’s functional groups (alchol, secondary 
amine (blue), and carboxylic acid) and key residues of ASCT2, Asp476. Cys479 
(sulfhydryl in yellow), Asn483 (behind CSE121), and Thr480.  The benzyl ether of 
CSE121 rests over a methionine residue (M399) of TM7 (transmembrane 7, teal) 
(sulfhydryl in yellow). Image visualized by PyMOL Molecular Graphics System, Version 
1.3, Schrödinger, LLC. 
 
Interestingly, the benzyloxy of CSE121 is positioned over a methionine residue, M399, 
which is equivalent to methionine M311 of GltPh that the benzyloxy of TBOA interacts 
with in the published crystal structure.  Upon examinating the conformation of CSE121 
docked into ASCT2, it was encouraging to see the generated poses resembling the 
conformation of TBOA bound into GltPh (Figure 8).   
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Figure 8: Crystal structure of GltPH with TBOA bound and intermolecular interactions 
in yellow dotted lines [Boudker et al. 2007].  Image visualized by The PyMOL Molecular 
Graphics System, Version 1.3, Schrödinger, LLC. 
 
Computational docking of an inactive stereo isomer of CSE121, CSE113 (cis-3-hydroxy-
trans-4-benzyloxy-L-proline), revealed a plausible hydrophobic pocket through 
interaction with a phenyl alanine F405 (Figure 9).  Both prolinols rings of CSE121 and 
CSE113 overlay well with each forming an electrostatic interaction with Asp476 and 
hydrogen bonding interactions with residues Thr480, Asn483.  CSE113 consistently and 
significantly scores higher by both ChemScore (~18-23 vs ~11-13) and GoldScore than 
does CSE121 suggesting that the hydrophobic pocket of which the benzyl ether group of 
 
 
133 
CSE113 docks into confers higher potency.  Docking of CSE128 into ASCT2 (not 
shown) positions the phenoxy-ether near the phenyl alanine F405, the amine to Asp476 
and the α-carboxylic acid with an amide from the HP1 primary chain.  The orientation in 
this alignment leaves the trans-3-hydroxyl interaction with Cys479 intact while 
maintaining the interaction with phenyl alanine F405.  Although CSE128 does not score 
as high as CSE113 it does score comparably with CSE121.   
Figure 9: CSE113 (yellow) and CSE121 (purple) overlay in mouse ASCT2 homology 
model.  Shows two hydrophobic pockets, one near phenylalanine F405 on TM7β (teal); 
the other on top of a methionine residue (M399) on TM7α (teal) and under HP2 loop 
(red).  
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The only other underlying structureal difference between CSE121 and CSE113 is the 
stereo configuration of the 3 positioned hydroxyl.  The two poses of CSE121 and 
CSE113 in Figure 9 show the 3-hydroxyl of CSE121 to be above the proline plane and 
aligning with Cys479; however with CSE113 the 3-hydroxyl is below the proline ring 
plane with no interaction.  This supports our hypothesis that a hydrogen bond (donating) 
or strong dipole interaction is taking place with Cys479, and therefore only the trans-
hydroxy-prolines are tolerated.  Docking experiments where we have substituted Cys479 
in the ASCT-2 homology model for a threonine score in favor of the trans-3-hydroxy-
proline CSE121 over the cis-hydroxy-proline CSE113 (data not shown).  This may 
indicate that equally in ASCT1 there is a preference for ligands (substrate or 
nonsubstrate) that interact with the equivalent threonine residue T459.  A theoretical 
analog of CSE113 and CSE121 where both the hydroxyl and benzyl ether are trans to the 
L-carboxylate (3,4-trans-hydroxy-benzyloxy-L-proline) was created and docked into the 
homology model (Structure A).   
H2N
O
OH
O
-O Structure A 
This analog aligns in the model just as CSE113 does, although now with the hydroxyl 
functionality aligning with Cys479.  One would have predicted that this theoretical 
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analog would score higher than CSE113, however it scores relatively the same (≈18-23).  
Altogether this would suggest that interactions with the sulfhydryl group in this model 
are not properly weighted or defined in GOLD.  We were unable to resolve this issue 
without resorting to placing a constraint in favor of an interaction with Cys479 into the 
experiment.  
 
Figure 10: CSE130 (teal) and CSE131 (gold) overlay docked into ASCT2 homology 
model.  Residues with hydrophobic side chains are labeled in white; polar residues are 
labeled in blue.  Docking depicts interactions with Cys479, Asp476, Thr480, Asn483 and 
amide/carbonyl of HP1 loop backbone. 
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Docking of our most potent inhibitors CSE131 and 130 identifies a hydrophobic 
pocket that extends from Met399 and along the beginning TM7α (Figure 10).  The 
orientation and alignment of these prolinols in the binding domain is consistent with that 
found for CSE121 where again the trans-3-hydroxyl aligns with Cys479, the secondary 
amine aligns with Asp476 and Thr480, and finally the α-carboxylic acid aligns with 
Asn483. These more highly conjugated prolinols also score quite high by ChemScore, 
between 23-27.  Figure 11 illustrates the plausible hydrophobic pocket (shown in white) 
identified by docking of CSE131 into the ASCT2 homology model.  
Figure 11.  CSE 131 docked in ASCT2 homology model depicting surface density.  
Residues with hydrophobic side chains are labeled in white, polar residues are labled in 
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blue.  Shows alignment of CSE131 to polar side chains Asp476 and Thr480 (red), 
Cys479 (yellow), Asn483 (dark blue).  
 
 
 
3.  DISCUSSION 
The ability to make use of a crystal homology model to analyze structure activity 
of a series of compounds provides an incredible advantage to understanding the 
molecular interactions that may be taking place between ligand and receptor, or in this 
case a transporter.  Site directed mutagenesis of specific residues in the ligand binding 
domain can then further strengthen our understanding of the important interactions taking 
place by narrowing down which amino acids are critical for binding.  Another strategy is 
to employ a conformationally restricted molecular scaffold when developing a series of 
potential inhibitors for screening.   Indeed, the unique conformations that such a scaffold 
forces will efficiently guide a developing pharmacophore model.  Collectively these 
strategies make a very compelling argument for the necessary polar molecular 
interactions taking place between high affinity ligands and ligand binding site, the 
interactions often necessary to produce potent lead inhibitors.   
In this study we have identified trans-3 and trans-4-hydroxy-L-proline as high 
affinity substrates of ASCT1 and ASCT2 mediated transport by radiolabeled uptake and 
electrophysiological recordings of substrate transport induced anion current.  These two 
natural amino acid transporters noticeably prefer the trans-3-hydroxy-L-prolines analogs 
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over the cis-diastereomer equivalent.  This indicated that the hydroxyl group may be 
involved in hydrogen bonding or a strong dipole-dipole interaction with the ASC 
transporters through a key polar residue responsible in ligand recognition.  This is not 
surprising considering ASCT2’s selective transport of amino acids Ser, Cys, Gln, and 
Asn, or preferred substrates of ASCT1, all of which contain a capable hydrogen bonding 
functional group on their side chain, excluding alanine.   Furthermore, ASCT2 mediated 
transport of glutamate is pH sensitive.  In a more acidic environment the glutamate γ-
carboxylate becomes protonated and now binds ASCT2 by interaction with a 
fundamental residue responsible for ligand recognition.  This molecular interaction likely 
occurs through a hydrogen bond in ASCT transporters versus an electrostatic interaction 
as seen in the EAATs via an arginine residue [Utsunomiya-Tate et al. 1998].  The pH 
sensitivity of ASCT2 has also been demonstrated through inhibition or radiolabeled 
uptake by Nγ-aryl-glutamine analogs (Esslinger et al. BOMC 2005).  The prevalent view 
is that cysteine 479 in ASCT2 or threonine 459 in ASCT1 are responsible for 
discriminating between acidic and neutral amino acids.  Unfortunately, the modeling 
software GOLD does not recognize all the necessary interactions and often docks trans-
3- or 4-hydroxy-proline nonspecifically with the carbon peptide backbone or by improper 
alignment of the α-carboxylate with Asp476 of the ASCT2 homology model.  However, 
it is visually apparent that the energy minimized structures of the trans-hydroxy-prolines 
are capable of aligning with Cys479 and Asp476 through the secondary amine and 
hydroxyl group where cis-hydroxy-prolines are not.   
 
 
139 
We have been successful in using trans-4-hydroxy-L-proline as a molecular 
scaffold to synthesize inhibitors of the ASCT neutral amino acid transporters.  Our first 
lead in this series, although not all that potent, was CSE115 a trans-3-hydroxy-cis-4-
methoxy-L-proline.  Surprisingly, the methyl analog of this CSE110, trans-3-hydroxy-
cis-4-methyl-L-proline, showed no activity when tested at the ASCT transporters.  A 
rational explanation for the observed loss in activity from substitution of a methoxy for a 
methyl prolinol may be that the two compounds adopt different boat conformations.  The 
substituted methyl prolinol positions the amine away from the hydroxyl group.  In 
comparison, the methoxy substituent positions the amine close to the hydroxyl group in 
prolinol CSE115.  The resulting energy minimized structures and docking of CSE110 and 
CSE115 using SYBYL supports this idea.  The conformation CSE110 adopts essentially 
would not allow for interaction of the prolinol functional groups with Cys479 and 
Asp476 to occur simultaneously, whereas the conformation of CSE115 does.   
The extension of CSE115 to produce the isopropoxy-prolinol CSE122 provided 
no additional benefit in activity.  Introduction of a phenoxy to produce CSE118 did add a 
measurable increase in affinity.  However, the greatest increase in potency came from the 
extension of CSE115 to produce CSE121, a benzyloxy substituent.   Although it is not 
exactly clear as to why this substitution provides greater activity than the phenol ether 
CSE118, it may stem from the added flexibility of the benzyl group.   This may help to 
position the aromatic ring slightly underneath the HP2 loop where it can fully interact 
with Met399.   
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Although incomplete, this prolinol series has already begun to describe a 
pharmacophore model for designing inhibitors of the ASCT transporters and may have 
also provided some leads to achieving an ASCT subtype selective inhibitor.  One 
interesting avenue to pursue ASCT1 selective inhibitors could include analogs of cis-3-
phenyl-4-trans-hydroxy-L-proline, CSE103.  The 3-positioned cis-methyl prolinol 
CSE109 from our screening showed slight selectivity for ASCT1 over ASCT2.  This 
selectivity is further improved by substitution for a phenyl, CSE103, observed by an 
increase in activity at ASCT1 and no detectable change in activity at ASCT2 relative to 
the CSE109.  This may also have important implications for designing selective 
inhibitors of the EAATs.  Another possibility may be to create analogs of CSE128, trans-
3-hydroxy-trans-4-phenyl-L-proline, by extension of the phenol ring to exploit the 
hydrophobic pocket near phenyl alanine F405 or equivalent in ASCT1.  Docking 
experiments of this prolinol derivative suggested that analogs of this configuration would 
be a valid approach to probing this hydrophobic pocket and still maintain the key 
interactions with Cys479 and Asp476 or equivalent in ASCT1.   
In investigating the structure activity of the various EAAT’s inhibitors it is 
revealed that extension of the benzyloxy group of TBOA to create a diphenyl amide 
analog (TFB-TBOA) [Shimamoto et al. 2004] produced an inhibitor with over a 250-fold 
improved potency.   Another class of EAAT inhibitors in which this improvement in 
potency has also been observed is the various analogs of aryl-aspartamides where the 
substitution of a phenyl amide group for a fluorene or a biphenyl substituent dramatically 
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increased potency.  Thus, when confronted whether or not to optimize activity of the 
benzyl-ether derivative CSE121 by addition of a methyl, fluorine, methoxy, or isopropyl 
groups to the benzyloxy ring we instead choose to pursue more conjugated substituent’s 
such as a biphenyl, naphthyl or diphenylether analogs.  Of the three tested, addition of a 
biphenyl to generate (2S, 3R, 4R)-3-hydroxy-4-O-methyl-p-biphenyl-proline (CSE131) 
was the most potent inhibitor at both ASCT transporters.  To the best of our knowledge, 
this compound is also the most potent ASCT transport inhibitor yet to be reported.   
The prolinol scaffold and biphenyl group of CSE131 has granted unparalleled 
inhibitory activity at the ASCT transporters.  Although this is the first time a compound 
of this potency has been reported at system ASC, inhibitors of even greater potency are 
common at the EAATs.   Already, the developing pharmacophore at the ASCT 
transporters very much resembles that of the EAATs.  With respect to the key amino acid 
binding residues and the hydrophobic pocket, pharmacologic evaluation would suggest 
that the ASC/EAAT family of transporters is well conserved.  It remains to be seen 
whether these prolinol inhibitors of ASC transport also act at the EAATs or for that 
matter any of the other neutral amino acid transporters such as system A or system N.   
The computational docking of these prolinols into a homology model has allowed 
for a unique perspective to help explain trends and activity observed with the presented 
series of prolinols we have created.  Notably, the homology model combined with the 
known activities of our prolinols has helped confirm the relevance of Cys479 in ASCT2 
or Thr459 in ASCT1 as a crucial interaction for binding of ligand for either translocation 
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or as an inhibitor.  Though, computational modeling does have its limitations, as 
observed by the insistence of the software to score CSE113 as high as it does even though 
this diasteriomer is inactive.  Our strategy was to use the conformationally restricted 
prolinol scaffold to support the homology model.  Thus far both strategies have supported 
one another and this has proved useful in elucidating structure activity. 
4. Conclusion. 
We have described a novel series of prolinols that act as potent inhibitors of the neutral 
amino acid transport mediated by ASCT1 and ASCT2.  Significant gains in potency were 
achieved by incorporation and extension of a benzylic ether substituent to a hydroxy-L-
proline scaffold in a specific stereo and regio configuration.  As a result of the 
conformationally constrained proline ring, the activity of this series of prolinols has 
important implications concerning the structure and function of the ligand binding 
domain at the ASCT / EAAT family of transporters.  This work itself has also been 
beneficial in establishing a synthetic method for developing prolinol analogs and will 
likely facilitate the synthesis of next generation neutral amino acid transport inhibitors.  
Ultimately it is hoped that the identified inhibitors from this study will provide as useful 
pharmacologic tools to evaluate the physiological significance of the ASCT1 and ASCT2 
transporters. 
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Prolinols as selective ASCT inhibitors 
In searching for a practical scaffold to synthesize selective ASC transport inhibitors our 
group identified both trans-4-hydroxy-L-proline and trans-3-hydroxy-L-proline as high 
affinity selective substrates of ASC (1 and 2) mediated transport via radio-labeled uptake 
and substrate induced current electrophysiological techniques.  Particularly, hydroxy-
proline analogs (Figure 12) were an attractive target that was pursued because of the 
conformationally restricted ring which would allow us to effectively delineate transporter 
structure and activity relationship (Bridges, R. et al. 1990).  Additionally, these analogs 
resemble the high affinity endogenous ASC transporter substrates L-serine, L-threonine 
(For characterization of ASC transport see, Arriza J., et al. 1993; Utsunomiya-Tate, N.  et 
al. 1996; or review Broer, A. 1999) as well as the unnatural amino acid L-homoserine 
(data not yet published).  In short, a series of diverse, substituted hydroxy-L-proline 
analogs with an array of different stereo- and regiochemistry was synthesized to be 
evaluated as inhibitors of amino acid transport, specifically ASC transport.  From this 
series we identified a number of potent ASCT selective inhibitors that may be used to 
further elucidate the role and function of this transporter.  This work has been beneficial 
in establishing a synthetic method for developing prolinol analogs and will likely 
facilitate the synthesis of next generation inhibitors of the system ASC transporters. 
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Figure 12:  Substituted prolinol targets.   
 
A key point to be resolved during the development and synthesis of these prolinols was 
the elucidation of their stereo and regiochemistry.  The stereochemistry of the 
synthesized prolinol compounds was established from the fully protected (N-Cbz & 
benzyl ester) 3,4-epoxy-prolines from which they are derived.  The two stereoisomers are 
easily separable which allowed their stereochemistry to be easily determined by two 
dimensional nuclear overhauser effect spectroscopy (NOESY) on a 500 MHz NMR 
(mixing time of 0.7 seconds).  One NOE that was readily observable by these epoxides 
(trans and cis) was between the α carbon proton H-1 (refer to Figure 13) and H-4 of the 
methylene that is adjacent to the amine.  When comparing the trans-epoxide to the cis- 
epoxide, the H-3 & H-2 proton display a strong NOE to the H-4 proton of the cis-3,4-
epoxide compared to a very weak or nonexistent NOE correlation between the H-3 or H-
2 protons and the H-4 proton of the trans-3,4-epoxide.  This suggests that the stereo 
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chemistry of both isomers was properly assigned and is also consistent to that previously 
reported by (Robinson, J.K.; et al.  1998).   
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Figure 13: Proton and carbon numbering scheme used in 
1
H-NMR & 
13
C-NMR 
assignments.  “A” represents any atom or group.   
 
The regiochemistry of the final product hydroxy-proline derivatives was determined by 
2D correlation spectroscopy or COSY.  Figure 14 illustrates an example of how the 
proton assignments and regiochemistry were made from a COSY experiment of prolinol 
product CSE122.  The numerical labels such as 0.09 (2,2) indicate intensity (first 
number) and protons correlated in parentheses.  The methylene protons H-4 & H-5 are 
easily spotted at ppm 3.4-3.56 by their strong J2 coupling and chemical shift.  It is clear 
that the methylene protons are coupled to a proton at ppm 4.1.   
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Figure 14:  gCOSY of CSE 122, shows correlation intensity in 0.0x and proton # in (x,x).  
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Importantly, one of these methylene protons is more strongly coupled to this proton, a 
result of a small dihedral angle between these two protons suggesting they reside on the 
same plane of the proline ring.  The alpha proton H-1, seen at ppm 3.98, is weakly 
coupled to only one other proton at ppm 4.58.  This proton has small couplings with two 
other protons at ppm 3.42 and 4.1 (a methylene proton).  The weak J3 couplings 
(opposite plane of the proline ring) and its chemical shift suggest this proton is H-2 and 
therefore the proton at ppm 4.1 is H-3.  The methylene protons were then assigned 
according to coupling intensity with the H-3 proton, with H-4 at ppm 3.56 and H-5 at 
ppm 3.42.  This assignment is also consistent with the small J4 coupling observed 
between H-2 and H-5.    
 
 
Experimental section: 
Proton 
1
H and carbon 
13
C nuclear magnetic resonance (NMR) spectra were obtained from 
Varian 500 MHz spectrometers as specified.  Both 
1
H and 
13
C spectra are reported in 
parts per million (ppm or δ) downfield from tetramethylsilane as an internal standard.  All 
chemical shifts reported were referenced to residual protonated D2O or DMSO solvent 
peaks at 4.75 or 2.5 ppm, respectively, for 
1
H proton spectra and 39.5 ppm for 
13
C carbon 
spectra unless specified otherwise.  Multiplicity is reported as doublets (d), doublet of 
doublets (dd) etc. where Σ represents the sum of all couplings, b = broad.  N.O.e. 
experiments were performed on a Varian 500 MHz using 2D NOESY parameters with 
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zero-quantum suppression and mixing times of 0.7 s to determine the stereochemistry of 
diastereomers.  Gradient correlation spectroscopy (gCOSY) to determine regiochemistry 
was also performed using a Varian 500 MHz.  Optical rotations of final compounds 
dissolved in methanol or DMSO, as specified, with concentrations given in g/100 mL 
were determined via a Perkin-Elmer Model 241 polarimeter in a 1.0 dm glass cell sodium 
D line.  High resolution mass spectra (HRMS) were determined on a Waters LC-MS 
spectrometer using caffeine or trimethoprim as a mass standard at m/z 195.0882 or 
291.1457 respectively for HRMS.  All reagents were purchased from Acros Organics and 
used without further purification.  Solvents as well as 40-60 µM silica gel for flash 
chromatography were obtained from EMD chemicals (Gibbstown, NJ).  Intermediates 
were isolated by silica gel used without further purification, unless specified otherwise.  
A mobile phase consisting of 95% CH2Cl2 / 4% MeOH / 1% AcOH or hexanes / ethyl 
acetate was used for TLC and flash chromatography, as specified.  Ion exchange 
chromatography was carried out using Bio-rad AG® 50W cation exchange resin which 
was pre-equilibrated in 1M HCl followed by deionized water.  Semi-prep reverse phase 
HPLC was carried out using a C18, 250 mm x 21.2 mm, 10 µ, Chromegabond WR 120A 
column from ES Industries using acetonitrile / water 0.5% ammonium acetate.   
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Synthesis section 1 
General procedure for synthesis of cis-4-hydroxy-L-proline: 
Cis-4-Hydroxy-L-proline was synthesized from trans-4-hydroxy-L-proline as previously 
reported [Papaloannou; et al. 1990]. Explained briefly, trans-4-hydroxy-L-proline was 
protected using Boc anhydride under standard conditions and workup, 1:1 MeOH / 
triethylamine and 1.2 equivalents of Boc anhydride reflux overnight.  The isolated N-
tBoc-trans-4-hydroxy-L-proline was then converted to the N-tBoc-cis-proline lactone by 
standard Mitsunobu esterification by adding PPH3, diethyl azodicarboxylate (DEAD) in 
THF at 0˚C and then stirring overnight at rt.  Standard workup including dilution with 
Et2O and multiple washes with water.   The N-tBoc-proline lactone can then be converted 
to cis-4-hydroxy-proline in a one pot reaction in 2.0 M HCl, (2.2 eq) which is then 
diluted with water and lyophilized to concentrate leaving cis-4-hydroxy-L-proline.  
Analysis of product by 
1
H and 
13
C NMR is in agreement with NMR spectra reported in 
literature.   
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Scheme 1: Synthesis of N-Cbz-trans- and cis-3,4-epoxy-proline-benzyl ester 13a & 13b.  
(i)  benzylchloroformate, H2O, NaOH, rt; (ii) benzylbromide, Na2CO3, NaI, rt;  (iii)  p-
toluenesulfonyl-Cl, pyridine, 0˚C;  (iv)  tBuOH, phenylselenide, reflux;  (v)  CH2Cl2, 
H2O2, 0˚C-RT;  (vi)  mCPBA, CH2Cl2, reflux. 
 
 
General procedure for synthesis of N-Cbz-(cis- or trans)-3,4-epoxy-L-proline benzyl 
ester: 
To arrive at prolinol targets 1-4, trans-4-hydroxy-L-proline was converted to the 
protected trans- and cis-3,4-epoxides 13a & 13b as outlined in Scheme 1 with only slight 
modifications in conditions to that previously reported [Robinson; et al. 1998].  Briefly, 
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the amine of trans-4-hydroxy-L-proline was protected using benzylchloroformate in 
water at a pH ~10.  The acid functionality of N-Cbz-trans-4-hydroxy-L-proline was then 
protected using benzylbromide, Na2CO3, NaI, in DMF at room temperature (~22˚C) and 
isolated by flash chromatography.  Compound 9 (Scheme 1) was then converted to the 4-
tosylate using p-toluenesulphonyl chloride in pyridine at 0˚C for 1 week.  It was 
important to allow this reaction to proceed under cool conditions as to avoid possible 
racemization of the chiral alpha center.  The resulting N-Cbz-4-tosyl-L-proline benzyl 
ester was then separated by silica gel.  The tosyl group was then displaced via 
nucleophilic substitution with reduced phenyl selenide, prepared by reduction of 
diphenyldiselenide using NaBH4 (sodium borohydide) in tert-butanol at reflux.  The 
isolated phenylseleno proline was then oxidized in an elimination reaction using H2O2 in 
CH2Cl2 at 0˚C to produce the fully protected 3,4-dehydro-L-proline 12.  It was extremely 
important to perform this reaction in cold, dilute conditions to avoid overheating and a 
possible H2O2 driven explosion.  The protected 3,4-dehydro-L-proline 12, once isolated, 
was then treated with mCPBA (meta-chloro-peroxybenzoic acid) in CH2Cl2 at reflux to 
give the protected trans- and cis-3,4-epoxy-prolines at ratios of 6:4 respectively. The 
trans- and cis-epoxides were efficiently isolated by silica gel with overall modest yield of 
53% for the entire synthetic scheme.  The epoxide intermediates 13a or 13b were then 
used directly in an acid catalyzed ring opening addition step (Scheme 3) or converted to 
the free acid prior to an addition under basic conditions (Scheme 4). 
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N-Cbz-4-hydroxyproline 8:  BRL: 247 
trans-4-Hydroxyproline (27.5 g, 209.7 mmol) 7 was dissolved into 200mL of 50% 
MeOH in water.  This was then chilled on ice bath to 0˚C.  To this mixture was added 
85.9 mL of benzyl chloroformate (0.252 mmol; 1.2 eq; 50% vol. in toluene) dropwise.  
Pellets of NaOH were added to maintain the pH at ~9-10 (monitored by litmus paper).  
The mixture was then allowed to warm to rt (22˚C).  The mixture was allowed to stir over 
night at rt and the pH closely monitored and maintained at pH = 10 by addition of NaOH 
pellets.  The mixture was then diluted by addition of 200 mL water and then extracted 
with 3 x 200 mL toluene (to remove remaining benzyl chloroformate).  The aqueous 
layer was then salted with NaCl until saturated and the pH was adjusted to ~2 by addition 
of HCl conc.  This was then extracted with 4 x 200 mL of ethyl acetate.  The ethyl acetate 
washes were then combined and concentrated via rotovap, leaving an oil residue.  
Dichloromethane (50 mL) was added 4 times to remaining oil and then removed by 
vacuum.  Hexanes (50 mL) was then added to the oil and again removed by vacuum, 
leaving a sticky foam N-Cbz-4-hydroxyproline crude (quantitative yield) which was then 
used w/o any further purification.  This residue can also be recrystallized in 10:1, 
hexanes:CH2Cl2.  
1
H and 
13
C NMR spectra were in agreement with 
1
H and 
13
C NMR 
spectra previously reported [Robinson; et al. 1998]. 
 
N-Cbz-4-hydroxyproline benzyl ester 9:  BRL: 151 
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N-Cbz-4-hydroxyproline (40.00 g, 150.8 mmol) 8 was dissolved into 110 mL DMF.  To 
this mixture was added 45.85 g of K2CO3 (2.2 eq; 331.7 mmol) and 2.30 g of NaI (0.1 
eq).  The reaction flask was purged with argon and 55.4 mL of benzylbromide (3 eq; 452 
mmol) was added dropwise.  This mixture was then stirred over night at rt.  The reaction 
was then diluted with 300 mL ethyl acetate and washed with water (8 x 200 mL) to 
remove DMF, followed by washing with 100 mL brine.  The organic layer was dried over 
Na2SO4 and concentrated to a yellow oil.  The oil was then washed several times with 100 
mL hexanes to remove any remaining benzyl bromide and then separated by silica gel in 
hexanes : ethyl acetate, 3:2, isolating N-Cbz-4-hydroxyproline benzyl ester at Rf = 0.25 in 
nearly quantitative yield.  
1
H and 
13
C NMR spectra were in agreement with 
1
H and 
13
C 
NMR spectra previously reported [Robinson; et al. 1998]. 
 
N-Cbz-4-p-toluenesulphonyl-ether-proline-benzyl ester 10:  BRL: 205 
N-Cbz-4-hydroxyproline benzyl ester (21.77 g, 61.3 mmol) 9 was dissolved into 150 mL 
cold pyridine 0˚C.  Immediately, 12.976 g of p-toluenesulfonyl chloride (1.1 eq.; 67.4 
mmol) was added.  The flask containing this mixture was then purged with argon and 
placed into a refrigerator at ~0˚C for one full week with occasional vortex.  After one 
week it was observed that a significant amount of pyridine-HCl had formed and all the 
starting material appeared to have been consumed (determined by TLC).  The mixture 
was then taken up into 100 mL Et2O and 50 mL ethyl acetate and washed 2 x 100 mL 
cold 5% HCl and then 3 x 200 mL water.  The organic layers were combined and dried 
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over Na2SO4, filtered and concentrated to an oil.  The product N-Cbz-4-p-
toluenesulphonyl-ether-proline-benzyl ester 10 was isolated by silica gel in hexanes / 
ethyl acetate, 7:3; Rf = 0.25 to recover 28.05 g, (90% yield).  
1
H and 
13
C NMR spectra 
were in agreement with 
1
H and 
13
C NMR spectra previously reported [Robinson; et al. 
1998]. 
 
N-Cbz-4-phenylseleno-L-proline-benzyl ester 11:  BRL: 211 
Diphenyldiselenide (9.504 g, 0.6 eq.; 30.2 mmol) was dissolved into 60 mL of tBuOH 
and purged of air by vacuum and replaced with argon.  The solution was brought to a 
reflux where of NaBH4 (2.293 g, 1.2 eq, 60.3 mmol) was added slowly over 15 min.  This 
mixture was refluxed for 30 min until the mixture had turned completely white.  To this 
was added N-Cbz-4-p-toluenesulphonyl-ether-proline-benzyl ester 10 (25.6 g, 50.2 
mmol) in 40mL tBuOH.  The reflux was continued under argon for ~3 h then allowed to 
cool to rt.  The mixture was then diluted with 200 mL ethyl acetate and washed 3 x 250 
mL water followed by 100 mL brine then treated with MgSO4 to dry, filtered and 
concentrated to a crude oil.  The product N-Cbz-4-phenylseleno-L-proline-benzyl ester 
11 was isolated by silica gel 3:1 hexanes : ethyl acetate at Rf = 0.3, recovering 22.21 g, 
(89% yield).   
1
H and 
13
C NMR spectra were in agreement with 
1
H and 
13
C NMR spectra 
previously reported [Robinson; et al. 1998]. 
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N-Cbz-3,4-dehydro-L-proline-benzyl ester 12:  BRL: 212 
N-Cbz-4-phenylseleno-L-proline-benzyl ester 11 (22.11 g, 44.7 mmol) was dissolved in 
80 mL CH2Cl2 (warning! explosive conditions: needs to be performed in more dilute  
conditions than in this example or ~200 mL per 10 g of starting material).  The solution 
was chilled on ice bath over argon and 4.9 mL pyridine (1.34 eq.; 60 mmol) was added 
followed by addition of 11.50 mL 30% H2O2 (2.5 eq.; 112.0 mmol) drop wise.  The 
solution was gradually allowed to return to room temp over the course of one hour where 
it was stirred for 2.5 h.  The solution, now brown in color, was diluted with 100 mL 
CH2Cl2 and washed with 100 mL of 5% NaHSO4, 2 x 50 mL NaHCO3, and 3 x 150 mL 
water.  The organic layer was dried over Na2SO4 and filtered.  A total of 12.02 g of N-
Cbz-3,4-dehydro-L-proline-benzyl ester 12 was isolated by silica gel in mobile phase of  
4:1 hexanes / etheyl acetate; Rf = 0.15; (80% yield).  
1
H and 
13
C NMR spectra were in 
agreement with 
1
H and 
13
C NMR spectra previously reported [Robinson; et al. 1998]. 
 
N-Cbz-trans-3,4-epoxy-L-proline-benzyl ester 13a and N-Cbz-cis-3,4-epoxy-L-
proline-benzyl ester 13b:  BRL: 287 
N-Cbz-3,4-dehydro-L-proline-benzyl ester (9.80 g, 29.0 mmol) 12 was dissolved into 12 
mL CH2Cl2.  To this was added mCPBA (14.3 g, 70% weight; 58.1 mmol; 2 eq.)  and 
2,8-di-tert-butyl-4-methylphenol (30 mg, radical inhibitor).  The solution was heated to 
reflux and allowed to stir overnight under argon balloon.  An additional 1 eq. of mCPBA 
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(7.15 g) was added and the solution was allowed to reflux again overnight.  The flask was 
then placed on an ice bath where a white precipitate formed and was subsequently filtered 
using cold dichloromethane to wash.  The CH2Cl2 was removed by rotovap leaving a 
white solid residue.  The residue was taken up into 150 mL Et2O and washed 8 times with 
100 mL (aq) NaHCO3, 2 x 100 mL water, and 100 mL brine then dried over Na2SO4 and 
filtered.  The remaining oil was then separated by silica gel in 4:1 hexanes / ethyl acetate.  
The trans isomer 5.228 g, N-Cbz-3,4-trans-epoxy-L-proline-benzyl ester 13a, was 
isolated at Rf = 0.2  and the cis isomer 4.100 g, N-Cbz-3,4-cis-epoxy-L-proline-benzyl 
ester 13b being isolated at Rf = 0.1, a total yield of 91% and ratio of 5:4 trans / cis.  
1
H 
and 
13
C NMR spectra for both diastereomers were in agreement with 
1
H and 
13
C NMR 
spectra previously reported [Robinson; et al. 1998]. 
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Scheme 2: Synthesis of 3,4-dehydroprolines.  (i) NaH, THF, CS2, iodomethane, 22˚C; 
(ii) H2O, NaHCO3, microwave 100˚C; (iii)  benzylbromide, Na2CO3, NaI, rt;  (iv).  H2O, 
Na2CO3, microwave 100˚C. 
 
Procedure for alternative synthesis of N-Cbz-3,4-dehydro-L-proline-benzyl ester 12 
or N-Cbz-3,4-dehydro-L-proline 12a 
In searching for a synthetic route to produce 3,4-dehydro-L-prolines with fewer synthetic 
steps than through tosyl and selenide intermediates (scheme 1), we designed an 
alternative route by using a xanthate intermediate 9a or 10a.  We reasoned that the free 
acid 3,4-dehydro-proline 12a or benzyl ester protected 3,4-dehydro-proline 12 could be 
generated via microwave elimination of a methyl xanthate 9a or 10a as seen in Scheme 2.  
Briefly, N-Cbz-trans-4-hydroxy-L-proline 8 was used in an esterification with CS2 and 
iodomethane using NaH as a base in THF to produce N-Cbz-trans-4-methylxanthate-L-
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proline 9a.  From this the benzyl-ester derivative 10a (N-Cbz-trans-4-methylxanthate-L-
proline benzyl ester) were synthesized under standard conditions as shown in Scheme 1 
(ii).  Both methyl xanthate conjugated prolines 9a and 10a were successfully eliminated 
under open container pyrolysis like conditions using microwave radiation, sodium 
carbonate as a base, and water as a semi-solvent to produce 3,4-dehydroprolines 12a and 
12.   
 
N-Cbz-trans-4-methylxanthate-L-proline 9a:  BRL: 131 
To 3.635 g (13.7 mmol) of N-Cbz-trans-4-hydroxy-L-proline 8 was added 35 mL of dry 
THF and slow addition of 1.73 g of NaH (95%; 5 eq.; 68.5 mmol).  The solution was then 
purged with argon and allowed to stir for 10 min.  To this was added 4.14 mL of CS2 
(68.5 mmol; 5 eq.) and allowed to stir for 2 h at rt, forming the xanthate salt. To the flask 
was then added 2.87 mL of iodomethane (48.0 mmol; 3.5 eq) and allowed to stir 
overnight at rt and under argon balloon.  The reaction mixture was then chilled on ice 
bath where ~10 mL of glacial acetic acid was added to quench the excess NaH (heavy 
white precipitate forms).  The quenched reaction mixture was then diluted with 100 mL 
of Et2O, filtered using excess ether, and then concentrated by rotovap, leaving a yellow / 
brown oil.  The final product, 4.19 g, N-Cbz-trans-4-methylxanthate-L-proline 9a was 
isolated by silica gel at Rf = 0.15 in 97% CH2Cl2, 2% MeOH 1% AcOH, 70% yield as a 
crude mixture which was used in the next step without further purification. 
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N-Cbz-trans-4-methylxanthate-L-proline benzyl ester 10a:  BRL: 133 
To 3.40 g (9.57 mmol) of N-Cbz-trans-4-methylxanthate-L-proline 9a was added 30 mL 
DMF, 2.64 g (19.1 mmol; 2 eq.) of K2CO3, and 143 mg of NaI (0.957 mmol; 0.1 eq.).  
The reaction flask was purged with argon, and 3.58 mL of benzyl bromide (98 %; 29.3 
mmol; 3 eq).  The mixture was allowed to stir at rt for 24 h under argon balloon.  The 
solution was taken up into 100 mL ethyl acetate and then washed with H2O (4 x 300 mL).  
The organic layer was separated and dried with MgSO4, filtered and concentrated to a 
yellow oil.  The final product N-Cbz-trans-4-methylxanthate-L-proline benzyl ester 10a 
was isolated by silica gel in 4: 1 hexanes / ethyl acetate, Rf = 0.25, with a quantitative 
yield.   
 
1
H-NMR (400 MHz, CDCl3) δ 7.40-7.20 (m, 10H), 5.95 (d, J = 2.2 Hz, 1H), 5.25-5.16 
(m, 1H), 5.17 (s, 1H), 5.07 (s, 1H), 5.00 (s, 1H), 4.62-4.52 (ddd, J = 44.0Σ, 28.6, 8.1 Hz, 
1H), 3.99 (d, J = 12.4 Hz, 1H), 3.88 (s, 1H), 2.67-2.59 (m, J = 8.1, 2.2 Hz, 1H), 2.53 (s, 
3H), 2.36 (m, J = 8.1, 2.1 Hz, 1H). 
 
N-Cbz-3,4-dehydro-L-proline 12a:  BRL:177 
A pressure flask containing a mixture of 0.240 g of N-Cbz-trans-4-methylxanthate-L-
proline (0.675 mmol) 9a, 1 mL ethanol, 10 mL water, and 42 mg Na2CO3 (anhydrous; 0.5 
eq) was placed into a microwave on medium (100 watt noncontinous radiation; retail 
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purchased Sunbeam microwave) for ~3-4 min.  The contents were allowed to cool to rt 
(keep in hood; xanthate elimination creates a very undesirable smell).  The reaction 
mixture was diluted with 20 mL water and the pH was adjusted to ~2-3 by addition of 
H3PO4.  The aqueous mixture was salted with NaCl until saturated, then extracted with 3 
x 50 mL ethyl acetate, dried with Na2SO4, and concentrated to a crude orange colored oil. 
The product N-Cbz-3,4-dehydro-L-proline 12a was isolated by silica gel (96% CH2Cl2, 
3% MeOH, 1% AcOH, Rf = 0.25) for 0.120 g of total recovered product, a 72% yield.  
 
1
H-NMR (400 MHz, CDCl3) δ 9.91 (b, 1H [COOH]), 7.37-7.27 (m, 5H), 5.98-5.93 (ddd, 
J = 21.3Σ, 14.9, 6.11, 2.0 Hz 1H), 5.82-5.75 (ddd, J = 35.7Σ, 29.6, 6.1, 2.2 Hz, 1H), 5.25-
5.13 (m, J = 1.7 Hz, 2H), 5.06 (dd, J = 4.0Σ, 2.2 Hz, 1H), 4.32-4.27 (m, J = 2.2, 2.0, 1.7 
Hz, 2H). 
 
N-Cbz-3,4-dehydro-L-proline benzyl ester 12: BRL: 195 
A pressure flask containing a mixture of 0.551 g (1.28 mmol) of N-Cbz-trans-4-
methylxanthate-L-proline benzyl ester 10a, 1 mL ethanol, 10 mL water, and 68 mg 
Na2CO3 (anhydrous; 0.5 eq; 0.64 mmol) was placed into a microwave on medium low 
(100 watt noncontinous radiation, retail purchased Sunbeam microwave) for ~7 min.  The 
contents were allowed to cool to rt (keep in hood).  The reaction mixture was diluted with 
20 mL water and then extracted with 3 x 50 mL Et2O, washed 2 x 50 mL water, dried 
over Na2SO4, and concentrated to a crude orange oil. The product N-Cbz-3,4-dehydro-L-
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proline benzyl ester 12 was isolated by a silica gel (70% hexanes, 30% ethyl acetate, Rf = 
0.25) for 0.362 g of total recovered product, an 84% yield.  
 
1
H-NMR (400 MHz, CDCl3) δ 7.40-7.25 (m, 10H), 6.01-5.94 (ddd, J = 19.0Σ, 5.9, 1.5 Hz, 
1H), 5.80-5.74 (ddd, J = 16.8Σ, 5.9, 2.2 Hz, 1H), 5.26-5.04 (m, 5H), 4.40-4.26 (m, J = 
5.9Σ, 2.2, 1.5 Hz, 2H). 
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Figure 15:  Synthesized ether substituted prolinols. 
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Scheme 3: Synthesis of ether substituted prolinols.  (i) BF3·Et2O, CH2Cl2, desired 
alcohol, 22˚C; (ii) 10% Pd/C (.10% weight. eq.), H2, MeOH, H2O, NH4OAc. 
 
Procedure for synthesis of ether substituted prolinols: 
A series of ether substituted prolinols (Figure 15) were synthesized to act as selective 
inhibitors of the ASC transporters.  This was accomplished by a BF3•Et2O catalyzed 
nucleophillic ring opening of the epoxide 13a or 13b by an alcohol and subsequent 
deprotection via a 10% Pd/C catalyzed hydrogenation to produce trans-hydroxy 
derivative 15 or cis-hydroxy derivatives 17a & 17b (Scheme 3).  Under optimized 
conditions, BF3•Et2O as a catalyst provided far superior product yields (quantitative) as 
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opposed to using toluene sulfonic acid which produced multiple undesired products, 
including nucleophillic addition of the tosyl (tosic acid) group itself as a major product.  
It was also observed that ring opening of trans-epoxide 13a under these conditions 
produced exclusively one regioisomer, the N-Cbz-trans-3-hydroxy-cis-4-ether-L-proline 
benzyl ester 14 (Figure 16). Whereas the ring opening of the cis-epoxide 13b produced 
both regioisomers 16a & 16b in ratios, 10:1, that strongly favored the 3- positioned 
alcohol 16a, consistent with azide or HCl ring opening of these epoxides (Herdeis; et al. 
2007; Robinson; et al. 1998).  Separation of these two regioisomers was carried out by 
reverse phase HPLC after the addition step following hydrolysis of the benzyl ester with 
KOH or just after hydrogenation depending upon the ether R group present.  Of 
importance, however, but not fully explored, the cis-3-ether-trans-4-hydroxy-proline 
regioisomer of 15 can be obtained with reasonable yield if the free acid trans-3,4-epoxy-
proline derivative 13c (shown in Scheme 4) is used as the starting reagent instead of fully 
protected trans-3,4-epoxy-proline 13a in the BF3•Et2O catalyzed addition step under 
similar conditions and following separation by HPLC.  This was observed when using 
MeOH or isopropanol as the nucleophilic agent.  The resulting ether substituted prolinol 
14, 16a or 16b could then be deprotected under standard palladium (Pd / carbon) 
catalyzed hydrogenation to afford the final products 15, 17a, or 17b in good yield.  
Surprisingly, hydrogenation under these conditions was selective in removal of the 
benzyl carbamate and the benzyl ester while leaving the benzyl ether group intact.  For 
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additional precaution, ammonium acetate (NH4OAc) was added to the reaction mixture as 
an inhibitor of debenzylation during the hydrogenation step [Sajiki 1995].   
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Figure 16:  Regioselective addition and ring opening of protected trans- and cis-3,4-
epoxy-L-prolines. 
 
 
 
N-Cbz-trans-3-hydroxy-cis-4-methoxy-L-proline benzyl ester: BRL: 294 
To 0.514 g (1.45 mmol) of N-Cbz-trans-3,4-epoxy-L-proline benzyl ester 13a was added 
5 mL of dry (MgSO4 treated) CH2Cl2 and 2.0 mL (~34 eq.; 50 mmol) absolute MeOH.  
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The flask was capped, purged with argon and chilled on an ice bath with argon balloon.  
Once cooled, 1.15 mL (48%; 3.0 eq.; 4.36 mmol) of BF3•Et2O was added to the mixture.  
The mixture was allowed to return to rt and stir over night.  The reaction mixture was 
quenched by the addition of 20 mL saturated NaHCO3 solution which was allowed to stir 
for ~30 min.  The mixture was then diluted with 100 mL CH2Cl2, washed with 3 x 100 
mL water, 50 mL brine, dried over Na2SO4 and concentrated by rotovap to a foam.  The 
final product N-Cbz-trans-3-hydroxy-cis-4-methoxy-L-proline benzyl ester, 467 mg, and 
unreacted epoxide starting material, 115 mg, were isolated by silica gel (75% hexanes, 
25% ethyl acetate, Rf product = 0.1 ; Rf epoxide = 0.3) for a total yield of 83% product 
and complete recovery in molecular equivalents of unreacted starting material.  The 
material was used in the next step without further purification. 
 
1
H-NMR (500 MHz, CDCl3) (2 conformational isomers) δ 7.33-7.25 (m, 10H), 5.27-5.01 
(m, 4H), 4.50 and 4.40 (s, 1H), 3.85-3.75 (m, J = 4.89, 4.4 Hz, 2H), 3.70 (d, J = 4.9 Hz, 
1H), 3.57 (m, 1H), 3.15 and 3.12 (s, 3H). 
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CSE115
Chemical Formula: C6H11NO4
Molecular Weight: 161.16
 
trans-3-hydroxy-cis-4-methoxy-L-proline:  BRL: 298 / CSE115 
To 0.417 g (1.08 mmol) of Cbz-3-trans-hydroxy-4-cis-methoxy-L-proline benzyl ester 
was added 4 mL methanol which was then transferred to a pressure flask containing 42 
mg of 10% Pd/carbon (0.1 eq. weight), 1 mL water and 42 mg (~0.5 eq.) NH4OAc.  The 
pressure flask was connected to a Parr shaker, the air was removed by vacuum and 
replaced with 40 psi H2 (g).  The assembly was allowed to shake for 3 h.  The pressure 
flask was vented and the solution diluted with 10 mL water and then filtered through 
CM-cellulose (carboxy-methyl-cellulose), using excess water for consecutive washes.  
The filtrate was then frozen and placed onto a lyophilizer until dry.  The remaining 
residue was washed 3 x 10 mL ethyl acetate / CH2Cl2 (1:1), and dried leaving 0.172 g of 
a white solid, trans-3-hydroxy-cis-4-methoxy-L-proline with a yield of 99%.   
 
1
H-NMR (500 MHz, D2O 4.75) δ 4.65 (s, 1H, H-2), 4.02 (s, 1H, H-1), 3.91 (s, 1H, H-3), 
3.53 (s, 2H, H-4 and 5), 3.25 (s, 3H).  
13
C-NMR (500 MHz, D2O) ppm 170.7, 82.8, 74.8, 
67.4, 56.3, 48.9.  HRMS m/e calcd. For C6H12NO4 = 162.0749, found 162.0766.  [ α ]
22
Na 
= -15
◦
 (c = 0.14, EtOH). 
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N-Cbz-cis-3-hydroxy-trans-4-methoxy-L-proline benzyl ester and N-Cbz-trans-3-
methoxy-cis-4-hydroxy-L-proline benzyl ester:  BRL: 295 
To 0.280 g (0.792 mmol) of N-Cbz-cis-3,4-epoxy-L-proline benzyl ester 13b was added 
3 mL (dry MgSO4 treated) CH2Cl2 and 1 mL MeOH (~30 eq.; 25 mmol).  The flask was 
purged with argon and cooled on ice bath for 10 min.  Once cooled, 0.625 mL of 
BF3•Et2O (48%; 3.0 eq.; 2.38 mmol) was added dropwise and the solution was allowed to 
return to rt.  After stirring overnight the reaction was quenched by the addition of 20 mL 
saturated solution of NaCO3.  This was then further diluted with 100 mL CH2Cl2 and 
washed 3 x 100 mL water and 1 x 100 mL brine, dried with Na2SO4 and filtered.  The 
two regioisomer products N-Cbz-cis-3-hydroxy-trans-4-methoxy-L-proline benzyl ester 
and N-Cbz-trans-3-methoxy-cis-4-hydroxy-L-proline benzyl ester, 0.288 g, were isolated 
together by silica gel (70 % hexanes, 30% ethyl acetate, Rf  = 0.15) a 94% yield.  The 
material was used in the next step without further purification. 
 
 
N-CBZ-cis-3-hydroxy-4-trans-methoxy-L-proline:  BRL: 278 
To 0.410 g (1.06 mmol) of N-Cbz-cis-3-hydroxy-trans-4-methoxy-L-proline benzyl ester 
and N-Cbz-trans-3-methoxy-cis-4-hydroxy-L-proline benzyl ester was added 10 mL 
THF, 1 mL water and 72 mg (1.2 eq.; 1.28 mmol) KOH.  The mixture was allowed to stir 
for 2 h at rt where it was observed by TLC (hexanes : EtOAc, 7 : 3) that all starting 
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material was consumed.  The mixture was concentrated to an oil by rotovap and diluted 
with 20 mL water.  The pH of this solution was adjusted to ~2 by addition of H3PO4 and 
NaCl was added until saturated.  The mixture was then extracted with 2 x 100 mL ethyl 
acetate.  The separated organic layers were combined, washed 20 mL pH of ~2 brine, 
dried with NaSO4, filtered and concentrated.  The free acid products, 290 mg (0.979 
mmol; 92% yield), were separated from the crude oil by silica gel (94% CH2Cl2, 5% 
MeOH, 1% AcOH, Rf = 0.2) and again concentrated.  A portion of this regioisomer 
mixture was isolated by reverse phase HPLC (C18, 250mm x 21.2mm, 10µ) (88% 0.05 
M NH4OAc, 12% acetonitrile, 9 mL/min) at retention times of 44 min. for N-Cbz-cis-3-
hydroxy-4-trans-methoxy-L-proline or 46 min for the other isomer and concentrated by 
freezing / lyophilization.  The material was used in the next step without further 
purification. 
 
1
H-NMR (500 MHz, D2O 4.65) (2 conformational isomers) δ 7.26-7.20 (m, 5H), 5.02-
4.95 (dd, J = 25.4, 12.2 Hz, 1H), 4.94 (s, 1H), 4.34 and 4.33 (s, 1H), 4.23 and 4.18 (d, J = 
6.4 Hz, 1H), 3.74 and 3.73 (s, 1H), 3.74-3.73 (m, 1H), 3.50 and 3.42 (d, 12.0 Hz, 1H), 
3.23 and 3.21 (s, 3H).   
 
 170 
+H2N
COO-
O
OH
CSE124
Chemical Formula: C6H11NO4
Molecular Weight: 161.16
 
cis-3-hydroxy-trans-4-methoxy-L-proline:  BRL: 292 / CSE124 
To 90.0 mg (0.305 mmol) of N-Cbz-cis-3-hydroxy-4-trans-methoxy-L-proline was added 
3 mL MeOH and 1 mL water.  This was transferred to a pressure flask containing 10 mg 
of wet 10% Pd/carbon (0.1 eq. weight) and 12 mg NH4OAc (0.5 eq.).  The reaction flask 
was placed onto a Parr shaker, the air was removed by vacuum and replaced by 40 psi H2 
(g).  The flask was allowed to shake for 8 h where the flask was vented and mixture was 
diluted with ~ 20 mL water.  The contents were then filtered through CM-cellulose using 
excess water for consecutive washes.  The filtrate was frozen and lyophilized to a white 
residue which was washed 3 x 20 mL ethyl acetate / dichloromethane (1:1) and dried 
leaving a white solid residue; 44.0 mg of cis-3-hydroxy-trans-4-methoxy-L-proline a 
90% yield.   
1
H-NMR (500 MHz, D2O 4.75) δ 4.56 (d, J = 3.8 Hz, 1H, H-2), 4.22 (d, J = 3.8 Hz, 1H, 
H-1), 4.01 (d, J = 3.5 Hz, 1H, H-3), 3.62-3.59 (dd, J = 13.0, 3.5 Hz, 1H, H-5), 3.41-3.39 
(d, J = 13.0 Hz, 1H, H-4), 3.35 (s, 3H).  
13
C-NMR (500 MHz, D2O) δ 170.3, 83.9, 72.4, 
65.2, 56.5, 48.36.  HRMS m/e calcd. For C6H11NO4 = 162.0749, found 162.0753.  [ α 
]
22
Na = -10
◦
 (c = 0.23, EtOH). 
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N-Cbz-trans-3-hydroxy-cis-4-isopropoxy-L-proline benzyl ester: BRL: 290 
To 0.460 g (1.30 mmol) of N-Cbz-trans-3,4-epoxy-L-proline benzyl ester 13a was added 
4 mL of dry (MgSO4 treated) CH2Cl2 and 2.0 mL isopropanol (~20 eq.; 26 mmol).  The 
flask was capped, purged with argon and chilled on an ice bath with argon balloon.  Once 
cooled, 1.03 mL of BF3•Et2O (48%; 3 eq.; 3.90 mmol) was added to the mixture.  The 
mixture was allowed to return to rt and stir over night.  The reaction mixture was 
quenched by the addition of 20 mL saturated NaHCO3 solution which was allowed to stir 
for ~30 min.  The mixture was then diluted with 100 mL CH2Cl2, washed with water (3 x 
200 mL), washed with 50 mL brine, dried over Na2SO4 and concentrated.  The final 
product N-Cbz-trans-3-hydroxy-cis-4-isopropoxy-L-proline benzyl ester, 430 mg, and 
unreacted epoxide starting material, were isolated by silica gel (hexanes : ethyl acetate 3 : 
1, Rf product = 0.15 ; Rf epoxide = 0.3) for a total yield of 76% product and complete 
recovery in molecular equivalents of unreacted starting material (epoxide).   The material 
was used in the next step without further purification. 
 
1
H-NMR (500 MHz, CDCl3) (2 conformational isomers) δ 7.33-7.22 (m, 10H), 5.28-5.03 
(m, 4H), 4.49 and 4.44 (s, 1H), 4.43 and 4.37 (s, 1H), 3.91-3.89 (d, J = 2.4 Hz, 1H), 3.86-
3.82 and 3.81-3.77 (dd, J = 11.5, 4.9 Hz, 1H), 3.65-3.58 (m, J = 6.1 Hz, 1H), 3.53-3.50 
(d, J = 2.4 Hz, 1H), 1.07-1.00 (m, J = 5.9 Hz, 6H).  
13
C-NMR (500 MHz, CDCl3) (2 
conformational isomers) δ 167.2 and 166.8, 152.9 and 152.4, 133.8 and 133.0, 125.9, 
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125.9, 125.8, 125.6, 125.5, 125.4, 125.4, 125.4, 125.3, 125.2, 76.5, 75.8, 74.8, 74.6, 74.6, 
74.3, 67.8 and 67.7, 64.8 and 64.7, 64.4 and 64.3, 63.7 and 63.2, 48.2 and 48.0, 19.7 and 
19.6, 19.5 and 19.5. 
 
+H2N
COO-
O
OH
CSE122
Chemical Formula: C8H15NO4
Molecular Weight: 189.21
 
trans-3-hydroxy-cis-4-isopropoxy-L-proline:  BRL: 297 / CSE122 
To 0.190 g (0.460 mmol) of Cbz-3-trans-hydroxy-4-cis-methoxy-L-proline benzyl ester 
was added 4 mL methanol which was then transferred to a pressure flask containing 19 
mg (0.1 eq. weight) of 10 % Pd / carbon, 1 mL water and 18 mg (0.5 eq.) of NH4OAc.  
The pressure flask was connected to a Parr shaker, the air was removed by house vacuum 
and replaced with 40 psi H2 (g).  The assembly was allowed to shake for 3 h.  The 
pressure flask was vented and the solution diluted with 10 mL water and then filtered 
through CM-cellulose (carboxy-methyl-cellulose), using excess water for consecutive 
washes.  The filtrate was then frozen and placed onto a lyophilizer until dry.  The 
remaining residue was washed 3 x 20 mL EtOAc / CH2Cl2 (1:1), and dried leaving 80.0 
mg of a white solid, trans-3-hydroxy-cis-4-isopropoxy-L-proline with a yield of 92%.  
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1
H-NMR (500 MHz, D2O 4.75) δ 4.58 (s, 1H, H-2), 4.10 (d, J = 4.0 Hz, 1H, H-3), 3.99 
(s, 1H, H-1), 3.75-3.70 (m, J = 6.1 Hz, 1H), 3.56-3.53 (dd, J = 12.7, 4.0 Hz, 1H, H-4), 
3.47-3.44 (d, J = 12.7 Hz, 1H, H-5), 1.06 (d, J = 6.1 Hz, 3H), 1.01 (d, J = 6.1 Hz, 3H).  
13
C-NMR (500 MHz, D2O) (2 conformational isomers) δ 170.7, 78.4 and 78.2, 75.7 and 
75.7, 70.9 and 70.8, 67.6 and 67.4, 49.7, 21.4 and 21.4, 20.6 and 20.5.  HRMS m/e calcd. 
For C8H16NO4 = 190.1079, found 190.1089.  [ α ]
22
Na = -5
◦
 (c = 0.24, EtOH). 
 
N-Cbz-cis-3-hydroxy-trans-4-isopropoxy-L-proline benzyl ester:  BRL: 296 
To 0.407 g (1.15 mmol) of N-Cbz-cis-3,4-epoxy-L-proline benzyl ester 13b was added 5 
mL (dry MgSO4 treated) CH2Cl2 and 2 mL isopropanol (~23 eq.; 26 mmol).  The flask 
was purged with argon and cooled on ice bath for 10 min.  Once cooled, 0.910 mL of 
BF3•Et2O (48%; 3 eq.; 3.45 mmol) was added dropwise and the solution was allowed to 
return to rt.  After stirring overnight the reaction was quenched by the addition of 20 mL 
saturated solution of NaCO3.  This was then further diluted with 20 mL CH2Cl2 and 
washed 3 x 100 mL water and 1 x 100 mL brine, dried with Na2SO4 and concentrated by 
rotovap.  The two regioisomer products N-Cbz-cis-3-hydroxy-trans-4-isopropoxy-L-
proline benzyl ester and N-Cbz-trans-3-isopropoxy-cis-4-hydroxy-L-proline benzyl ester, 
0.440 g, were isolated together by silica gel (3:1 hexanes : EtOAc, Rf  = 0.20) a 92% 
yield.  The material as a regioisomer mixture was used in the next step without further 
purification. 
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N-Cbz-cis-3-hydroxy-4-trans-isopropoxy-L-proline:  BRL: 305 
To 0.400 g (0.967 mmol) of N-Cbz-cis-3-hydroxy-trans-4-isopropoxy-L-proline benzyl 
ester and N-Cbz-trans-3-isopropoxy-cis-4-hydroxy-L-proline benzyl ester was added 10 
mL THF, 1 mL water and 81 mg KOH (1.5 eq.; 1.45 mmol).  The mixture was allowed to 
stir for 2 h at rt until complete, as determined by TLC (50% hexanes, 49% ethyl acetate, 
1% AcOH).  The mixture was concentrated to an oil by rotovap and diluted with 20 mL 
water.  The pH of solution was adjusted to ~2 by addition of H3PO4 and NaCl was added 
until saturated.  The mixture was then extracted with 3 x 100 mL EtOAc.  The separated 
organic layers were combined, dried with Na2SO4, filtered and concentrated to a residue.  
The free acid products, 280 mg (0.866 mmol; 89% yield), were separated by silica gel 
(60% hexanes, 39% ethyl acetate, 1% AcOH, Rf = 0.1) and again concentrated.  A 
portion of the regioisomer mixture were isolated by reverse phase HPLC (C18, 250mm x 
21.2mm, 10µ) (85% 0.05 M NH4OAc, 15% acetonitrile, 9 mL/min) at retention times of 
48 min for N-Cbz-cis-3-hydroxy-4-trans-methoxy-L-proline & 52 min. for the other 
isomer and concentrated by freezing / lyophilization.  The material was used in the next 
step without further purification. 
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+H2N
COO-
O
OH
CSE127
Chemical Formula: C8H15NO4
Molecular Weight: 189.21
 
cis-3-hydroxy-trans-4-isopropoxy-L-proline:  BRL: 305 / CSE127 
To 21.0 mg (0.0650 mmol) of N-Cbz-cis-3-hydroxy-4-trans-isopropoxy-L-proline was 
added 3 mL MeOH and 1 mL water.  This was transferred to a pressure flask containing 5 
mg of wet 10% (0.25 eq. weight) Pd/carbon and 5 mg (0.5 eq) NH4OAc.  The reaction 
flask was placed onto a Parr shaker, the air was removed by vacuum and replaced by 40 
psi H2 (g).  The flask was allowed to shake for 8 h where the flask was vented and 
mixture was diluted with ~ 20 mL water.  The contents were then filtered through CM-
cellulose using excess water for consecutive washes.  The filtrate was frozen and 
lyophilized to a white solid and washed with EtOAc / CH2Cl2 1:1 (3 x 20 mL) and dried 
by rotovap leaving a white solid; 11.6 mg of cis-3-hydroxy-trans-4-isopropoxy-L-proline 
a 94% yield.   
 
1
H-NMR (500 MHz, D2O 4.75) δ 4.48 (d, J = 3.9 Hz, 1H, H-2), 4.24 (d, J = 3.9 Hz, 1H, 
H-1), 4.21 (d, J = 3.6 Hz, 1H, H-3), 3.82-3.78 (m, J = 5.9 Hz, 1H), 3.65-3.62 (dd, J = 
12.7, 3.6 Hz, 1H, H-5), 3.15 (d, J = 12.7 Hz, 1H, H-4), 1.12-1.10 (m, J = 5.9, 3.9 Hz, 6H).  
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13
C-NMR (500 MHz, D2O) (2 conformational isomers) δ 79.9, 73.5, 71.4, 65.3, 49.3, 
21.3, 21.2.  HRMS m/e calcd. For C8H16NO4 = 190.1079, found 190.1092.  [ α ]
22
Na = - 7 
◦
 (c = 0.13, EtOH). 
 
 
N-Cbz-trans-3-hydroxy-cis-4-benzyloxy-L-proline benzyl ester: BRL: 288 
To 0.564 g (1.59 mmol) of N-Cbz-trans-3,4-epoxy-L-proline benzyl ester 13a was added 
5 mL of dry (MgSO4 treated) CH2Cl2 and 2.5 mL benzyl alcohol (~15 eq; 24 mmol) 
(treated with molecular civs).  The flask was capped, purged with argon and chilled on an 
ice bath under argon balloon.  Once cooled, 1.26 mL (48%; 3 eq.; 4.78 mmol) of 
BF3•Et2O was added to the mixture.  The mixture was allowed to return to rt and stir for 
48 h.  The reaction was quenched by the addition of 40 mL saturated NaHCO3 solution 
and allowed to stir for 30 min.  The mixture was then diluted with 100 mL CH2Cl2, 
washed water (2 x 200 mL), washed with 50 mL brine, dried over Na2SO4 and 
concentrated to a white residue by rotovap.  The final product N-Cbz-trans-3-hydroxy-
cis-4-benzyloxy-L-proline benzyl ester, 0.710 mg (1.54 mmol), was isolated by silica gel 
(85% hexanes, 15% ethyl acetate, Rf = 0.10) for a total yield of 96%.  The material was 
used in the next step without further purification. 
 
1
H-NMR (500 MHz, CDCl3) (2 conformational isomers) δ 7.33-7.18 (m, 15H), 5.18-5.10 
(m, 1H), 5.05 (s, 1H), 5.03-4.92 (m, 1H), 4.55 (s, 1H), 4.50-4.39 (m, 2H), 3.91 (dd, J = 
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10.3, 5.1 Hz, 1H), 3.85-3.77 (m, J = 11.7, 5.1 Hz, 1H), 3.67-3.62 (dd, J = 12.0, 11.7 Hz, 
1H), 3.42 (s, 2H).   
 
 
+H2N
COO-
O
OH
CSE121
Chemical Formula: C12H15NO4
Molecular Weight: 237.25
 
trans-3-hydroxy-cis-4-benzyloxy-L-proline:  BRL: 289 / CSE121 
To 0.710 g (1.56 mmol) of Cbz-3-trans-hydroxy-4-cis-benzyloxy-L-proline benzyl ester 
was added 5 mL methanol which was then transferred to a pressure flask containing 71 
mg (0.1 eq. weight) of 10% Pd/carbon, 0.3 mL water and 59.3 mg (0.5 eq.; 0.769 mmol) 
NH4OAc.  The pressure flask was connected to a Parr shaker, the air was removed by 
vacuum and replaced with 40 psi H2 (g).  The assembly was allowed to shake for 3 h.  
The pressure flask was vented and the contents were diluted with 30 mL water and 
filtered through CM-cellulose using excess water for consecutive washes.  The filtrate 
was then frozen and placed onto a lyophilizer until dry.  The remaining residue was 
washed EtOAc / CH2Cl2 1:1 (3 x 20 mL), and dried leaving 0.340 mg of a white crude 
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residue trans-3-hydroxy-cis-4-benzyloxy-L-proline, a yield of 93%.  A portion of this 
crude product was isolated by reverse phase HPLC (C18, 250mm x 21.2mm, 10µ) (92% 
0.05 M NH4OAc, 8% acetonitrile, 9 mL/min) at a retention time of 42 min. The collected 
fractions containing the desired product were concentrated by freezing / lyophilization.  
Once dry ~20 mL of water was added, the solution was again frozen and lyophilized until 
dry removing any remaining NH4OAc.  This was repeated until NH4OAc was no longer 
present, leaving a white residue trans-3-hydroxy-cis-4-benzyloxy-L-proline, CSE 121.   
 
1
H-NMR (500 MHz, D2O 4.75) δ 7.37-7.30 (m, 5H), 4.71 (s, 1H, H-2), 4.56-4.47 (dd, J = 
31.1, 11.5 Hz, 2H, methylene), 4.09 (s, 1H, H-3), 4.04 (s, 1H, H-1), 3.55-3.54 (d, J = 1.5 
Hz, 2H, H-4 and 5).  
13
C-NMR (500 MHz, D2O) δ 170.5, 136.7, 128.6, 128.2, 128.2, 
80.8, 75.1, 71.0, 67.5, 49.4.  HRMS m/e calcd.  For C12H16NO4 = 238.1079, found 
238.1094.  [ α ]
22
Na = -13
◦
 (c = 0.08, EtOH). 
 
 
N-Cbz-cis-3-hydroxy-trans-4-benzyloxy-L-proline benzyl ester and N-Cbz-trans-3-
benzyloxy-cis-4-hydroxy-L-proline benzyl ester: BRL: 264 
To 0.484 g (1.37 mmol) of N-Cbz-cis-3,4-epoxy-L-proline benzyl ester 13b was added 5 
mL of dry (MgSO4 treated) CH2Cl2, 20 mL benzyl alcohol (treated with molecular civs), 
and 13.0 mg (0.10 eq) of p-toluensulfonic acid monohydrate.  The mixture was heated to 
~60˚C and stirred for several days until the reaction appeared to be complete as 
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determined by TLC (hexanes : ethyl acetate, 1:1, Rf = 0.4). The solution was then 
allowed to cool to rt, diluted with 100 mL Et2O and washed with water (3 x 100 mL).  
After drying with Na2SO4, the separated organic solution was filtered and run through a 
silica plug using 90% hexanes 10% ethyl acetate to remove most of the excess benzyl 
alcohol.  The product was then eluted with 1:1 hexanes / ethyl acetate and concentrated.  
The final products N-Cbz-cis-3-hydroxy-trans-4-benzyloxy-L-proline benzyl ester and 
N-Cbz-trans-3-benzyloxy-cis-4-hydroxy-L-proline benzyl ester, 0.426 g (0.923 mmol), 
were isolated by silica gel (7: 3 hexanes : ethyl acetate, Rf product = 0.15) for a total yield 
of 67% including both regioisomers.  Note: this addition was repeated by using 3.0 eq. of 
BF3•Et2O catalyst instead of tosic acid and under similar conditions as in the trans-
epoxide – benzyl alcohol coupling.  Yield improved dramatically, 197 mg of the two 
regioisomers were isolated starting from 160 mg of starting material, a 95% yield.  The 
resulting products as a regioisomer mixture were used in the next step without further 
purification. 
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+H2N
COO-
O
OH
CSE113
Chemical Formula: C12H15NO4
Molecular Weight: 237.25
 
cis-3-hydroxy-trans-4-benzyloxy-L-proline:  BRL: 267 / CSE113 
To 0.426 g (0.923 mmol) of Cbz-3-trans-hydroxy-4-cis-benzyloxy-L-proline benzyl ester  
was added 5 mL methanol which was then transferred to a pressure flask containing 40 
mg (0.1 eq. weight) of 10% Pd/carbon, 2 mL MeOH, 1 mL water and 36 mg (~0.5 eq.; 
0.47 mmol) of NH4OAc.  The pressure flask was connected to a Parr shaker, the air was 
removed by vacuum and replaced with 40 psi H2 (g).  The assembly was allowed to shake 
for 1.5 h where the reaction was complete as determined by TLC (7 : 3 hexanes/ EtOAc).  
The pressure flask was vented and the contents were diluted with 30 mL water and 
filtered through CM-cellulose (carboxy-methyl-cellulose), using excess water for 
consecutive washes.  The filtrate was then frozen and lyophilized until dry.  The 
remaining residue was washed  with EtOAc / CH2Cl2 1:1 (3 x 20 mL), and dried leaving 
an 0.206 mg of an off white solid, a mixture of cis-3-hydroxy-trans-4-benzyloxy-L-
proline and trans-3-benzyloxy-cis-4-hydroxy-L-proline, and possibly 3,4 dihydroxy 
proline as a result of debenzylation.  A portion of this crude product was isolated by 
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reverse phase HPLC (C18, 250mm x 21.2mm, 10µ) (92% 0.05 M NH4OAc, 8% 
acetonitrile, 9 mL/min) and concentrated by lyophilization.  Once dry ~20 mL of water 
was added, the solution was again frozen and lyophilized until dry (removes remaining 
NH4OAc).  This was repeated until NH4OAc was no longer present, leaving cis-3-
hydroxy-trans-4-benzyloxy-L-proline, CSE113.  
 
1
H-NMR (500 MHz, D2O 4.75) δ 7.38-7.35 (m, 5H), 4.60 (s, 1H, H-2), 4.59 (s, 2H, 
methylene), 4.27-4.26 (d, J = 3.9 Hz, 1H, H-1), 4.21-4.20 (d, J = 3.9 Hz, 1H, H-3), 3.66-
3.62 (dd, J = 13.2, 3.9 Hz, 1H, H-5), 3.44-3.42 (d, J = 13.2 Hz, 1H, H-4).  
13
C-NMR (500 
MHz, D2O) δ 172.8, 139.2, 131.3, 131.1, 130.9, 84.7, 75.4, 73.8, 67.9, 51.4.  HRMS m/e 
calcd. For C12H16NO4 = 238.1079, found 238.1064.  [ α ]
22
Na = -20
◦
 (c = 0.22, EtOH). 
 
 
(2S, 3R, 4R)-N-Cbz-3-hydroxy-4-o-methyl-α-napthyl-proline benzyl ester: BRL: 300 
To 0.285 g (0.806 mmol) of N-Cbz-trans-3,4-epoxy-L-proline benzyl ester 13a was 
added 2 mL of dry (MgSO4 treated) CH2Cl2 and 0.191 g (98%, 1.5 eq.; 1.20 mmol) of 1-
naphthylenemethanol.  The flask was capped, purged with argon and chilled on an ice 
bath with argon balloon.  Once cooled, 64 µL (48%; 0.3 eq.; 0.242 mmol) of BF3•Et2O  
was added to the stirring solution mixture.  The mixture was allowed to return to rt and 
stir over night.  The reaction was quenched by the addition of 20 mL saturated NaHCO3 
solution and allowed to stir for ~30 min.  The contents of the flask were then diluted with 
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100 mL CH2Cl2, washed with water (3 x 100 mL), 50 mL brine, dried over Na2SO4 and 
concentrated to a white crude.  The final product (2S, 3R, 4R)-N-Cbz-3-hydroxy-4-o-
methyl-α-napthyl-proline benzyl ester, 0.220 mg (0.430 mmol), was isolated by silica gel 
(7 : 3 hexanes, EtOAc, Rf = 0.1) a yield of 53%, only a portion of product was isolated, 
and recovery of 30 mg epoxide starting material.  The product was used in the next step 
without further purification. 
 
+H2N
COO-
O
OH
CSE132
Chemical Formula: C16H17NO4
Molecular Weight: 287.31
 
(2S, 3R, 4R)-3-hydroxy-4-o-methyl-α-napthyl-proline:  BRL: 307 / CSE132 
To 0.120 g (0.235 mmol) of (2S, 3R, 4R)-N-Cbz-3-hydroxy-4-o-methyl-α-napthyl-
proline benzyl ester was added 5 mL methanol which was heated to dissolve and then 
transferred to a pressure flask containing 20 mg of 10% Pd/carbon (0.167 eq. weight), 
and 0.5 mL water.  The pressure flask was connected to a Parr shaker, the air was 
removed by vacuum and replaced with 40 psi H2 (g).  The assembly was allowed to shake 
over night until it was clear by TLC that all the starting material was consumed (50/49/1; 
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hexanes / EtOAc / AcOH).  The pressure flask was vented and the contents were diluted 
with 30 mL water, followed by filtration through CM-cellulose (carboxy-methyl-
cellulose), using excess water for consecutive washes.  The filtrate was then frozen and 
placed onto a lyophilizer until dry.  The remaining residue was washed EtOAc / CH2Cl2 
1:1 (3 x 20 mL), and dried leaving 58.0 mg of a white solid, primarily consisting of the 
desired prolinol product, a yield of 86%.  A portion of this semi pure prolinol product 
was isolated by reverse phase HPLC (C18, 250mm x 21.2mm, 10µ) (75% 0.05 M 
NH4OAc, 25% acetonitrile, 9 mL/min) at a retention time of ~44 min. The collected 
fractions containing the desired prolinol were combined and concentrated by 
lyophilization.  Once dry ~20 mL of water was added, the solution was again frozen and 
lyophilized until dry (removes remaining NH4OAc).  This was repeated until NH4OAc 
was no longer present, leaving a white residue (2S, 3R, 4R)-3-hydroxy-4-o-methyl-α-
napthyl-proline, CSE 132.   
 
1
H-NMR (500 MHz, d6-DMSO) δ 8.84 (b, 2H (-NH2
+
), 8.05 (d, J = 7.8 Hz, 1H), 7.93 (d, 
J = 7.3 Hz, 1 H), 7.87 (d, J = 7.8 Hz, 1H), 7.57-7.51 (m, 3H),  7.46 (dd, J = 7.8, 7.3 Hz, 
1H), 5.66 (b, 1H, (-OH)), 4.95-4.88 (dd, J = 19.6, 12.2 Hz, 2H), 4.58 (s, 1H, H-2), 3.94 
(d, J = 2.4 Hz, 1H, H-3), 3.50 (s, 1H, H-1), 3.47 (d, J = 12.7 Hz, 1H, H-5), 3.28-3.25 (dd, 
J = 12.7, 3.4 Hz, 1H, H-4).  
13
C-NMR (500 MHz, d6-DMSO) δ 166.5, 133.3, 131.0, 
128.3, 128.2, 126.3, 125.8, 125.3, 124.0, 119.7, 113.6, 82.1, 75.8, 69.7, 68.2, 48.6.  
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HRMS m/e calcd.  For C16H18NO4 = 288.1236, found 288.1230.  [ α ]
22
Na = -18
◦
 (c = 0.1, 
DMSO). 
 
 
 
(2S, 3R, 4R)-N-Cbz-3-hydroxy-4-o-methyl-p-biphenyl-proline benzyl ester: BRL: 
301 
To 0.305 g (0.862 mmol) of N-Cbz-trans-3,4-epoxy-L-proline benzyl ester 13a was 
added 2 mL of dry (MgSO4 treated) CH2Cl2 and 0.318 g (98%, 2.0 eq.; 1.72 mmol) of 4-
biphenylmethanol.  The flask was capped, purged with argon and chilled on an ice bath 
under argon balloon.  Once cooled, 91 µL (48%; 0.4 eq.; 0.345 mmol) of BF3•Et2O was 
added to the stirring solution.  The mixture was allowed to return to rt and stir over night.  
The reaction was quenched by the addition of 20 mL saturated NaHCO3 solution and 
allowed to stir for an additional 30 min.  The contents of the flask were then diluted with 
100 mL CH2Cl2, washed with water (3 x 100 mL), washed with 50 mL brine, dried over 
Na2SO4 and concentrated to a white solid by rotovap.  The final product (2S, 3R, 4R)-N-
Cbz-3-hydroxy-4-o-methyl-p-biphenyl-proline benzyl ester, 0.395 mg (0.735 mmol), was 
isolated by silica gel (7 : 3 hexanes : EtOAc, Rf = 0.1), a yield of 85%, and some 
remaining epoxide starting material.  The product was used in the next step without 
further purification. 
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+H2N
COO-
O
OH
CSE131
Chemical Formula: C18H19NO4
Molecular Weight: 313.35
 
(2S, 3R, 4R)-3-hydroxy-4-o-methyl-p-biphenyl-proline:  BRL: 304 / CSE131 
To 0.105 g (0.195 mmol) of (2S, 3R, 4R)-N-Cbz-3-hydroxy-4-o-methyl-p-biphenyl-
proline benzyl ester was added 5 mL methanol which was heated to dissolve and then 
transferred to a pressure flask containing 11 mg of 10% Pd/carbon (0.10 eq. weight), 8 
mg (0.5 eq) NH4OAc and 0.5 mL water.  The pressure flask was connected to a Parr 
shaker, the air was removed by vacuum and replaced with 40 psi H2 (g).  The assembly 
was allowed to shake for 2 h until the reaction had completed as determined by TLC 
(50/49/1; hexanes/ethyl acetate/AcOH).  The pressure flask was vented and the contents 
were diluted with 30 mL water, followed by filtration through CM-cellulose using excess 
water for consecutive washes.  The filtrate was then frozen and lyophilized until dry.  The 
remaining residue was washed EtOAc / CH2Cl2 1 : 1 ( 3 x 20 mL), and dried over Na2SO4 
leaving 51.0 mg of a white solid crude, primarily consisting of the desired prolinol 
product, a yield of 84%.  A portion of this crude product was isolated by reverse phase 
HPLC (C18, 250mm x 21.2mm, 10µ) (75% 0.05 M NH4OAc, 25% acetonitrile, 9 
mL/min) at a retention time of ~38 min. The collected fractions containing the desired 
prolinol were combined and concentrated by lyophilization.  Once dry, 20 mL of water 
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was added, the solution was again frozen and lyophilized until dry (removes remaining 
NH4OAc).  This was repeated until NH4OAc was no longer present, leaving a white 
residue (2S, 3R, 4R)-3-hydroxy-4-o-methyl-p-biphenyl-proline, CSE 131.   
 
1
H-NMR (500 MHz, d6-DMSO 2.50) δ 8.82 (b, 1.5H, NH3
+
), 7.66-7.65 (d, J = 7.6 Hz, 
2H), 7.62-7.60 (d, J = 7.8 Hz, 2H), 7.47-7.44 (dd, J = 7.6, 7.3 Hz, 2H), 7.41-7.40 (d, J = 
7.6 Hz, 2H), 7.37-7.34 (dd, J = 7.3, 7.1 Hz, 1H), 5.64 (s, 1H, OH), 4.54 (s, 1H, H-2), 
4.53-4.46 (dd, J = 21.5, 22.7 Hz, 2H, methylene), 3.86 (s, 1H, H-3), 3.49 (s, 1H, H-1), 
3.46-3.43 (d, J = 12.5 Hz, 1H, H-5), 3.33 (H2O), 3.27-3.25 (d, J = 10.5 Hz, 1H, H-4).  
13
C-NMR (500 MHz, d6-DMSO) δ 170.2, 140.0, 139.2, 137.1, 128.9, 128.3, 127.4, 126.6, 
126.4, 81.8, 75.4, 69.5, 68.2, 46.7.  HRMS m/e calcd.  For C18H20NO4 = 314.1392, found 
314.1378.  [ α ]
22
Na = -7
◦
 (c = 0.12, DMSO). 
 
 
 
(2S, 3R, 4R)-N-Cbz-3-hydroxy-4-o-methyl-3-biphenylether-proline benzyl ester: 
BRL: 302 
To 0.275 g (0.778 mmol) of N-Cbz-trans-3,4-epoxy-L-proline benzyl ester 13a was 
added 3 mL of dry (MgSO4 treated) CH2Cl2 and 1 mL (7.34 eq.; 5.74 mmol) of 3-
phenoxybenzyl alcohol.  The flask was capped, purged with argon and chilled on an ice 
bath under argon balloon.  Once cooled, 0.614 mL (48%; 3 eq.; 2.33 mmol) of BF3•Et2O  
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was added to the mixture.  The mixture was allowed to return to rt and stir for 48 h.  The 
reaction was quenched by the addition of 20 mL saturated NaHCO3 and allowed to stir 
for 30 min.  The mixture was then diluted with 60 mL CH2Cl2, washed with water (3 x 
200 mL), washed with 50 mL brine, dried over Na2SO4 and concentrated via rotovap to a 
solid residue.  The final product (2S, 3R, 4R)-N-Cbz-3-hydroxy-4-o-methyl-3-
biphenylether-proline benzyl ester, 0.270 g (0.488 mmol), was isolated by silica gel (7 : 3 
hexanes : EtOAc, Rf = 0.10) for a total yield of 63%.  The product was used in the next 
step without further purification. 
 
+H2N
COO-
O
OH
O
CSE130
Chemical Formula: C18H19NO5
Molecular Weight: 329.35
 
(2S, 3R, 4R)-3-hydroxy-4-o-methyl-3-biphenylether-proline:  BRL: 303 / CSE130 
To 0.270 g (0.488 mmol) of (2S, 3R, 4R)-N-Cbz-3-hydroxy-4-o-methyl-3-biphenylether-
proline benzyl ester was added 5 mL methanol which was then transferred to a pressure 
flask containing 30 mg of 10% Pd/carbon (0.1 eq. weight), 0.3 mL water and 19.0 mg 
(0.5 eq.; 0.246 mmol) NH4OAc.  The pressure flask was connected to a Parr shaker, the 
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air was removed by vacuum and replaced with 40 psi H2 (g).  The assembly was allowed 
to shake for 2 h.  The pressure flask was vented and the contents were diluted with 20 mL 
water, followed by filtration through CM-cellulose using excess water for consecutive 
washes.  The filtrate was then frozen and placed onto a lyophilizer until dry.  The 
remaining residue was washed with 1:1 EtOAc : CH2Cl2 (3 x 20 mL), and dried leaving 
0.144 mg of a white solid crude, primarily consisting of the desired prolinol, a yield of 
90%.  A portion of this crude product was isolated by reverse phase HPLC (C18, 250mm 
x 21.2mm, 10µ) (75% 0.05 M NH4OAc, 25% acetonitrile, 9 mL/min) at a retention time 
of ~42 min. The collected fractions containing the prolinol product were combined and 
concentrated by lyophilization.  Once dry 20 mL of water was added, the solution was 
again frozen and lyophilized until dry (removes remaining NH4OAc).  This was repeated 
until NH4OAc was no longer present, leaving a white residue (2S, 3R, 4R)-3-hydroxy-4-
o-methyl-3-biphenylether-proline, CSE 130.   
 
1
H-NMR (500 MHz, d6-DMSO 2.50) δ 8.81 (b, 1.5H, NH3
+
), 7.40-7.37 (dd, J = 14.7Σ, 7.3 
Hz, 2H), 7.34-7.31 (dd, J = 7.8, 7.6 Hz, 1H), 7.15-7.09 (m, J = 18.1, 7.6 Hz, 2H), 6.99 
(m, 3H), 6.87 (d, J = 7.6, 1H), 5.62 (s, 1H, OH), 4.51 (s, 1H, H-2), 4.48-4.41 (dd, J = 
23.0, 12.0 Hz, 2H, methylene), 3.83 (s, 1H, H-3), 3.47 (s, 1H, H-1), 3.43-3.41 (d, J = 12.2 
Hz, 1H, H-5), 3.25-3.23 (d, J = 11.0 Hz, 1H, H-4).  
13
C-NMR (500 MHz, d6-DMSO) δ 
169.1, 156.7, 156.4, 140.3, 130.1, 129.7, 123.4, 122.7, 118.5, 117.8, 117.5, 81.9, 75.4, 
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69.3, 68.1, 48.7.  HRMS m/e calcd.  For C18H20NO5 = 330.1328, found 330.1341.  [α]
22
Na 
= -29
◦
 (c = 0.14, DMSO). 
 
 
Synthesis section 5 
Procedure for synthesis of alkyl, aryl or phenol-ether prolinols: 
A considerable amount of time was spent in the discovery and optimization of 
synthesizing alkyl, aryl and phenol-ether substituted prolinols figure 17.  Generation of 
these targets via nucleophillic substitution under basic conditions required the free acid  
proline epoxide so as to avoid racemization of the chiral α center during the addition step 
(Scheme 4).   This was accomplished by hydrolysis of the benzyl ester protection group 
of the proline olefin 12 to give the free acid olefin 12a.  Epoxidation of the free acid 
olefin with mCPBA (meta-chloroperoxybenzoic acid) under CH2Cl2 reflux w/ 1% radical 
inhibitor produced the trans-epoxide 13c in excellent yields with no detectable cis-
epoxide.  Epoxidation by dimethyldioxirane or peracidic acid were also met with the 
same results, however, in lower overall yield.   
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Figure 17:  Synthesized alkyl, aryl and phenol-ether prolinols. 
 
Initial attempts to ring open the epoxide of 13c via nucleophillic addition using Grignard 
reagents or organolithiums alone or in preparations with soft lewis acids CeCl3, CuBr 
(catalytic or stoichiometric, (including Gilman reagent (R2CuMgX or R2CuLi)), or 
copper (1) acetate and even SmI2 catalyzed Barbier addition were all unsuccessful.  As a 
last ditch effort, the N-protected prolinol derivatives 18a and 18b were finally obtained 
from the epoxide by transformation of the organolithium reagent to a higher order 
cuprate, a rearrangement & complexation between 2 eq organolithium reagent  and 1 eq 
CuCN (Lipshutz et al 1982; Lipshutz et al 1984) in Et2O  at approximately -40˚C 
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(Scheme 4; iii).  The prolinol products were isolated together by silica gel in yields of 90-
95% with regioisomer ratio’s of nearly 1 : 1.  
N
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+
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Scheme 4: Synthesis of alkyl, aryl or phenol-ether prolinols.  (i) KOH, THF, H2O, 22˚C; 
(ii) mCPBA, CH2Cl2; (iii) 2 eq. R2Cu(CN)Li2, Et2O, -40˚C, Inert atmosphere; (iv) Na
+
 
phenoxide in THF, rt; (v) 10% Pd/C (10% weight. eq), 40 psi H2, MeOH, H2O, NH4OAc. 
 
Similarly, the N-protected phenoxy prolinols 20a & 20b were synthesized from the free 
acid trans-epoxide 13c by the addition of a sodium phenoxide in THF at rt in 
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regioisomeric ratios of 12:1, 3-hydroxy : 4-hydroxy respectively, with overall respectable 
yields of 80-85%.  Hydrogenolysis of the N-benzylcarbamate (Cbz) of protected prolinols 
18a, 18b, 20a, or 20b via 10% Pd / carbon at 40 psi H2(g) in methanol and subsequent 
separation of the regioisomers by reverse phase HPLC afforded the substituted prolinol 
products 19a, 19b, 21a and 21b.   
 
 
N-Cbz-3,4-dehydro-L-proline 12a:  BRL:256 
To 8.26 g (24.5 mmol) of N-Cbz-3,4-dehydro-L-proline benzyl ester 12 was added 50 
mL THF, 5 mL H2O and 1.65 g (1.2 eq.; 29.4 mmol) KOH.  The mixture was stirred for 
2 h at rt.  The mixture was concentrated by rotovap until dry in which 20 mL of water 
was added to dissolve the remaining residue.  The pH of this mixture was adjusted to ~2 
by addition of H3PO4 and NaCl was added until saturated.  The contents were then 
extracted with EtOAc (3 x 200 mL).  The ethyl acetate washes were combined and dried 
over Na2SO4, filtered and concentrated via rotovap to a yellow oil.  The product, 6.05 g,  
N-Cbz-3,4-dehydro-L-proline 12a was isolated by silica gel (60% hexanes, 39% ethyl 
acetate, 1% AcOH; Rf  = 0.2) a quantitative yield.  The material was used in the next step 
without further purification. 
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N-Cbz-trans-3,4-epoxy-L-proline 13c:  BRL:257 
To 2.37 g (9.60 mmol) of N-Cbz-3,4-dehydro-L-proline 12a was added 20 mL CH2Cl2, 
4.73 g (2 eq; 19.2 mmol) of 70% mCPBA, and 10 mg of (0.4% weight) 2,6-ditertbutyl-4-
methyl phenol.  The mixture was then refluxed under argon balloon overnight.  Another 
2.00 g (0.85 eq) of mCPBA was added to the reaction mixture and reflux was continued 
overnight.  The mixture, now with white precipitate, was cooled over ice bath and filtered 
using 20 mL cold CH2Cl2 to wash.  The product, 1.68 g of N-Cbz-trans-3,4-epoxy-L-
proline 13c, was separated from the crude mixture consisting of excess mCPBA by a 
series of two silica gel columns; the first using 50% hexanes, 49% ethyl acetate, 1% 
AcOH as a mobile phase and the second using 96% CH2Cl2, 3% MeOH, 1% AcOH.  
Recovered epoxide product resulted in a yield of 67%, however, this represents only 
isolated product from two columns; a higher yield was possible with further purification 
via flash chromatography. 
 
1
H-NMR (500 MHz, CDCl3) (2 conformational isomers) δ 10.30 (b, 1H [COOH]), 7.35-
7.26 (m, 5H), 5.18-5.11 (m, J = 20.8, 12.5 Hz, 1H), 5.12 (s, 1H), 4.75 and 4.68 (s, 1H), 
3.97 and 3.92 (d, J = 12.7 Hz, 1H), 3.88 and 3.85 (d, J = 2.7 Hz, 1H), 3.69 (s, 1H), 3.56-
3.53 (d, J = 12.7 Hz, 1H). 
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(2S, 3S, 4R)-N-Cbz-3-hydroxy-4-phenyl-proline and (2S, 3S, 4R)-N-Cbz-3-phenyl-4-
hydroxy-proline:  BRL: 263 
To a flame dried round bottom flask was added 0.143 g (1.60 mmol; 3 eq) of CuCN 
(dried by high vacuum) and 5 mL dry (MgSO4 treated) Et2O.  The flask was capped with 
a septum, purged air vacuum / argon balloon, and chilled to -40˚C (acetone bath / cold 
finger controled).  Once cooled, 1.60 mL (3.19 mmol; 6 eq) of 2.0 M phenyl-lithium in 
THF was added and the mixture was then allowed to warm to -10˚C and kept at this 
temperature for ~15 min and then returned to -40˚C where 0.140 g (0.532 mmol) of N-
Cbz-trans-3,4-epoxy-L-proline 13c in 2 mL dry (MgSO4 treated) Et2O  also at -40˚C was 
added via sterile syringe.  The flask was then allowed to warm to -10˚C and stir 
overnight.  After stirring overnight, the reaction mixture was allowed to warm to 0˚C and 
was quenched by the addition of 20 mL saturated NH4Cl.  The mixture was then warmed 
to rt, the pH was adjusted to ~2 by addition of H3PO4 and salted with NaCl until 
saturated.  The products were then extracted with EtOAc (3 x 100 mL).  The organic 
washes were combined, dried over Na2SO4, and concentrated to a solid residue via 
rotovap.  The products, 0.171 g of (2S, 3S, 4R)-N-Cbz-3-hydroxy-4-phenyl-proline and 
(2S, 3S, 4R)-N-Cbz-3-phenyl-4-hydroxy-proline were isolated as a regioisomer mixture 
by silica gel (50% hexanes, 49% ethyl acetate, 1% AcOH) for the first column followed 
by a second column ( 96% CH2Cl2, 3% MeOH, 1% AcOH), a 94% yield.  The material 
was used in the next step without further purification. 
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+H2N
COO-
OH
+H2N
COO-
OH
CSE103
Chemical Formula: C11H13NO3
Molecular Weight: 207.23
CSE104
Chemical Formula: C11H13NO3
Molecular Weight: 207.23
 
(2S, 3S, 4R)-3-hydroxy-4-phenyl-proline and (2S, 3S, 4R)-3-phenyl-4-hydroxy-
proline:  BRL: 293 / CSE104 and CSE103 
To a 0.200 g (0.586 mmol) regioisomer mixture of (2S, 3S, 4R)-N-Cbz-3-hydroxy-4-
phenyl-proline and (2S, 3S, 4R)-N-Cbz-3-phenyl-4-hydroxy-proline was added 3 mL 
MeOH.  The mixture was transferred to a pressure flask containing 20.0 mg (0.1 eq 
weight) 10% Pd / carbon, 0.5 mL H2O and 23.0 mg (0.5 eq: 0.298 mmol) NH4OAc.  The 
flask was placed on a Parr shaker, the air was removed by vacuum, and replaced by 40 
psi H2 (g).  The apparatus was allowed to shake for 3 h at rt.  The pressure flask was 
vented and the contents were diluted with 30 mL water and filtered through CM-cellulose 
using excess water for consecutive washes.  The filtrate was then frozen and lyophilized 
until dry.  The remaining residue was washed with EtOAc : CH2Cl2 1:1 (3 x 20 mL), and 
dried leaving 0.108 mg (89% yield) of an off white solid, a crude mixture of (2S, 3S, 
4R)-3-hydroxy-4-phenyl-proline and (2S, 3S, 4R)-3-phenyl-4-hydroxy-proline, 
regioisomeric ratio of 4.4 : 5.6 respectively.  A portion of this crude was separated by 
reverse phase HPLC (C18, 250 mm x 21.2 mm, 10µ) (92% 0.05 M NH4OAc, 8% 
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acetonitrile, 9 mL / min).  Fractions containing a specific isomer were combined and 
concentrated by lyophilization.  Once dry, 20 mL of water was added to dissolve the 
remaining residue and the solution was again frozen and lyophilized until dry (removes 
remaining NH4OAc).  This was repeated until NH4OAc was no longer present affording 
(2S, 3S, 4R)-3-hydroxy-4-phenyl-proline (CSE104) or (2S, 3S, 4R)-3-phenyl-4-hydroxy-
proline (CSE103) as separate white solids. 
 
(2S, 3S, 4R)-3-phenyl-4-hydroxy-proline : CSE103 
1
H-NMR (500 MHz, D2O 4.75) δ 7.42-7.39 (dd, J = 7.3, 7.1 Hz, 2H), 7.35-7.31 (m, J = 
7.6 Hz, 3H), 4.52-4.49 (dd, J = 12.7, 6.4 Hz, 1H, H-3), 4.21 (d, J = 8.8 Hz, 1H, H-1), 
3.66-3.62 (dd, J = 11.5, 6.1 Hz, 1H, H-5), 3.38-3.31 (m, J = 8.8, 6.1 Hz, 2H, H-2 & 4).  
13
C-NMR (500 MHz, D2O) δ 172.6, 136.8, 129.1, 127.9, 127.6, 75.4, 64.7, 55.8, 49.6.  
HRMS m/e calcd.  For C11H14NO3 = 208.0974, found 208.0996.  [ α ]
22
Na = -16
◦
 (c = 0. 
23, H2O), [ α ]
22
Na = -15
◦
 (c = 0.24, EtOH). 
 
(2S, 3S, 4R)-3-hydroxy-4-phenyl-proline : CSE104 
1
H-NMR (500 MHz, D2O 4.75) δ 7.41-7.38 (dd, J = 7.6, 7.1, 2H), 7.33-7.30 (m, J = 7.6 
Hz, 3H), 4.63-4.61 (dd, J = 8.8, 4.4 Hz, 1H, H-2), 4.21-4.20 (d, J = 5.6 Hz, 2H, H-1), 
3.91-3.86 (dd, J = 9.8, 5.4 Hz, 1H, H-5), 3.58-3.51 (m, 2H, H-3 & 4).  
13
C-NMR (500 
MHz, D2O) δ 171.0, 137.1, 129.1, 127.8, 127.0, 76.4, 64.6, 50.8, 47.9.  HRMS m/e calcd.  
For C11H14NO3 = 208.0974, found 208.0982.  [ α ]
22
Na = -43
◦
 (c = 0.08, EtOH). 
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(2S, 3S, 4R)-N-Cbz-3-hydroxy-4-methyl-proline and (2S, 3S, 4R)-N-Cbz-3-methyl-4-
hydroxy-proline:  BRL: 259 
To a flame dried round bottom flask was added 0.730 g (8.50 mmol; 2.5 eq) of CuCN 
(dried by high vacuum) and 10 mL dry (MgSO4 treated) Et2O.  The flask was capped 
with a septum, purged air with vacuum, filled with argon balloon, and cooled to -60˚C 
(acetone bath / cold finger controled).  Once cooled, 10.0 mL (16.3 mmol; 5 eq) of 1.6 M 
methyl-lithium in Et2O was added via sterile syringe and the mixture was allowed to stir 
for ~15 min until all the CuCN appeared to be dissolved (a clear colorless solution).  
Once equilibrated, 0.840 g (3.20 mmol) of N-Cbz-trans-3,4-epoxy-L-proline 13c in 10 
mL dry (MgSO4 treated) Et2O  at -60˚C was added via sterile syringe.  The flask was then 
allowed to warm to -40˚C and stir overnight under argon balloon.  After stirring 
overnight, the reaction mixture was allowed to warm to 0˚C and was quenched by the 
addition of 30 mL saturated NH4Cl.  The mixture was then warmed to rt, the pH was 
adjusted to ~2 by addition of H3PO4 and salted with NaCl until saturated.  The products 
were then extracted with of EtOAc (3 x 100 mL).  The organic washes were then 
combined, dried over NaSO4, and concentrated to a crude regioisomer mixture, 0.766 g.  
The products, (2S, 3S, 4R)-N-Cbz-3-hydroxy-4-methyl-proline and (2S, 3S, 4R)-N-Cbz-
3-methyl-4-hydroxy-proline (ratio of 1:1) were isolated as a regioisomer mixture by silica 
gel from two columns (50% hexanes, 49% ethyl acetate, 1% AcOH and 96% CH2Cl2, 3% 
MeOH, 1% AcOH) an 86% yield and recovery of epoxide starting material.  A portion of 
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these regioisomers were separated by reverse phase HPLC (C18, 250 mm x 21.2 mm, 10 
µ) (85% 0.05 M NH4OAc, 15% acetonitrile, 9 mL/min) at a retention time of 22 min for 
(2S, 3S, 4R)-N-Cbz-3-methyl-4-hydroxy-proline and 24 min for (2S, 3S, 4R)-N-Cbz-3-
hydroxy-4-methyl-proline.  The fractions containing an individual isomer were combined 
and concentrated by lyophilization to afford the product as white solid.  Each separate 
isomer was used in the next synthetic step without further purification. 
 
 
+H2N
COO-
OH
CSE109
Chemical Formula: C6H11NO3
Molecular Weight: 145.16  
(2S, 3S, 4R)-3-methyl-4-hydroxy-proline:  BRL: 268 / CSE109 
To 70.0 mg (0.251 mmol) of (2S, 3S, 4R)-N-Cbz-3-methyl-4-hydroxy-proline was added 
2 mL MeOH..  The mixture was transferred to a pressure flask containing 7.0 mg (0.1 eq. 
weight) 10% Pd/carbon, and 6.3 (0.5 eq) NH4OAc.  The flask was placed on a Parr 
shaker, the air was removed by vacuum, and replaced by 40 psi H2 (g).  The apparatus 
was allowed to shake for ~2 h at rt.  The pressure flask was vented and the contents were 
diluted with 30 mL water and filtered through CM-cellulose using excess water for 
consecutive washes.  The filtrate was then frozen and lyophilized until dry.  The 
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remaining residue was washed with 1:1 EtOAc : CH2Cl2 ( 3 x 20 mL), resuspended in 10 
mL water and again dried by lyophilization leaving 33.0 mg of (2S, 3S, 4R)-3-methyl-4-
hydroxy-proline (CSE109) as a white solid, a 92% yield. 
 
1
H-NMR (500 MHz, D2O 4.75) δ 4.09 (dd, J = 4.9, 2.4 Hz, 1H, H-3), 3.66 (d, J = 5.9 Hz, 
1H, H-1), 3.50-3.46 (dd, J = 12.2, 4.9 Hz, 1H, H-5), 3.29-3.26 (dd, J = 12.2, 2.4 Hz, 1H, 
H-4), 2.37-2.33 (dd, J = 6.8, 5.9 Hz, 1H, H-2), 1.13 (d, J = 6.8 Hz, 3H, methyl).  
13
C-
NMR (500 MHz, D2O) δ 176.2, 77.4, 68.3, 52.8, 47.6, 18.6.  HRMS m/e calcd.  For 
C6H12NO3 = 146.0817, found 146.0822.  [ α ]
22
Na = -4
◦
 (c = 0.25, H2O). 
 
 
+H2N
COO-
OH
CSE110
Chemical Formula: C6H11NO3
Molecular Weight: 145.16
 
(2S, 3S, 4R)-3-hydroxy-4-methyl-proline:  BRL: 254 / CSE110 
To 80.0 mg (0.286 mmol) of (2S, 3S, 4R)-N-Cbz-3-hydroxy-4-methyl-proline was added 
5 mL MeOH..  The mixture was transferred to a pressure flask containing 20.0 mg (0.25 
weight %) 10% Pd/carbon.  The flask was placed on a Parr shaker, the air was removed 
by vacuum, and replaced by 40 psi H2 (g).  The apparatus was allowed to shake for ~24 h 
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at rt.  The pressure flask was vented and the contents were diluted with 30 mL water and 
filtered through CM-cellulose using excess water for consecutive washes.  The filtrate 
was then frozen and lyophilized until dry.  The remaining residue was washed with 1:1 
EtOAc / CH2Cl2 (3 x 20 mL), resuspended in 10 mL water and again dried by 
lyophilization leaving 34.0 mg of (2S, 3S, 4R)-3-hydroxy-4-methyl-proline (CSE110) as 
a white residue, a 82% yield. 
 
1
H-NMR (500 MHz, D2O 4.75) δ 4.27 (d, J = 4.4 Hz, 1H, H-2), 4.20 (d, J = 4.40 Hz, 1H, 
H-1), 3.65-3.61 (dd, J = 11.7, 6.60 Hz, 1H, H-4), 3.01-2.99 (dd, J = 11.7, 3.4 Hz, 1H, H-
5), 2.42-2.39 (dd, 6.6 Hz, 3.4 Hz, 1H, H-3), 1.00 (d, J = 7.3 Hz, 3H, methyl).  
13
C-NMR 
(500 MHz, D2O) ppm 170.7, 76.3, 65.0, 49.8, 40.6, 15.4.  HRMS m/e calcd.  For 
C6H12NO3 = 146.0817, found 146.0829.  [ α ]
22
Na = -12 
◦
 (c = 0.31, H2O). 
 
 
(2S, 3S, 4R)-N-Cbz-3-hydroxy-4-phenoxy-proline and (2S, 3S, 4S)-N-Cbz-3-
phenoxy-4-hydroxy-proline:  BRL: 272 
To a round bottom flask containing 1.00 g (7.34 eq; 10.6 mmol) of phenol in 4 mL dry 
THF (distilled) was added 0.245 g (0.95 eq) of NaH slowly.  The flask was then cooled 
over ice bath and argon balloon.  To this mixture was added 0.381 g (1.45 mmol) N-Cbz-
trans-3,4-epoxy-L-proline 13c in 2 mL dry THF (distilled) at 0˚C.  The mixture was then 
allowed to warm to rt and then heated to reflux under condenser and argon balloon and 
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stirred overnight.  The reaction was then cooled on ice bath and 20 mL of 10% H3PO4  
(aq) was added to quench the reaction.  The mixture was then salted with NaCl until 
saturated and extracted with EtOAc (3 x 100 mL).  The organic extracts were combined, 
dried over NaSO4, and concentrated to a crude solid residue.  The products, 0.330 g of 
(2S, 3S, 4R)-N-Cbz-3-hydroxy-4-phenoxy-proline and (2S, 3S, 4S)-N-Cbz-3-phenoxy-4-
hydroxy-proline (12:1 respectively) were isolated as a regioisomer mixture by silica gel 
(50% hexanes, 49% ethyl acetate, 1% AcOH) and ( 96% CH2Cl2, 3% MeOH, 1% AcOH) 
from  two columns to afford the product, a 64% yield not including recovered starting 
material.  The regioisomer mixture was used in the next step without further purification. 
 
 
+H2N
COO-
O
OH
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COO-
O
OH
CSE117
Chemical Formula: C11H13NO4
Molecular Weight: 223.23
CSE118
Chemical Formula: C11H13NO4
Molecular Weight: 223.23
 
(2S, 3S, 4R)-3-hydroxy-4-phenoxy-proline and (2S, 3S, 4S)-3-phenoxy-4-hydroxy-
proline:  BRL: 279 / CSE118 and CSE117 
To a 0.550 g (1.54 mmol) regioisomer mixture of (2S, 3S, 4R)-N-Cbz-3-hydroxy-4-
phenyl-proline and (2S, 3S, 4R)-N-Cbz-3-phenyl-4-hydroxy-proline was added 10 mL 
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MeOH.  The mixture was transferred to a pressure flask containing 83.0 mg (0.15 eq. 
weight) 10% Pd/carbon, 0.2 mL H2O and 60.0 mg (0.5 eq: 0.77 mmol) NH4OAc.  The 
flask was placed on a Parr shaker, the air was removed by vacuum, and replaced by 50 
psi H2 (g).  The apparatus was allowed to shake overnight at rt.  The pressure flask was 
vented and the contents were diluted with 30 mL water and filtered through CM-cellulose 
using excess water for consecutive washes.  The filtrate was then frozen and lyophilized 
until dry.  The remaining residue was washed with 1:1 EtOAc / CH2Cl2 (3 x 20 mL), and 
dried leaving 0.308 mg of an off white solid, a crude mixture of (2S, 3S, 4R)-3-hydroxy-
4-phenoxy-proline and (2S, 3S, 4S)-3-phenoxy-4-hydroxy-proline, regioisomeric ratio of 
12:1 respectively and a (90% yield).  Additionally, there was a large recovery of 
unreacted starting material from the organic washes.  A portion of the product mixture 
was separated by reverse phase HPLC (C18, 250mm x 21.2mm, 10µ) (92% 0.05 M 
NH4OAc, 8% acetonitrile, 9 mL/min).  Collected fractions containing a single isomer 
were combined and concentrated by lyophilization.  Once dry, 20 mL of water was added 
to redissolve the remaining residue and the solution was again frozen and lyophilized 
until dry (removes remaining NH4OAc).  This was repeated until NH4OAc was no longer 
present leaving (2S, 3S, 4R)-3-hydroxy-4-phenoxy-proline (CSE118) or (2S, 3S, 4S)-3-
phenoxy-4-hydroxy-proline (CSE117) as a white solid. 
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(2S, 3S, 4S)-3-phenoxy-4-hydroxy-proline : CSE117 
1
H-NMR (500 MHz, D2O 4.75) δ 7.33-7.30 (dd, J = 7.6, 7.6 Hz, 2H), 7.05-7.02 (dd, J = 
8.1, 7.6 Hz, 1H), 7.00-6.98 (d, J = 8.1 Hz, 2H), 5.00 (d, J = 4.3 Hz, 1H, H-2), 4.59 (d, J = 
4.3 Hz, 1H, H-1), 4.56 (d, J = 4.0 Hz, 1H, H-3), 3.73-3.69 (dd, J = 13.0, 4.0 Hz, 1H, H-5), 
3.36 (d, J = 13.0 Hz, 1H, H-4).  
13
C-NMR (500 MHz, D2O) δ 169.6, 156.1, 129.8, 122.5, 
115.9, 81.2, 71.8, 64.2, 51.0.  HRMS m/e calcd.  For C11H14NO4 = 224.0923, found 
223.0911.  [ α ]
22
Na = -15
◦
 (c = 0.08, EtOH). 
 
(2S, 3S, 4R)-3-hydroxy-4-phenoxy-proline : CSE118 
1
H-NMR (500 MHz, D2O 4.75) δ 7.33-7.30 (dd, J = 7.3, 7.3 Hz, 2H), 7.04-7.01 (dd, J = 
8.3, 7.3 Hz, 1H), 6.93-6.92 (d, J = 8.3 Hz, 2H), 4.92 (d, J = 3.0 Hz, 1H, H-3), 4.67 (s, 1H, 
H-2), 4.10 (s, 1H, H-1), 3.76-3.73 (dd, J = 13.2, 3.0 Hz, 1H, H-4), 3.72-3.70 (d, J = 13.2 
Hz, 1H, H-5).  
13
C-NMR (500 MHz, D2O) δ 173.0, 157.8, 132.4, 125.0, 118.4, 81.9, 78.1, 
70.3, 51.7.  HRMS m/e calcd.  For C11H14NO4 = 224.0923, found 224.0937.  [ α ]
22
Na = -
81
◦
 (c = 0.1, EtOH). 
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Synthesis section 6 
Procedure for synthesis of 4,4-alkyl-hydroxy-L-prolines 
N
COO-P'
OH
P
N
COO-P'
P
O
N
COO-P'
P
HO
R
+H2N
COO-
HO
R
ia or ib ii
8 24 25 26
iiib or iiib
R = any alkyl or aryl group
P = trityl or Cbz protected
P' = H or ethyl ester
 
Scheme 5: Synthesis of 4-substituted-4-hydroxy-prolines.  (ia) CrO3, H2SO4, Acetone or 
(ib) Swern oxidation; (ii) organometallic / CuBr or CuCN catalyst (2eq.), Et2O, -20˚C; 
(iiia) 10% Pd/C (.10% weight. eq.), H2, MeOH, H2O, NH4
+
Acetate or (iiib) 1. KOH, 
THF;  2. HCl, THF.   
 
Protected 4-hydroxy-proline 8, N-trityl and ethyl ester or N-Cbz, was converted to the 4-
keto-proline 24 by either Swern oxidation or Jones oxidation respectively, in good yield 
80-85% (Scheme 5) [Bridges et al 1991].  Depending upon the protection group 
employed, triphenylmethyl (trityl) or Cbz, the stereochemistry of geminal addition via 
Grignard reagent to the 4-carbonyl was controlled.  Geminal addition to a N-trityl 
protected 4-keto-proline was selective preferring the trans-alcohol product, whereas, 
addition to a N-Cbz protected 4-keto-proline was selective preferring the cis product, 
with no detectable trace of a contaminating diastereomer.  The final protect 26 was 
obtained after deprotection under standard conditions and ion exchange.  Briefly, trans-4-
hydroxy-L-proline was protected under via 1.) thionyl-chloride, EtOH; 2.) 
triphenylmethylchloride, triethylamine, CH2Cl2 at 22˚C to produce N-trityl-trans-4-
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hydroxy-L-proline ethyl ester or benzylchloroformate, NaOH, H2O, 22˚C to produce N-
Cbz-trans-4-hydroxy-L-proline.  The protected 4-hydroxy proline was then oxidized to 
the 4-keto-proline via Swern oxidation (1. Oxalyl chrloride, DMSO 2. TEA) (if trityl 
protecting group was present) or by Jones oxidation (CrO3, H2SO4, Acetone) (if Cbz 
protecting group was present) and isolated by silica gel.  The isolated protected 4-keto-
proline was then transformed to the 4-alkyl-4-hydroxy proline via Cu(I) catalyzed 
(R2CuMgBr) Grignard or organo lithium (R2CuLi) addition at -20˚C in Et2O.  
Importantly, it was necessary to isolate the product by silica gel with 1% triethylamine 
(TEA) immediately after the Grignard or organo litium addition reaction when N-trityl-4-
keto-proline was used as a starting material so as to prevent decomposition.  Once 
isolated, the product was then deprotected under standard conditions using 1.2 eq. KOH 
in THF at 22˚C to hydrolyze the ethyl ester of N-trityl-4,4-alkyl-hydroxy-proline 
followed by dilute HCl 1.2 eq. in THF at rt and isolated by washing with 1:1 EtOAc, 
CH2Cl2 and ion exchange.   Alternatively, N-Cbz-4,4-alkyl-hydroxy-proline was 
deprotected by hydrogenolysis with 10% Pd/carbon (0.1 eq) at 22˚C in MeOH and 
isolated by washing with 1:1 EtOAc, CH2Cl2 and ion exchange.  The final product 
dissolved in water / buffer from the ion exchange, regardless of the protection groups 
used, was then concentrated by lyophilization to a dry solid.   
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N-Trityl-4-keto-L-proline ethyl ester:  BRL: 41  
To a 100 mL round bottom flask containing 20 mL CH2Cl2 was added 0.54 mL (6.20 
mmol; 1.2 eq) of COCl2 in 2 mL CH2Cl2.  The flask was then chilled to -60˚C (acetone 
bath and cold finger) under argon balloon.  To this was added 0.88 mL dry (molecular civ 
treated) DMSO in 1 mL dry (MgSO4 treated) CH2Cl2 drop wise.  The mixture was 
allowed to stir for 15 min before being brought up to -30˚C where 2.02 g (6.17 mmol) of 
N-trityl-trans-4-hydroxy-L-proline ethyl ester in 4 mL CH2Cl2 was added dropwise over 
10 min.  The resulting solution was allowed to stir for 1 h at -30˚C under argon balloon.  
To complete the reaction, 3.6 mL (> 5 eq) of triethylamine was slowly added.  The flask 
was then allowed to warm to rt where 100 mL of water was added.  The mixture was then 
extracted with Et2O (3 x 100 mL).  The organic extracts were combined, dried with 
Na2SO4 and concentrated via rotovap to a solid crude.  The remaining crude was then 
immediately separated by silica gel (90% hexanes, 9% ethylacetate, 1% TEA, Rf = 0.2).  
The fractions containing the product were combined, concentrated, and placed on a high 
vacuum pump leaving 1.51 g of N-trityl-4-keto-L-proline ethyl ester, as a white foam, a 
yield of 75%.  This product, once isolated, was then used within 4-6 h in the addition step 
(trityl group readily decomposes) without further purification.   
 
1
H-NMR (400 MHz, CDCl3 at 7.27 ppm) δ 7.58-7.56 (d, J = 8.1 Hz, 6H), 7.31-719 (m, 
9H), 4.30-4.18 (m, 3H), 3.86-3.81 (d, J = 19.8 Hz, 1H), 3.54-3.49 (d, J = 19.8 Hz, 1H), 
1.88-1.84 (d, J = 18.3 Hz, 1H), 1.34-1.31 (dd, J = 13.9, 6.6 Hz, 3H), 1.12-1.05 (dd, J = 
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18.3, 10.3, 1.5 Hz, 1H).  
13
C-NMR (400 MHz, CDCl3 at 77.00 ppm) δ 215.7, 173.5, 
143.6, 128.88, 128.2, 127.9, 126.8, 77.9, 61.1, 60.1, 57.1, 40.2, 14.2. 
 
N-Trityl-cis-4-methyl-trans-4-hydroxy-L-proline ethyl ester:  BRL: 70 
To a flame dried / argon purged flask containing 0.123 g (5.00 mmol; 2 eq) of Mg metal 
in 2 mL diethyl ether was added 0.315 mL (5.00 mmol; 2 eq) of iodomethane over 10 
min.  The mixture was allowed to stir for ~ 20 min until when it was observed that most 
or all of the Mg metal was consumed.  The flask was cooled to -20˚C under argon balloon 
where it was then transferred to a flask containing 0.359 mg (2.5 mmol; 1 eq) of Cu(I)Br 
(dried by vacuum) at -20˚C.  The mixture was allowed to stir for ~15 min. after which 
1.00 g (2.50 mmol) of N-trityl-4-keto-L-proline ethyl ester in 6 mL dry Et2O was added 
and allowed to stir overnight.  The reaction was then quenched by the addition of 15 mL 
saturated NH4Cl solution, and diluted with 100 mL Et2O.  The organic phase was washed 
with water (3 x 100 mL), dried over Na2SO4 and concentrated via rotovap to a light 
brown foam.  Immediately following the addition step the product, 0.624 g N-Trityl-cis-
4-methyl-trans-4-hydroxy-L-proline ethyl ester, was isolated by a silica gel (95% 
hexanes, 4% ethyl acetate, 1% TEA; Rf = 0.12), a yield of 60%.  
 
1
H-NMR (400 MHz, CDCl3 at 7.27 ppm ) δ 7.61-7.60 (d, J = 7.3 Hz, 6H), 7.32-728 (dd, J 
= 8.1, 7.3 Hz, 6H), 7.21-7.18 (dd, J = 7.3 Hz, 3H), 4.03-3.90 (m, 3H ), 3.63-3.60 (d, J = 
12.4 Hz, 1H), 2.99-2.96 (d, J = 12.4 Hz, 1H), 1.93-1.88 (dd, J = 13.2, 6.6 Hz, 1H), 1.71-
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1.31 (dd, J = 13.2, 8.1 Hz, 1H), 1.25 (s, 3H), 1.15-1.12 (dd, J = 7.3, 7.3 Hz, 3H).  
13
C-
NMR (400 MHz, CDCl3 at 77.00 ppm) δ 175.9, 144.0, 129.4, 127.8, 126.5, 77.8, 77.3, 
63.7, 62.1, 60.4, 46.7, 26.2, 14.0. 
 
+H2N
COO-
OH
CSE95
Chemical Formula: C6H11NO3
Molecular Weight: 145.16
 
cis-4-methyl-trans-4-hydroxy-L-proline:  BRL: 71 / CSE95 
To 0.111 g (0.276 mmol) of N-Trityl-cis-4-methyl-trans-4-hydroxy-L-proline ethyl ester 
was added 2 mL of THF, 0.2 mL H2O and 20.0 mg (90%, 1.2 eq) KOH.  The mixture 
was allowed to stir for 2 h at rt.  The solution was then concentrated to a solid residue by 
rotovap, and washed with water (2 x 10 mL).  The remaining residue was resuspended in 
2 mL THF and 0.33 mL (2.5 eq) of 2 M HCl was added.  After 1 h of stirring the solution 
was diluted with 10 mL water.  The THF was removed by rotovap leaving mostly water 
and dissolved product.  The sample was frozen and lyophilized to concentrate.  The 
remaining residue was washed 1:1 EtOAc / CH2Cl2 (3 x 10 mL).   The sample was then 
diluted with 5 mL water and isolated by cation exchange resin (sulphonic acid resin) 
using 10% NH4OAc to elute the final product, cis-4-methyl-trans-4-hydroxy-L-proline.  
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The collected fractions were combined and concentrated by lyophilization to afford 32 
mg of the product, an 83% yield.   
 
1
H-NMR (500 MHz, D2O at 4.75) δ 4.30-4.25 (dd, J = 10.4, 7.8 Hz, 1H, H-1), 3.22 (s, 
2H, H-4 & 5), 2.40-2.34 (dd, J = 13.6, 8.4 Hz, 1H, H-2), 1.98-1.92 (dd, J = 13.6, 10.4 Hz, 
1H, H-3), 1.38 (s, 3H).  
13
C-NMR (500 MHz, D2O) δ 175.1, 78.0, 61.0, 56.8, 42.9, 22.9.  
HRMS m/e calcd.  For C6H12NO3 = 146.0817, found 146.0803.  [ α ]
22
Na = -60
◦
 (c = 0.35, 
MeOH). 
 
 
N-Cbz-4-keto-L-proline ethyl ester:  BRL: 47 
To a round bottom flask containing 14.0 g (52.8 mmol) of N-Cbz-4-hydroxy-L-proline 8 
was added 26 mL acetone.  The solution was cooled on ice bath where 8.12 mL (0.106 
mmol; 2 eq) of Jones reagent (CrO3, H2SO4, 1.3 M in water) was added.  The mixture 
was allowed to warm to rt and stir for 3 h where the reaction appeared to be complete, as 
determined by TLC.  The reaction was quenched by the addition of 6 mL isopropanol.  
After stirring for another 2 h the flask was placed on a glass socket rotovap and the 
isopropanol/acetone was removed by reduced pressure. The remaining green residue was 
then diluted into 200 mL water, salted with NaCl and extracted with EtOAc (3 x 200 
mL).  The organic extracts were combined, dried with MgSO4, filtered and concentrated 
to an oil.  The remaining yellow oil was then separated by silica gel (90% CH2Cl2, 9% 
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MeOH, 1% AcOH, Rf = 0.3).  The fractions containing the product were combined and 
concentrated by rotovap to a solid residue and then recrystallized from CH2Cl2 leaving 
9.86 g (37.5 mmol) of N-Cbz-4-keto-L-proline, a 71% yield.  The product material was 
used in the next synthetic step without further purification. 
 
N-Cbz-trans-4-methyl-cis-4-hydroxy-L-proline:  BRL: 53 
To a flame dried / argon purged flask containing 0.231 g (9.40 mmol; 2.5 eq) Mg metal in 
2 mL dry diethyl ether was added 0.530 mL (8.40 mmol; 2.2 eq) of iodomethane slowly.  
The mixture was allowed to stir for ~ 20 min until when it was observed that most or all 
of the Mg metal was consumed.  The mixture was then cooled to -20˚C under argon 
balloon.  To this prepared Grignard was added 1.00 g (2.50 mmol) of N-Cbz-4-keto-L-
proline in 5 mL cold dry Et2O.  The mixture was allowed to return to rt and then refluxed 
for 2 h.  The reaction was then quenched by the addition of 15 mL saturated NH4Cl aq 
and allowed to stir an additional 30 min.  The mixture was then acidified with HCl to pH 
~2, salted with NaCl and extracted with EtOAc (3 x 100 mL).  The organic extracts were 
then combined, dried with MgSO4, filtered, and concentrated to a light brown residue.  
The product, 0.440 g (1.58 mmol) of N-Cbz-trans-4-methyl-cis-4-hydroxy-L-proline, 
was isolated by a silica gl (85% CH2Cl2, 14% MeOH, 1% AcOH; Rf = 0.25) with a yield 
of 41%; not including full recovery of unreacted starting material.  The isolated product 
was then used in the next deprotection step without further purification. 
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1
H-NMR (400 MHz, CDCl3 at 7.27 ppm) δ 8.73 (b, 1H), 7.33-7.27 (m, 5H), 5.18-5.07 
(m, 2H), 4.48-4.42 (dd, J = 15.4, 8.8 Hz, 1H), 3.70-3.64 (dd, J = 11.7 Hz, 1H), 3.37-3.32 
(dd, J = 10.3 Hz, 1H), 2.25-2.15 (m, 2H), 1.37-1.35 (d, J = 8.1 Hz, 3H).  
13
C-NMR (400 
MHz, CDCl3 at 77.00 ppm) (2 conformational isomers) δ 176.8 and 176.6, 155.4 and 
154.8, 135.9, 128.4 and 128.3, 128.0, 127.8 and 127.6, 76.8 and 76.2, 67.5 and 67.4, 59.4 
and 59.3, 58.8 and 58.5, 43.4 and 42.4, 24.2 and 20.6.  
 
 
+H2N
COO-
HO
CSE96
Chemical Formula: C6H11NO3
Molecular Weight: 145.16
 
cis-4-hydroxy-trans-4-methyl-L-proline:  BRL: 56 / CSE96 
To 0.200 g (0.716 mmol) of N-Cbz-cis-4-hydroxy-trans-4-methyl-L-proline was added 2 
2 mL MeOH which was transferred to a pressure flask containing 50 mg 10% Pd/carbon 
and 0.2 mL H2O.  This was then connected to a Parr shaker and the air was removed by 
vacuum.  The container was filled with 50 psi H2 (g) and the apparatus was allowed to 
shake overnight.  The flask was then vented and the contents were diluted with 20 mL 
water and filtered through CM-cellulose.  The filtrate was then frozen and concentrated 
by lyophilization to a light brown residue that was then washed with 1:1 EtOAc : CH2Cl2 
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(3 x 10 mL). The sample was then diluted with 5 mL water and isolated by cation 
exchange resin (sulphonic acid resin) using 10% ammonium acetate to elute the final 
product.  The collected fractions were combined and concentrated by lyophilization to 
afford 62 mg of cis-4-hydroxy-trans-4-methyl-L-proline, a 60% yield.   
 
1
H-NMR (400 MHz, D2O 4.75) δ 4.55-4.52 (dd, J = 9.1, 3.9 Hz, 1H, H-1), 3.37-3.34 (d, J 
= 11.6 Hz, 1H, H-5), 3.20-3.17 (d, J = 12.3, 1H, H-4), 2.35 (m, H-2 and 3), 1.36 (s, 3H).  
13
C-NMR (500 MHz, D2O) δ 76.8, 59.4, 57.1, 41.9, 22.4.  HRMS m/e calcd.  For 
C6H12NO3 = 146.0817, found 146.0823.  [ α ]
22
Na = -44
◦
 (c = 0.39, MeOH). 
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Appendix A:  NMR spectra of final product β-aryl-aspartamides & α-aryl-amide 
aspartates 
 239 
1-Biphenyl-α-amide-aspartate 
VerticalScaleFactor = 1
N
+
O
OH
O
NH
H
H
H
10.0 9.5 9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0
Chemical  Shift (ppm)
0
0.01
0.02
0.03
0.04
0.05
0.06
0.07
0.08
0.09
0.10
0.11
N
o
rm
a
liz
e
d
 I
n
te
n
s
it
y
2.000.978.622.190.94
DMSO-d6
2
.5
0
2
.6
8
2
.7
4
2
.7
5
2
.7
7
2
.7
8
3
.3
6
4
.1
0
4
.1
1
4
.1
2
4
.1
3
7
.3
4
7
.3
6
7
.3
9
7
.4
5
7
.4
9
7
.5
1
8
.3
4
9
.9
6
VerticalScaleFactor = 1
N
+
O
OH
O
NH
H
H
H
168 160 152 144 136 128 120 112 104 96 88 80 72 64 56 48 40 32
Chemical  Shift (ppm)
0.005
0.010
0.015
0.020
0.025
0.030
0.035
0.040
0.045
N
o
rm
a
liz
e
d
 I
n
te
n
s
it
y
DMSO-d6
3
4
.9
8
3
9
.1
8
3
9
.3
4
3
9
.5
1
3
9
.6
8
3
9
.8
4
3
9
.9
3
4
0
.0
1
4
9
.1
5
1
2
6
.7
21
2
6
.8
0
1
2
7
.4
8
1
2
8
.5
1
1
2
8
.8
6
1
3
0
.4
7
1
3
3
.5
2
1
3
6
.6
6
1
3
8
.4
4
1
6
6
.7
4
1
7
0
.8
9
 
 
 
 
Appendix A:  NMR spectra of final product β-aryl-aspartamides & α-aryl-amide 
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Appendix A:  NMR spectra of final product β-aryl-aspartamides & α-aryl-amide 
aspartates 
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Appendix A:  NMR spectra of final product β-aryl-aspartamides & α-aryl-amide 
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Appendix  B:  NMR spectra of hydroxy-L-proline derivatives 
 243 
trans-3-hydroxy-cis-4-methoxy-L-proline 
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Appendix  B:  NMR spectra of hydroxy-L-proline derivatives 
 244 
cis-3-hydroxy-trans-4-methoxy-L-proline 
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Appendix  B:  NMR spectra of hydroxy-L-proline derivatives 
 245 
trans-3-hydroxy-cis-4-isopropoxy-L-proline 
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Appendix  B:  NMR spectra of hydroxy-L-proline derivatives 
 246 
cis-3-hydroxy-trans-4-isopropoxy-L-proline 
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Appendix  B:  NMR spectra of hydroxy-L-proline derivatives 
 247 
trans-3-hydroxy-cis-4-benzyloxy-L-proline 
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Appendix  B:  NMR spectra of hydroxy-L-proline derivatives 
 248 
cis-3-hydroxy-trans-4-benzyloxy-L-proline 
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Appendix  B:  NMR spectra of hydroxy-L-proline derivatives 
 249 
(2S, 3R, 4R)-3-hydroxy-4-o-methyl-α-napthyl-proline 
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Appendix  B:  NMR spectra of hydroxy-L-proline derivatives 
 250 
(2S, 3R, 4R)-3-hydroxy-4-o-methyl-p-biphenyl-proline 
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Appendix  B:  NMR spectra of hydroxy-L-proline derivatives 
 251 
(2S, 3R, 4R)-3-hydroxy-4-o-methyl-3-biphenylether-proline 
VerticalScaleFactor = 1
OH
N
H2
+
O
O
O
-
O
9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0
Chemical  Shift (ppm)
0
0.05
0.10
0.15
N
o
rm
a
liz
e
d
 I
n
te
n
s
it
y
1.730.923.000.821.012.153.092.13
DMSO-d6
2
.0
7
2
.3
6
2
.5
0
2
.6
3
3
.2
3
3
.2
5
3
.3
3
3
.4
7
3
.8
3
4
.4
1
4
.4
3
4
.4
5
4
.5
1
5
.6
26
.8
6
6
.8
8
6
.9
9
7
.1
1
7
.3
7
7
.3
9
7
.4
0
8
.8
1
 
VerticalScaleFactor = 1
OH
N
H2
+
O
O
O
-
O
160 152 144 136 128 120 112 104 96 88 80 72 64 56 48 40
Chemical  Shift (ppm)
0.005
0.010
0.015
0.020
0.025
0.030
0.035
N
o
rm
a
liz
e
d
 I
n
te
n
s
it
y
DMSO-d6
3
9
.1
7
3
9
.3
4
3
9
.5
1
3
9
.6
8
3
9
.8
4
3
9
.9
3
4
0
.0
1
4
8
.6
8
6
8
.1
26
9
.3
2
7
5
.3
7
8
1
.9
21
1
7
.4
6
1
1
7
.8
2
1
1
8
.5
1
1
2
2
.6
6
1
2
3
.3
8
1
2
9
.7
2
1
3
0
.0
6
1
4
0
.2
9
1
5
6
.4
3
1
5
6
.6
9
 
 
Appendix  B:  NMR spectra of hydroxy-L-proline derivatives 
 252 
(2S, 3S, 4R)-3-hydroxy-4-phenyl-proline 
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Appendix  B:  NMR spectra of hydroxy-L-proline derivatives 
 253 
(2S, 3S, 4R)-3-phenyl-4-hydroxy-proline 
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Appendix  B:  NMR spectra of hydroxy-L-proline derivatives 
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(2S, 3S, 4R)-3-methyl-4-hydroxy-proline 
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(2S, 3S, 4R)-3-hydroxy-4-methyl-proline 
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(2S, 3S, 4S)-3-phenoxy-4-hydroxy-proline 
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(2S, 3S, 4R)-3-hydroxy-4-phenoxy-proline 
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cis-4-hydroxy-trans-4-methyl-L-proline 
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cis-4-methyl-trans-4-hydroxy-L-proline 
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